Intestinal Research

Original Articles

Familial aggregation of inflammatory bowel disease in patients with ulcerative colitis: Akshita Gupta, Sawan Bopanna, Saurabh Kedia, Dawesh Prakash Yadav, Sandeep Goyal, Saransh Jain, Govind Makharia, Vineet Ahuja; Intest Res 2017;15(3):388-394. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.388

Background/Aims

Familial occurrence of inflammatory bowel disease (IBD) is well documented. Reports from Western countries have shown a higher familial occurrence of ulcerative colitis (UC) in first- and second-degree relatives than that in the Asian UC population. No data are currently available from the Indian subcontinent in this regard. We present our data on the familial aggregation of UC.

Methods

Records of patients with UC followed at the Inflammatory Bowel Disease Clinic at the All India Institute of Medical Sciences, New Delhi from August 2004 to January 2016 were reviewed. Details regarding the prevalence of family history and characteristics of these patients were recorded. Affected family members were contacted and disease characteristics were noted for assessment of familial aggregation.

Results

Of the 2,058 UC patients included in the analysis, a positive family history of IBD was confirmed in 31 patients (1.5%), 24 (77.4%) of whom had only first-degree relatives affected. All the affected relatives had UC and none had Crohn's disease. Among first-degree relatives, siblings were found to have the highest prevalence of IBD (53.3%), followed by parents (26.7%).

Conclusions

The probability of occurrence of IBD in family members of affected North Indian UC patients is lower than that reported in Western populations.

Citations

Citations to this article as recorded by

The Impact of Smoking on Ulcerative Colitis and Interaction With Family History: A Population‐Based Cohort Study
Hyeong Sik Ahn, Heather Swan, Sayada Zartasha Kazmi, Young Shin Kim, Gahwi Hong, Seeun Choi, Taeuk Kang, Minjung Kim, Jaewoo Cha, Hoo Jae Hann, Hyun Jung Kim
Journal of Gastroenterology and Hepatology.2025; 40(2): 446. CrossRef
Inflammatory bowel disease in south Asia: a scoping review
Shabari Shenoy, Anuraag Jena, Carrie Levinson, Vishal Sharma, Parakkal Deepak, Tina Aswani-Omprakash, Shaji Sebastian, Jean-Frederic Colombel, Manasi Agrawal
The Lancet Gastroenterology & Hepatology.2025; 10(3): 259. CrossRef
Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection
Shadi Tabbarah, Hakam Sulaiman, Frank Ansah Owusu, Megha Rajeev Joshi, Nitheesha Reddy Marepalli, Nohelia Pino, Samra Saleem Azam, Aaliya Ali Ahmed, José Abraham Suárez Álvarez
Cureus.2024;[Epub] CrossRef
Childhood antibiotics as a risk factor for Crohn's disease: The ENIGMA International Cohort Study
Joyce W Y Mak, Sun Yang, Annalise Stanley, Xiaoqing Lin, Mark Morrison, Jessica Y L Ching, Junkun Niu, Amy L Wilson‐O'Brien, Rui Feng, Whitney Tang, Amy L Hamilton, Leo Or, Gina L Trakman, Winnie Y Y Lin, Joseph J Y Sung, Ming Hu Chen, Yinglei Mao, Michae
JGH Open.2022; 6(6): 369. CrossRef
Does the road to primary prevention of inflammatory bowel disease start from childhood?
Saurabh Kedia, Vineet Ahuja
JGH Open.2022; 6(6): 365. CrossRef
Cross Talk between Gut Microbiota and Intestinal Mucosal Immunity in the Development of Ulcerative Colitis
Junfeng Zou, Chen Liu, Shu Jiang, Dawei Qian, Jinao Duan, Anthony R. Richardson
Infection and Immunity.2021;[Epub] CrossRef
Factors Affecting Ulcerative Colitis Flare-Ups: Associations With Smoking Habits and Other Patient Characteristics
Nadim H Malibary, Mohammed A Ezzat, Ahmed M Mogharbel, Khalid A Kouzaba, Abdulaziz A Alkadi, Usama H Malki, Sultan M Gharib, Faisal M Altowairqi, Omar I Saadah, Mahmoud H Mosli
Cureus.2021;[Epub] CrossRef
Inflammatory bowel disease
Mayank Jain, Jayanthi Venkataraman
Indian Journal of Medical Research.2021; 153(4): 421. CrossRef
Familial aggregation of inflammatory bowel disease in India: prevalence, risks and impact on disease behavior
Rupa Banerjee, Partha Pal, Susan Hutfless, B Girish Ganesh, D Nageshwar Reddy
Intestinal Research.2019; 17(4): 486. CrossRef
Decreased Breg/Th17 Ratio Improved the Prognosis of Patients with Ulcerative Colitis
Xue Bing, Liang Linlang, Chen Keyan
Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1. CrossRef
Is the emergence of inflammatory bowel disease a prime example of “the third epidemiological transition”?
Saurabh Kedia, Vineet Ahuja
Indian Journal of Gastroenterology.2018; 37(3): 183. CrossRef

6,647 View
40 Download
12 Web of Science
11 Crossref

Ophthalmologic manifestations in patients with inflammatory bowel disease: Hye Jin Lee, Hyun Joo Song, Jin Ho Jeong, Heung Up Kim, Sun-Jin Boo, Soo-Young Na; Intest Res 2017;15(3):380-387. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.380

Abstract PDF PubReader ePub

Background/Aims

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), has been reported to have various ophthalmologic manifestations. The aim of this study was to evaluate the prevalence of ophthalmologic manifestations associated with IBD in Korea.

Methods

Sixty-one patients were examined between May 2013 and October 2014. We performed complete ophthalmologic examinations.

Results

Findings included 36 patients with CD and 25 with UC. The mean age of the patients was 34±16 years and disease duration was 45.3±23.9 months. Ophthalmologic manifestations were positive in 44 cases. Primary complication was diagnosed in 5 cases, as follows; iritis in 2 cases, episcleritis in one case, iritis with optic neuritis in 1 case, and serous retinal detachment in 1 case, without secondary complications. The most common coincidental complication was dry eye syndrome (DES), in 35 patients (57.4%). The prevalence of DES in the control group was 21.3%. The proportion of DES in patients with IBD was significantly higher than in the control group (P=0.002).

Conclusions

Ophthalmologic manifestations were high (72.1%) in IBD patients. Clinically significant primary ocular inflammation occurred in 8.2% of patients. The most common complication was DES. There was a higher rate of DES in patients with IBD compared to the control group. Evaluation of the eye should be a routine component in patients with IBD.

Citations

Citations to this article as recorded by

Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Yakup Kilic, Shahed Kamal, Farah Jaffar, Danujan Sriranganathan, Mohammed Nabil Quraishi, Jonathan P Segal
Inflammatory Bowel Diseases.2024; 30(2): 230. CrossRef
Isoliquiritin Ameliorates Ulcerative Colitis in Rats through Caspase 3/HMGB1/TLR4 Dependent Signaling Pathway
Zhiwei Miao, Mingjia Gu, Faisal Raza, Hajra Zafar, Jianyi Huang, Yuhang Yang, Muhammad Sulaiman, Jing Yan, Yi Xu
Current Gene Therapy.2024; 24(1): 73. CrossRef
Use of Systemic Steroids for Inflammatory Bowel Disease Can Increase Intraocular Pressure
Amrik Gil, Madeline Alizadeh, Daniel Yarmovsky, Ramya Swamy, Uni Wong
Gastro Hep Advances.2024; 3(4): 536. CrossRef
Ocular lesions in patients with ulcerative colitis
Antonina V. Varvarynets, Valerii D. Beliayev, Mykhailo M. Hechko, Artur V. Kurakh
Wiadomości Lekarskie.2024; 77(3): 445. CrossRef
The risk for ophthalmological conditions in ulcerative colitis: A population‐based case–control study. Is silica dust‐exposure associated with inflammatory eye disease?
Karim Makdoumi, Lucyn Ayoub, Ing‐Liss Bryngelsson, Pål Graff, Pernilla Wiebert, Per Vihlborg
Acta Ophthalmologica.2024; 102(7): 828. CrossRef
Ocular Manifestations of IBD: Pathophysiology, Epidemiology, and Iatrogenic Associations of Emerging Treatment Strategies
Holly Richardson, Giho Yoon, George Moussa, Aditi Kumar, Philip Harvey
Biomedicines.2024; 12(12): 2856. CrossRef
Analysis of the Incidence of Ocular Extraintestinal Manifestations in Inflammatory Bowel Disease Patients: A Systematic Review
Bruno Songel-Sanchis, Jesús Cosín-Roger
Diagnostics.2024; 14(24): 2815. CrossRef
Optical coherence tomography angiography findings of retinal vascular structures in children with celiac disease
Ishak Isik, Lutfiye Yaprak, Asli Yaprak, Ulas Akbulut
Journal of American Association for Pediatric Ophthalmology and Strabismus.2022; 26(2): 69.e1. CrossRef
Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era
Alix Cuny, Lucas Guillo, Cédric Baumann, Patrick Netter, Silvio Danese, Bénédicte Caron, Laurent Peyrin-Biroulet, Karine Angioi
Journal of Clinical Medicine.2022; 11(15): 4538. CrossRef
The Prevalence of Ocular Extra-Intestinal Manifestations in Adults Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Jing-Xing Li, Chun-Chi Chiang, San-Ni Chen, Jane-Ming Lin, Yi-Yu Tsai
International Journal of Environmental Research and Public Health.2022; 19(23): 15683. CrossRef
Ocular Manifestations of Inflammatory Bowel Disease
Janaki Shah, Aaditya Shah, Lynn Hassman, Alexandra Gutierrez
Inflammatory Bowel Diseases.2021; 27(11): 1832. CrossRef
Ocular manifestations of inflammatory bowel diseases: an update for gastroenterologists
Fabio CASTELLANO, Giovanni ALESSIO, Carmela PALMISANO
Minerva Gastroenterology.2021;[Epub] CrossRef
The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)—A Critical Review
Dominika Jakubczyk, Katarzyna Leszczyńska, Sabina Górska
Nutrients.2020; 12(7): 1973. CrossRef
Les manifestations oculaires au cours de la maladie de Crohn
D. Saadouli, K. Ben Mansour, M. Farae, I. Loukil, S. Yahyaoui, M.A. El Afrit
Journal Français d'Ophtalmologie.2020; 43(10): 1025. CrossRef
Evaluation of Objective Signs and Subjective Symptoms of Dry Eye Disease in Patients with Inflammatory Bowel Disease
Zsolt Barta, Levente Czompa, Aniko Rentka, Eva Zold, Judit Remenyik, Attila Biro, Rudolf Gesztelyi, Judit Zsuga, Peter Szodoray, Adam Kemeny-Beke
BioMed Research International.2019; 2019: 1. CrossRef
The optimal time to perform an ophthalmic examination of patients with inflammatory bowel disease
Ana Luiza Biancardi, Leandro Lopes Troncoso, Haroldo Vieira de Moraes Jr, Cyrla Zaltman
Intestinal Research.2019; 17(1): 153. CrossRef
Current clinical issue of skin lesions in patients with inflammatory bowel disease
Tomoya Iida, Tokimasa Hida, Minoru Matsuura, Hisashi Uhara, Hiroshi Nakase
Clinical Journal of Gastroenterology.2019; 12(6): 501. CrossRef
Manifestaciones extraintestinales de enfermedad inflamatoria intestinal
Amaranta Luzoro, Pablo Sabat, Leonardo Guzmán, Francisca Frias
Revista Médica Clínica Las Condes.2019; 30(4): 305. CrossRef
Corneal Manifestations of Inflammatory Bowel Disease
Levente Czompa, Zsolt Barta, Hassan Ziad, Gabor Nemeth, Aniko Rentka, Zsuzsa Aszalos, Eva Zold, Rudolf Gesztelyi, Judit Zsuga, Peter Szodoray, Adam Kemeny-Beke
Seminars in Ophthalmology.2019; 34(7-8): 543. CrossRef

6,785 View
104 Download
22 Web of Science
19 Crossref

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study: Haruhiko Ogata, Nobuo Aoyama, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi; Intest Res 2017;15(3):368-379. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.368

Abstract PDF PubReader ePub

Background/Aims

This study assessed the efficacy and safety of high-dose multimatrix mesalazine once-daily (QD) compared to another form of high-dose mesalazine.

Methods

In this multicenter, randomized, double-blind study, 280 patients with mildly to moderately active ulcerative colitis (UC) received multimatrix mesalazine 4.8 g/day QD or pH-dependent-release mesalazine 3.6 g/day three times daily for 8 weeks. The primary endpoint was the change in the UC-Disease Activity Index (UC-DAI) at the end of the treatment period.

Results

The change in the UC-DAI (mean±standard deviation) in the per-protocol set was −2.6±2.47 in the multimatrix mesalazine 4.8 g/day group (n=134) and −1.8±2.64 in the pH-dependent-release mesalazine 3.6 g/day group (n=129). The difference in the mean change between the 2 groups was −0.7 (two-sided 95% confidence interval, −1.3 to −0.1). The noninferiority of multimatrix mesalazine 4.8 g/day to pH-dependent-release mesalazine 3.6 g/day was verified within the noninferiority margin (1.1). The superiority of multimatrix mesalazine 4.8 g/day to pH-dependent-release mesalazine 3.6 g/day was also investigated and confirmed in the full analysis set, according to the study protocol. In subgroup analyses, the effectiveness of multimatrix mesalazine 4.8 g/day was consistent in all subgroups. There was no difference in safety between the 2 treatment groups.

Conclusions

Multimatrix mesalazine 4.8 g/day has higher efficacy and shows no difference in safety in mildly to moderately active UC, in comparison with pH-dependent-release mesalazine 3.6 g/day.

Citations

Citations to this article as recorded by

Analysis of the Medication Persistence Rate for and Adherence to Oral 5-Aminosalicylic Acid Preparations in Japanese Patients with Ulcerative Colitis: Study Using a Nationwide Claims Database
Takumi Ota, Takahiro Takebe, Yutaka Shimizu, Takashi Orido, Hiroyuki Tanaka, Shiro Nakamura
Digestion.2024; 105(3): 232. CrossRef
5-Aminosalicylic Acid Distribution into the Intestinal Membrane Along the Gastrointestinal Tract After Oral Administration in Rats
Yorinobu Maeda, Yuta Goto, Fumiya Ohnishi, Syoutarou Koga, Satoshi Kawano, Yuhzo Hieda, Takeshi Goromaru, Teruo Murakami
Pharmaceutics.2024; 16(12): 1567. CrossRef
Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S‐methyltransferase inhibition
Hiromu Morikubo, Taku Kobayashi, Ryo Ozaki, Shinji Okabayashi, Satoshi Kuronuma, Osamu Takeuchi, Tenyo Shiba, Hiroki Kiyohara, Mao Matsubayashi, Shintaro Sagami, Masaru Nakano, Osamu Ikezaki, Tadakazu Hisamatsu, Yoichi Tanaka, Toshifumi Hibi
Journal of Gastroenterology and Hepatology.2021; 36(8): 2116. CrossRef
Effect of Kangfuxin Liquid enema combined with mesalazine on gestational outcomes and quality of life in child-bearing female with active ulcerative colitis
Tong Wang, Hua Lu, Fangyuan Li, Qi Zhang
Medicine.2021; 100(5): e23915. CrossRef
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu I
Journal of Gastroenterology.2021; 56(6): 489. CrossRef
Efficacy of Multi Matrix System Mesalazine for the Induction of Remission in Patients with Ulcerative Colitis who Insufficiently Respond toother Mesalazine Formulations: A Japanese Single-center Study
Masaki Kato, Kohei Sugiyama, Maki Miyakawa, Masanao Nasuno, Hiroki Tanaka, Satoshi Motoya
Nippon Daicho Komonbyo Gakkai Zasshi.2021; 74(6): 357. CrossRef
pH‑dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review)
Helmut Deissler, Heinrich Krammer, Anton Gillessen
Biomedical Reports.2021;[Epub] CrossRef
Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
Hiroshi Nakase
Gut and Liver.2020; 14(1): 7. CrossRef
Inflammatory Bowel Disease – Non-biological treatment
Fernando Magro, Gonçalo Cordeiro, Andreia Martins Dias, Maria Manuela Estevinho
Pharmacological Research.2020; 160: 105075. CrossRef
Systematic review: safety of mesalazine in ulcerative colitis
P. Sehgal, J.‐F. Colombel, A. Aboubakr, N. Narula
Alimentary Pharmacology & Therapeutics.2018; 47(12): 1597. CrossRef

6,918 View
83 Download
9 Web of Science
10 Crossref

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study: Haruhiko Ogata, Akihiro Ohori, Haruo Nishino, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi; Intest Res 2017;15(3):358-367. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.358

Abstract PDF PubReader ePub

Background/Aims

This study compared the efficacy of once-daily administration of multimatrix mesalazine 2.4 g/day with multiple-dose mesalazine for the maintenance of remission.

Methods

In this multicenter, randomized, double-blind study, 203 patients with ulcerative colitis in remission received multimatrix mesalazine 2.4 g/day once-daily or time-dependent (controlled-release) mesalazine 2.25 g/day 3 times-daily for 48 weeks. The primary efficacy endpoint was the proportion of patients without rectal bleeding.

Results

The proportion of patients without rectal bleeding during the 48-week treatment period in the per protocol set was 84.8% (84/99) in the multimatrix mesalazine 2.4 g/day group and 78.0% (78/100) in the controlled-release mesalazine 2.25 g/day group. The difference between the 2 treatment groups was 6.8% (two-sided 95% confidence interval, −3.9% to 17.6%). The noninferiority margin of −10% was met in the comparison of multimatrix mesalazine 2.4 g/day once-daily with controlled-release mesalazine 2.25 g/day. Multimatrix mesalazine 2.4 g/day once-daily demonstrated consistent efficacy in all subgroups. There was no difference between the 2 treatment groups with regard to safety.

Conclusions

A once-daily dose of 2 multimatrix mesalazine tablets (2.4 g) was not inferior to controlled-release mesalazine 2.25 g/day 3 times-daily in maintaining absence of rectal bleeding in ulcerative colitis.

Citations

Citations to this article as recorded by

Culture-based characterization of gut microbiota in inflammatory bowel disease
Hyunjoon Park, Soyoung Yeo, Taekyu Lee, Yumin Han, Chang Beom Ryu, Chul Sung Huh
Frontiers in Microbiology.2025;[Epub] CrossRef
A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation
Masahiro Kishi, Fumihito Hirai, Noritaka Takatsu, Takashi Hisabe, Yasumichi Takada, Tsuyoshi Beppu, Ken Takeuchi, Makoto Naganuma, Kazuo Ohtsuka, Kenji Watanabe, Takayuki Matsumoto, Motohiro Esaki, Kazutaka Koganei, Akira Sugita, Keisuke Hata, Kitarou Fut
Journal of Gastroenterology.2022; 57(4): 246. CrossRef
Inflammatory Bowel Disease – Non-biological treatment
Fernando Magro, Gonçalo Cordeiro, Andreia Martins Dias, Maria Manuela Estevinho
Pharmacological Research.2020; 160: 105075. CrossRef
Systematic review: safety of mesalazine in ulcerative colitis
P. Sehgal, J.‐F. Colombel, A. Aboubakr, N. Narula
Alimentary Pharmacology & Therapeutics.2018; 47(12): 1597. CrossRef
How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
You Sun Kim
The Korean Journal of Gastroenterology.2018; 71(2): 74. CrossRef

5,922 View
61 Download
4 Web of Science
5 Crossref

Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease: Daniéla Oliveira Magro, Paulo Gustavo Kotze, Carlos Augusto Real Martinez, Michel Gardere Camargo, Dioze Guadagnini, Antonio Ramos Calixto, Ana Carolina Junqueira Vasques, Maria de Lourdes Setsuko Ayrizono, Bruno Geloneze, José Carlos Pareja, Mario José Saad, Claudio Saddy Rodrigues Coy; Intest Res 2017;15(3):352-357. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.352

Abstract PDF PubReader ePub

Background/Aims

Lipopolysaccharide (LPS) is a molecule formed by lipids and polysaccharides and is the major cell wall component of gram-negative bacteria. High LPS levels are known to block CD26 expression by activating Toll-like receptor 4. The aim of this study was to correlate the serum levels of LPS and CD26 in Crohn's disease (CD) patients with serum levels of C-reactive protein (CRP), interleukins, CD activity index, and tumor necrosis factor-α (TNF-α).

Methods

Serum samples were collected from 27 individuals (10 with active CD, 10 with inactive CD, and 7 controls) and the levels of LPS, CD26, TNF-α, interleukin-1β (IL-1β), IL-6, IL-17, and CRP were determined by enzyme-linked immunosorbent assay. The levels of LPS and CD26 were then tested for correlation with TNF-α, IL-1β, IL-6, IL-17, and CRP.

Results

Serum levels of LPS were significantly elevated in the active CD group (P=0.003). Levels of IL-1β (P=0.002), IL-6 (P=0.003), and IL-17 (P<0.001) were lower in the CD groups. Serum TNF-α levels were increased in the active CD group. The CRP levels were elevated in the CD groups when compared to controls (P<0.001). The CD26 levels were lower in the CD groups than in the control group (P<0.001). Among the variables analyzed, there was a correlation between LPS and CRP (r=−0.53, P=0.016) in the CD groups.

Conclusions

Individuals with CD exhibited higher serum levels of LPS varying from a 2- to 6-fold increase depending on disease activity, when compared with healthy controls. CD26 levels were lower in the CD groups. Both LPS and CD26 correlated with disease severity and serve as potential CD biomarkers.

Citations

Citations to this article as recorded by

ATHEROSCLEROTIC CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Ondřej Kučerka, Martin Malý, Petra Mináriková, Jan M. Horáček
Military Medical Science Letters.2025; 94(1): 27. CrossRef
Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
Kashif Rahim, Muhammad Shan, Ihtisham Ul Haq, Muhammad Nawaz, Sajida Maryam, Mansour Alturki, Abdulaziz Al Khzem, Kamel Metwally, Simona Cavalu, Saleh Alqifari, Galal Yahya
Journal of Inflammation Research.2024; Volume 17: 1897. CrossRef
Interaction between diet and genetics in patients with inflammatory bowel disease
Daniéla Oliveira Magro, Ligia Yukie Sassaki, Júlio Maria Fonseca Chebli
World Journal of Gastroenterology.2024; 30(12): 1644. CrossRef
Quantitative urinary proteome analysis reveals potential biomarkers for disease activity of Behcet’s disease uveitis
Weiwei Qin, Anyi Liang, Xiaoxu Han, Meifen Zhang, Youhe Gao, Chan Zhao
BMC Ophthalmology.2024;[Epub] CrossRef
Dietary fat induced chylomicron-mediated LPS translocation in a bicameral Caco-2cell model
Monic M. M. Tomassen, Coen Govers, A. Paul Vos, Nicole J. W. de Wit
Lipids in Health and Disease.2023;[Epub] CrossRef
Endothelial Glycocalyx Preservation—Impact of Nutrition and Lifestyle
Paula Franceković, Lasse Gliemann
Nutrients.2023; 15(11): 2573. CrossRef
Toll-like Receptors and Cytokine Modulation by Goat Milk Extracellular Vesicles in a Model of Intestinal Inflammation
Chiara Grazia De Ciucis, Floriana Fruscione, Livia De Paolis, Samanta Mecocci, Susanna Zinellu, Lisa Guardone, Giulia Franzoni, Katia Cappelli, Elisabetta Razzuoli
International Journal of Molecular Sciences.2023; 24(13): 11096. CrossRef
Longitudinal flux balance analyses of a patient with episodic colonic inflammation reveals microbiome metabolic dynamics
Arianna Basile, Almut Heinken, Johannes Hertel, Larry Smarr, Weizhong Li, Laura Treu, Giorgio Valle, Stefano Campanaro, Ines Thiele
Gut Microbes.2023;[Epub] CrossRef
Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124-E) has a nondetrimental effect on gut microbial communities in unchallenged mice
Rachele Gore, Mitra Mohsenipour, Jennifer L. Wood, Gayathri K. Balasuriya, Elisa L. Hill-Yardin, Ashley E. Franks, Manuela Raffatellu
Infection and Immunity.2023;[Epub] CrossRef
MEFV and NLRP3 Inflammasome Expression Is Attributed to Immature Macrophages and Correlates with Serum Inflammatory Proteins in Crohn´s Disease Patients
Frida Gorreja, Charles Caër, Stephen T. A. Rush, Sophia K. Forsskål, Anetta Härtlova, Maria K. Magnusson, Elinor Bexe Lindskog, Lars G. Börjesson, Mattias Block, Mary Jo Wick
Inflammation.2022; 45(4): 1631. CrossRef
Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
Jie Huang, Xinxin Liu, Yingying Wei, Xinlu Li, Shupei Gao, Lingli Dong, Xiaoquan Rao, Jixin Zhong
Frontiers in Immunology.2022;[Epub] CrossRef
Genetic Deletion of LRP5 and LRP6 in Macrophages Exacerbates Colitis-Associated Systemic Inflammation and Kidney Injury in Response to Intestinal Commensal Microbiota
Indumathi Manoharan, Daniel Swafford, Arulkumaran Shanmugam, Nikhil Patel, Puttur D Prasad, Riyaz Mohamed, Qingqing Wei, Zheng Dong, Muthusamy Thangaraju, Santhakumar Manicassamy
The Journal of Immunology.2022; 209(2): 368. CrossRef
The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review
Francisco Jorge Melo, Pedro Pinto-Lopes, Maria Manuela Estevinho, Fernando Magro
Inflammatory Bowel Diseases.2021; 27(7): 1153. CrossRef
Effects of Anthocyanin on Intestinal Health: A Systematic Review
Thaísa Agrizzi Verediano, Hércia Stampini Duarte Martino, Maria Cristina Dias Paes, Elad Tako
Nutrients.2021; 13(4): 1331. CrossRef
Anti-inflammatory activity of Jasminum grandiflorum L. subsp. floribundum (Oleaceae) in inflammatory bowel disease and arthritis models
Riham A. El-Shiekh, Dorria Hussein, Attia H. Atta, Samar M. Mounier, Mohamed R. Mousa, Essam Abdel-Sattar
Biomedicine & Pharmacotherapy.2021; 140: 111770. CrossRef
Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management
Jasmijn A. M. Sleutjes, Jeanine E. Roeters van Lennep, C. Janneke van der Woude, Annemarie C. de Vries
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef
Phase angle through electrical bioimpedance as a predictor of cellularity in inflammatory bowel disease
Sabrina A Fernandes, Carina Rossoni, Vivian W Koch, Marcello Imbrizi, Rosana Evangelista-Poderoso, Letícia Pereira Pinto, Daniéla Oliveira Magro
Artificial Intelligence in Gastroenterology.2021; 2(4): 111. CrossRef
Correlation between Antibodies to Bacterial Lipopolysaccharides and Barrier Proteins in Sera Positive for ASCA and ANCA
Aristo Vojdani, Elroy Vojdani, Martha Herbert, Datis Kharrazian
International Journal of Molecular Sciences.2020; 21(4): 1381. CrossRef
CD26/DPP4 - a potential biomarker and target for cancer therapy
Njanja Enz, Gwendolyn Vliegen, Ingrid De Meester, Wolfgang Jungraithmayr
Pharmacology & Therapeutics.2019; 198: 135. CrossRef
Is there a possible correlation between antibodies against lipopolysaccharide, intestinal and blood-brain barrier proteins in IBD subjects?
Aristo Vojdani
Autoimmunity Reviews.2019; 18(6): 639. CrossRef
CD26 in autoimmune diseases: The other side of “moonlight protein”
Yunjuan Zhao
International Immunopharmacology.2019; 75: 105757. CrossRef
Remission in Crohn’s disease is accompanied by alterations in the gut microbiota and mucins production
Daniéla Oliveira Magro, Andrey Santos, Dioze Guadagnini, Flavia Moreira de Godoy, Sylvia Helena Monteiro Silva, Wilson José Fernandes Lemos, Nicola Vitulo, Sandra Torriani, Lilian Vital Pinheiro, Carlos Augusto Real Martinez, Mario José Abdalla Saad, Clau
Scientific Reports.2019;[Epub] CrossRef
Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults
Tiansheng Wang, Jeff Y. Yang, John B. Buse, Virginia Pate, Huilin Tang, Edward L. Barnes, Robert S. Sandler, Til Stürmer
Diabetes Care.2019; 42(11): 2065. CrossRef
Emerging concepts in non-invasive monitoring of Crohn’s disease
Wojciech Marlicz, Karolina Skonieczna-Żydecka, Konstantinos John Dabos, Igor Łoniewski, Anastasios Koulaouzidis
Therapeutic Advances in Gastroenterology.2018;[Epub] CrossRef
VISCERAL FAT IS INCREASED IN INDIVIDUALS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS WITH HEALTHY CONTROLS
Daniéla Oliveira MAGRO, Maria Rita Lazzarini BARRETO, Everton CAZZO, Michel Gardere CAMARGO, Paulo Gustavo KOTZE, Claudio Saddy Rodrigues COY
Arquivos de Gastroenterologia.2018; 55(2): 142. CrossRef

6,651 View
55 Download
24 Web of Science
25 Crossref

Japanese physicians' attitudes towards enteral nutrition treatment for pediatric patients with Crohn's disease: a questionnaire survey: Takashi Ishige, Takeshi Tomomasa, Hitoshi Tajiri, Atsushi Yoden; Intest Res 2017;15(3):345-351. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.345

Abstract PDF PubReader ePub

Background/Aims

Enteral nutrition (EN) is recommended for the treatment of pediatric Crohn's disease (CD) in Japan. However, the indications and treatment protocols for EN vary among hospitals. In the present study, we aimed to determine how EN was administered to pediatric patients and whether physicians followed treatment guidelines in their practices.

Methods

Two types of questionnaires were administered to 32 physicians who were involved in the treatment of pediatric CD. The consensus questionnaire evaluated the physicians' attitudes towards EN, whereas the efficacy questionnaire collected data on patients with CD, aged <17 years, who had undergone induction therapy between 2006 and 2011.

Results

A total of 23 physicians responded to the questionnaires. The results of the consensus questionnaire indicated that 82% and 59% of study participants recommended EN treatment for all newly diagnosed pediatric patients with CD and all relapsed patients, respectively. Exclusive EN (EEN) and elemental formula were recommended by 84% and 85% of physicians, respectively. The efficacy questionnaire revealed that 57 of the 58 patients received EN. Elemental formula was used in 39 of 40 patients who were treated with EEN. Of these 40 patients, 27 were treated with EEN alone; of these, 22 (81%) achieved remission without any other treatment. The mean duration of EEN was 15.9 days.

Conclusions

EN is widely recommended by physicians treating pediatric CD in Japan. In contrast to Western countries, clinicians used elemental formula more often and with a shorter EEN treatment duration.

Citations

Citations to this article as recorded by

A kizárólagos enteralis táplálás hazai gyakorlata gyermekkori Crohn-betegségben
Kriszta Katinka Boros, Veronika Kovács, Éva Nemes, Orsolya Kadenczki, Gábor Veres, Katalin Eszter Müller
Orvosi Hetilap.2024; 165(26): 1002. CrossRef
An Overview of Nutritional Interventions in Inflammatory Bowel Diseases
Ramit Magen-Rimon, Andrew S. Day, Ron Shaoul
Nutrients.2024; 16(18): 3055. CrossRef
Enteral Nutrition Prescription in Children and Adults with Inflammatory Bowel Diseases: Gaps in Current Gastroenterology Practice in Saudi Arabia
Sarah Ajabnoor, Atheer Attar, Noof BinJahlan, Nawal Almutairi, Shimaa Bashmail, Almoutaz Hashim, Alastair Forbes, Hani Jawa
Nutrients.2023; 15(1): 232. CrossRef
Implementation of exclusive enteral nutrition in pediatric patients with Crohn’s disease—results of a survey of CEDATA-GPGE reporting centers
Sarah Peters, Serdar Cantez, Jan De Laffolie
Molecular and Cellular Pediatrics.2022;[Epub] CrossRef
Global attitudes on and the status of enteral nutrition therapy for pediatric inflammatory bowel disease
Juan Luo, Yong-Mei Xie, Mei Wu, Jin-Gui Zhao, Liang-Liang Hu
Frontiers in Medicine.2022;[Epub] CrossRef
Elemental Diet Enriched with Amino Acids Alleviates Mucosal Inflammatory Response and Prevents Colonic Epithelial Barrier Dysfunction in Mice with DSS-Induced Chronic Colitis
Di Guo, Jun Yang, Fangmei Ling, Lei Tu, Junrong Li, Yidong Chen, Kaifang Zou, Liangru Zhu, Xiaohua Hou
Journal of Immunology Research.2020; 2020: 1. CrossRef
Exclusive enteral nutrition in children with inflammatory bowel disease: Physician perspectives and practice
Shaun S C Ho, Andrew S Day
JGH Open.2019; 3(2): 148. CrossRef
Global Variation in Use of Enteral Nutrition for Pediatric Crohn Disease
Morgan Lawley, Jessica W. Wu, Victor M. Navas‐López, Hien Q. Huynh, Matthew W. Carroll, Min Chen, Pavel Medvedev, Andrew S. Day, Séamus Hussey, Rotem Sigall‐Boneh, Arie Levine, Eytan Wine
Journal of Pediatric Gastroenterology and Nutrition.2018;[Epub] CrossRef
Living on Liquids: Surviving and Thriving on Exclusive Enteral Nutrition
Kelly Issokson
American Journal of Gastroenterology.2017; 112(10): 1491. CrossRef

6,712 View
50 Download
9 Web of Science
9 Crossref

Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases: Young Sun Kim, Sung-Ae Jung, Kang-Moon Lee, Soo Jung Park, Tae Oh Kim, Chang Hwan Choi, Hyun Gun Kim, Won Moon, Chang Mo Moon, Hye Kyoung Song, Soo-Young Na, Suk-Kyun Yang; Intest Res 2017;15(3):338-344. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.338

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Inflammatory bowel disease (IBD) is a chronic disabling gastrointestinal disorder that diminishes the quality of life of the affected individuals. Limited data are available regarding the impact of IBD on the daily life of Koreans.

Methods

Self-administered, computer-aided, internet-based questionnaires were distributed to members of a Korean patient organization for IBD from March to April 2013, by the Korean Association for the Study of Intestinal Diseases.

Results

A total of 599 patients with IBD (387 with Crohn's disease [CD] and 212 with ulcerative colitis [UC]) were enrolled. The majority of patients (81%) expressed feelings of fatigue, weakness, and being worn out in their daily lives during times of flare; this percentage was reduced to 61% during remission. Respondents were absent from work or school for an average period of 18 days because of illness, within the first 6 months; the majority of respondents (64%) felt stressed about their absence. Forty-six percent of the respondents reported having received unfair comments at work, or having suffered discrimination. Forty-seven percent of the respondents felt that IBD had negatively affected their income and earnings. Compared with patients with UC, those with CD reported a more frequent negative impact of IBD on work, or more economic burden. More than half of the respondents (61%) reported that IBD had prevented them from making or keeping friends.

Conclusions

IBD significantly impacts daily life, including work, education, and social relationships. Treatment that addresses the full spectrum of life of a patient would be more effective.

Citations

Citations to this article as recorded by

Increased Risks for Suicide, Self-Harm, Substance Use, and Psychiatric Disorders in Adults With Inflammatory Bowel Disease: A Nationwide Study in the United States From 2007 to 2017
Chung Sang Tse, Chien-Hsiang Weng, Michelle Kwon, Courtney Benjamin Wolk, Lily A Brown, Kanika Malani, Samir A Shah, Sean D Fine
Inflammatory Bowel Diseases.2024; 30(1): 150. CrossRef
Histologic features and predicting prognosis in ulcerative colitis patients with mild endoscopic activity
Seung Yong Shin, Hee Sung Kim, Kisung Kim, Chang Won Choi, Jung Min Moon, Jeong Wook Kim, Hyun Jin Joo, Jeongkuk Seo, Muhyeon Sung, Chang Hwan Choi
The Korean Journal of Internal Medicine.2024; 39(1): 68. CrossRef
Patient experiences in ulcerative colitis: conceptual model and review of patient-reported outcome measures
Chong Kim, Fiona L. Brown, Caroline Burk, Milena Anatchkova, Nashmel Sargalo, Ankita Kaushik
Quality of Life Research.2024; 33(5): 1373. CrossRef
Colonic Dysregulation of Major Metabolic Pathways in Experimental Ulcerative Colitis
Ji Yeon Noh, Naser Farhataziz, Michael T. Kinter, Xin Yan, Yuxiang Sun
Metabolites.2024; 14(4): 194. CrossRef
Patient Advisory Groups in Inflammatory Bowel Disease: A Collaborative Relationship Between Patients and Researchers
Linda Yoo, Mara Shapiro, Ihsan Kahveci, Isabela Hernandez, Rachael Whittemore, Tanvi Kale, Samantha Winders, Kendra Kamp
Crohn's & Colitis 360.2024;[Epub] CrossRef
A Phenomenological Investigation of Trauma in 18 Adults Living With Inflammatory Bowel Disease
Heidi Glynn, Simon R. Knowles
Clinical Nursing Research.2023; 32(1): 159. CrossRef
Interplay of broccoli/broccoli sprout bioactives with gut microbiota in reducing inflammation in inflammatory bowel diseases
Johanna Holman, Molly Hurd, Peter L. Moses, Gary M. Mawe, Tao Zhang, Suzanne L. Ishaq, Yanyan Li
The Journal of Nutritional Biochemistry.2023; 113: 109238. CrossRef
Medical consultation in ulcerative colitis: Key elements for improvement
Yago González-Lama, Elena Ricart, Ana Cábez, Pilar Fortes, Susana Gómez, Francesc Casellas
World Journal of Gastroenterology.2023; 29(6): 917. CrossRef
The relationship of major depressive disorder with Crohn's disease activity
Carolina Bortolozzo Graciolli Facanali, Carlos Walter Sobrado Junior, Renério Fraguas Junior, Marcio Roberto Facanali Junior, Lucas Rodrigues Boarini, Lucas Faraco Sobrado, Ivan Cecconello
Clinics.2023; 78: 100188. CrossRef
Characteristics and Treatment Outcomes of Transition among Patients with Inflammatory Bowel Disease
Eun Jin Yoo, Sang-Hoon Cho, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Yonsei Medical Journal.2023; 64(9): 541. CrossRef
The impact of gastrointestinal conditions on psychosocial factors associated with the biopsychosocial model of health: A scoping review
Elizabeth Dent, Nicola Davinson, Stephanie Wilkie
Applied Psychology: Health and Well-Being.2022; 14(2): 626. CrossRef
Ilex rotunda Thunb Protects Against Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Restoring the Intestinal Mucosal Barrier and Modulating the Oncostatin M/Oncostatin M Receptor Pathway
Yao Li, Xu Yang, Jia-ni Yuan, Rui Lin, Yun-yuan Tian, Yu-xin Li, Yan Zhang, Xu-fang Wang, Yan-hua Xie, Si-wang Wang, Xiao-hui Zheng
Frontiers in Pharmacology.2022;[Epub] CrossRef
The association between inflammatory bowel disease and mental ill health: a retrospective cohort study using data from UK primary care
Nosheen Umar, Dominic King, Joht Singh Chandan, Neeraj Bhala, Krish Nirantharakumar, Nicola Adderley, Dawit T. Zemedikun, Phil Harvey, Nigel Trudgill
Alimentary Pharmacology & Therapeutics.2022; 56(5): 814. CrossRef
Association of inflammatory bowel disease with suicidal ideation, suicide attempts, and suicide: A systematic review and meta-analysis
Qin Xiong, Fuyou Tang, Yilin Li, Fengjiao Xie, Lei Yuan, Chengjiao Yao, Ruike Wu, Juan Wang, Qiuxiang Wang, Peimin Feng
Journal of Psychosomatic Research.2022; 160: 110983. CrossRef
Modelling symptoms to suicide risk in individuals with inflammatory bowel disease
Valentina Mihajlovic, Dean A Tripp, Jill A Jacobson
Journal of Health Psychology.2021; 26(12): 2143. CrossRef
Risk of Inflammatory Bowel Disease Following Appendectomy in Adulthood
Wei-Sheng Chung, Sunny Chung, Chung-Y Hsu, Cheng-Li Lin
Frontiers in Medicine.2021;[Epub] CrossRef
Gastrointestinal microbiome, what is behind faecal microbiota transplantation?
P. Thomson, P. Núñez, R. Quera, C. Bay
New Microbes and New Infections.2021; 42: 100898. CrossRef
Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study
Jooyoung Lee, Jong Pil Im, Kyungdo Han, Jihye Kim, Hyun Jung Lee, Jaeyoung Chun, Joo Sung Kim
Gut and Liver.2020; 14(1): 89. CrossRef
Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management
G. Pellino, D. S. Keller, G. M. Sampietro, V. Annese, M. Carvello, V. Celentano, C. Coco, F. Colombo, N. Cracco, F. Di Candido, M. Franceschi, S. Laureti, G. Mattioli, L. Pio, G. Sciaudone, G. Sica, V. Villanacci, R. Zinicola, S. Leone, S. Danese, A. Spin
Techniques in Coloproctology.2020; 24(2): 105. CrossRef
Inflammatory bowel disease fatigue: an analysis of definitions, risk factors and impact and their implications for assessment and management
Doireann Ni Dhalaigh, Anna Marie Greaney, Dawn Farrell
Gastrointestinal Nursing.2020; 18(5): 42. CrossRef
Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
Jung Rock Moon, Chang Kyun Lee, Sung Noh Hong, Jong Pil Im, Byong Duk Ye, Jae Myung Cha, Sung-Ae Jung, Kang-Moon Lee, Dong Il Park, Yoon Tae Jeen, Young Sook Park, Jae Hee Cheon, Hyesung Kim, BoJeong Seo, Youngdoe Kim, Hyo Jong Kim
Gut and Liver.2020; 14(4): 459. CrossRef
Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations
Francesc Casellas, Daniel Guinard Vicens, Santiago García-López, Yago González-Lama, Federico Argüelles-Arias, Manuel Barreiro-de Acosta, Laura Marín Sánchez, Juan Manuel Mendive, Roberto Saldaña, Ana Cabez, Susana Gómez, Estíbaliz Loza
European Journal of Gastroenterology & Hepatology.2020; 32(12): 1514. CrossRef
Preconception Care Program for Women with Inflammatory Bowel Disease Using Intervention Mapping: A Protocol for Program Development
Young Jin Lee, Yeon Hee Kim, Hae Won Kim
International Journal of Environmental Research and Public Health.2020; 17(24): 9365. CrossRef
Herbs-partitioned moxibustion alleviates aberrant intestinal epithelial cell apoptosis by upregulating A20 expression in a mouse model of Crohn’s disease
Jing Zhou, Lu-Yi Wu, Liu Chen, Ya-Jing Guo, Yi Sun, Tao Li, Ji-Meng Zhao, Chun-Hui Bao, Huan-Gan Wu, Yin Shi
World Journal of Gastroenterology.2019; 25(17): 2071. CrossRef
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
María Chaparro, Manuel Barreiro-de Acosta, José Manuel Benítez, José Luis Cabriada, María José Casanova, Daniel Ceballos, María Esteve, Hipólito Fernández, Daniel Ginard, Fernando Gomollón, Rufo Lorente, Pilar Nos, Sabino Riestra, Montserrat Rivero, Pilar
Therapeutic Advances in Gastroenterology.2019;[Epub] CrossRef
Application of Herbaceous Medications for Inflammatory Bowel Disease as a Complementary and Alternative Therapy
Zili Lin, Huiyi Wu, Yiming Fu, Shixue Dai
Inflammatory Bowel Diseases.2019; 25(12): 1886. CrossRef
Analysis of the Nutrients and Food Products Intake of Polish Males with Ulcerative Colitis in Remission
Dominika Głąbska, Dominika Guzek, Gustaw Lech
Nutrients.2019; 11(10): 2333. CrossRef
Are there also negative effects of social support? A qualitative study of patients with inflammatory bowel disease
Alexander Palant, Wolfgang Himmel
BMJ Open.2019; 9(1): e022642. CrossRef
Reactive Oxygen Species Deficiency Due to Ncf1-Mutation Leads to Development of Adenocarcinoma and Metabolomic and Lipidomic Remodeling in a New Mouse Model of Dextran Sulfate Sodium-Induced Colitis
Lina Carvalho, Joana R. M. Gomes, Ludgero C. Tavares, Ana R. Xavier, Karel D. Klika, Rikard Holmdahl, Rui A. Carvalho, M. Margarida Souto-Carneiro
Frontiers in Immunology.2018;[Epub] CrossRef
Complementary and alternative medicine in patients with inflammatory bowel disease: A survey performed in a tertiary center in Chile
Antonia Fernández, Daniela Simian, Rodrigo Quera, Lilian Flores, Patricio Ibáñez, Jaime Lubascher, Carolina Figueroa, Udo Kronberg, Gonzalo Pizarro, Daniela Fluxá
Complementary Therapies in Medicine.2018; 40: 77. CrossRef
IBD2020 global forum: results of an international patient survey on quality of care
Peter Irving, Johan Burisch, Richard Driscoll, Mats Olsson, John R Fullarton, Barry S Rodgers-Gray, Simon PL Travis
Intestinal Research.2018; 16(4): 537. CrossRef
Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study
Jaeyoung Chun, Jong Pil Im, Ji Won Kim, Kook Lae Lee, Chang Hwan Choi, Hyunsoo Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, You Sun Kim, Yoon Tae Jeen, Dong Soo Han, Won Ho Kim, Joo Sung Kim
Gut and Liver.2018; 12(5): 544. CrossRef

7,115 View
94 Download
32 Web of Science
32 Crossref

NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases: Toshiyuki Sato, Tetsuya Takagawa, Yoichi Kakuta, Akihiro Nishio, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Yuko Kita, Takako Miyazaki, Masaki Iimuro, Nobuyuki Hida, Kazutoshi Hori, Hiroki Ikeuchi, Shiro Nakamura; Intest Res 2017;15(3):328-337. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.328

Abstract PDF PubReader ePub

Background/Aims

Recent genome-wide analyses have provided strong evidence concerning adverse events caused by thiopurine drugs such as azathioprine (AZA) and 6-mercaptopurine. The strong associations identified between NUDT15 p.Arg139Cys and thiopurine-induced leukopenia and severe hair loss have been studied and confirmed over the last 2 years. However, other coding variants, including NUDT15 p.Val18_Val19insGlyVal, NUDT15 p.Val18Ile, and FTO p.Ala134Thr, and a noncoding variation in RUNX1 (rs2834826) remain to be examined in detail in this respect. Therefore, we investigated the correlation between these adverse events and the 5 recently identified variants mentioned above among Japanese patients with inflammatory bowel diseases (IBD).

Methods

One hundred sixty thiopurine-treated patients with IBD were enrolled. Genotyping was performed using TaqMan SNP Genotyping Assays or Sanger sequencing.

Results

None of the 5 variants were associated with gastrointestinal intolerance to AZA. However, NUDT15 p.Arg139Cys was significantly associated with the interval between initiation and discontinuation of AZA among patients with gastrointestinal intolerance. This variant was strongly associated with early (<8 weeks) and late (≥8 weeks) leukopenia and severe hair loss. Moreover, it correlated with the interval between initiation of thiopurine therapy and leukopenia occurrence, and average thiopurine dose. NUDT15 p.Val18_Val19insGlyVal, NUDT15 p.Val18Ile, FTO p.Ala134Thr, and RUNX1 rs2834826 exhibited no significant relationship with the adverse events examined.

Conclusions

Of the 5 variants investigated, NUDT15 p.Arg139Cys had the strongest impact on thiopurine-induced leukopenia and severe hair loss; therefore, its genotyping should be prioritized over that of other variants in efforts to predict these adverse events in Japanese patients with IBD.

Citations

Citations to this article as recorded by

A case of rapidly progressive hair loss due to azathioprine, and the prevalence of NUDT15 variants among Japanese patients with autoimmune blistering diseases: A single‐center retrospective observational study
Sho Katayama, Kentaro Izumi, Inkin Ujiie, Hideyuki Ujiie
The Journal of Dermatology.2025; 52(2): 363. CrossRef
Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study
Motoki Makuuchi, Yoichi Kakuta, Junji Umeno, Toshimitsu Fujii, Tetsuya Takagawa, Takashi Ibuka, Miki Miura, Yu Sasaki, Sakuma Takahashi, Hiroshi Nakase, Hiroki Kiyohara, Keiichi Tominaga, Yosuke Shimodaira, Sakiko Hiraoka, Nobuhiro Ueno, Shunichi Yanai, T
Journal of Gastroenterology.2024; 59(6): 468. CrossRef
Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn’s disease: a Korean nationwide population-based study
Yu Kyung Jun, Eunjeong Ji, Hye Ran Yang, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef
A systematic review of aspects of NUDT15 pharmacogenomic variants and thiopurine-induced myelosuppression
Rachel Palmer, Jaime Peters
RPS Pharmacy and Pharmacology Reports.2024;[Epub] CrossRef
m6A modification in inflammatory bowel disease provides new insights into clinical applications
Jiamin Zhang, Bimei Song, Yue Zeng, Chao Xu, Liang Gao, Yan Guo, Jingbo Liu
Biomedicine & Pharmacotherapy.2023; 159: 114298. CrossRef
Targeting FTO by Dac51 contributes to attenuating DSS-induced colitis
Chunyan Peng, Chang Zheng, Fan Zhou, Ying Xie, Lei Wang, Deyan Chen, Xiaoqi Zhang
International Immunopharmacology.2023; 116: 109789. CrossRef
Single-Nucleotide Polymorphisms, c.415C > T (Arg139Cys) and c.416G > A (Arg139His), in the NUDT15 Gene Are Associated with Thiopurine-Induced Leukopenia
Tetsuichiro Isono, Daiki Hira, Yoshito Ikeda, Masahiro Kawahara, Satoshi Noda, Atsushi Nishida, Osamu Inatomi, Noriki Fujimoto, Akira Andoh, Tomohiro Terada, Shin-ya Morita
Biological and Pharmaceutical Bulletin.2023; 46(3): 412. CrossRef
Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia
Minu Singh, Divya Bhaskar, Prateek Bhatia, Rozy Thakur, Pankaj Sharma, Deepak Bansal, Richa Jain, Amita Trehan
Cancer Chemotherapy and Pharmacology.2023; 92(1): 51. CrossRef
Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review
Devendra Desai, Anuraag Jena, Vishal Sharma, Toshifumi Hibi
Expert Review of Clinical Pharmacology.2023; 16(7): 643. CrossRef
Safety and efficacy of personalized versus standard initial dosing of thiopurines: Systematic review and meta-analysis of randomized trials
Anuraag Jena, Chhagan L Birda, Arup Choudhury, Vishal Sharma
Expert Opinion on Drug Safety.2023; 22(12): 1253. CrossRef
Comparative assessment of anti-cancer drugs against NUDT15 variants to prevent leucopenia side effect in leukemia patients
V. Janakiraman, M. Sudhan, Khalaf F. Alsharif, Ibrahim F. Halawani, Shiek S.S.J. Ahmed, Shankargouda Patil
Journal of Genetic Engineering and Biotechnology.2023; 21(1): 82. CrossRef
A rare case of Azathioprine-induced leukopenia in an European woman
Wautier Séverine, De Koninck Xavier, Coche Jean-Charles
Acta Clinica Belgica.2022; 77(1): 163. CrossRef
NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine
Kanyarat Khaeso, Patcharee Komvilaisak, Su-on Chainansamit, Nontaya Nakkam, Kunanya Suwannaying, Pitchayanan Kuwatjanakul, Keiko Hikino, Areerat Dornsena, Sirimas Kanjanawart, Napat Laoaroon, Suda Vannaprasaht, Takeshi Taketani, Wichittra Tassaneeyakul
Drug Metabolism and Pharmacokinetics.2022; 43: 100436. CrossRef
Nudix Hydroxylase 15 Mutations Strongly Predict Thiopurine-Induced Leukopenia Across Different Asian Ethnicities: Implications for Screening in a Diverse Population
Xin-Hui Khoo, Shin Yee Wong, Nik Razima Wan Ibrahim, Ruey Terng Ng, Kee Seang Chew, Way Seah Lee, Zhi Qin Wong, Raja Affend Raja Ali, Shahreedhan Shahrani, Alex Hwong-Ruey Leow, Ida Normiha Hilmi
Frontiers in Medicine.2022;[Epub] CrossRef
NUDT15Genotyping in Thiopurine Drug Therapy
Jong Kwon Lee, Rihwa Choi, Soo-Youn Lee
Laboratory Medicine Online.2022; 12(4): 217. CrossRef
Personalized medicine to implementation science: Thiopurines set for the leap
Vishal Sharma, Saurabh Kedia, Vineet Ahuja
JGH Open.2022; 6(10): 651. CrossRef
Pharmacogenetic determinants of thiopurines in an Indian cohort
Shaik Mohammad Naushad, Mekala Janaki Ramaiah, Vijay Kumar Kutala, Tajamul Hussain, Salman A. Alrokayan
Pharmacological Reports.2021; 73(1): 278. CrossRef
The Emerging Clinical Application of m6A RNA Modification in Inflammatory Bowel Disease and Its Associated Colorectal Cancer
Xinwei Xu, Jintu Huang, Dickson Kofi Wiredu Ocansey, Yuxuan Xia, Zihan Zhao, Zhiwei Xu, Yongmin Yan, Xu Zhang, Fei Mao
Journal of Inflammation Research.2021; Volume 14: 3289. CrossRef
Importance of NUDT15 Polymorphisms in Thiopurine Treatments
Yoichi Tanaka, Yoshiro Saito
Journal of Personalized Medicine.2021; 11(8): 778. CrossRef
Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease
Kang Chao, Yibiao Huang, Xia Zhu, Jian Tang, Xueding Wang, Lang Lin, Huili Guo, Caibin Zhang, Miao Li, Qingfan Yang, Jie Huang, Lingna Ye, Pinjin Hu, Min Huang, Qian Cao, Xiang Gao
Alimentary Pharmacology & Therapeutics.2021; 54(9): 1124. CrossRef
Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations
Kanyarat Khaeso, Sariya Udayachalerm, Patcharee Komvilaisak, Su-on Chainansamit, Kunanya Suwannaying, Napat Laoaroon, Pitchayanan Kuwatjanakul, Nontaya Nakkam, Chonlaphat Sukasem, Apichaya Puangpetch, Wichittra Tassaneeyakul, Nathorn Chaiyakunapruk
Frontiers in Pharmacology.2021;[Epub] CrossRef
High-resolution melt analysis enables simple genotyping of complicated polymorphisms of codon 18 rendering the NUDT15 diplotype
Yoichi Kakuta, Yasuhiro Izumiyama, Daisuke Okamoto, Takeru Nakano, Ryo Ichikawa, Takeo Naito, Rintaro Moroi, Masatake Kuroha, Yoshitake Kanazawa, Tomoya Kimura, Hisashi Shiga, Hisaaki Kudo, Naoko Minegishi, Yosuke Kawai, Katsushi Tokunaga, Masao Nagasaki,
Journal of Gastroenterology.2020; 55(1): 67. CrossRef
An intronic FTO variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patients
Sylvia Chen, Wei Zhi Tan, Natalia Sutiman, Cindy Lim, Sze Sing Lee, Wai Fook Leong, Madeline Tjai, Chunyan Wang, Chris San Choon Kong, Sai Wei Chuah, Brian John Schwender, Webber Chan, Hang Hock Shim, Wee Chian Lim, Chiea Chuen Khor, Khoon Lin Ling, Balra
The Pharmacogenomics Journal.2020; 20(3): 505. CrossRef
Precision therapy of 6‐mercaptopurine in Chinese children with acute lymphoblastic leukaemia
Yue Zhou, Li Wang, Xiao‐Ying Zhai, Li Wen, Fang Tang, Fan Yang, Xi‐Ting Liu, Lei Dong, Li‐Juan Zhi, Hai‐Yan Shi, Guo‐Xiang Hao, Yi Zheng, Evelyne Jacqz‐Aigrain, Tian‐You Wang, Wei Zhao
British Journal of Clinical Pharmacology.2020; 86(8): 1519. CrossRef
NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
Katsuyoshi Matsuoka
Intestinal Research.2020; 18(3): 275. CrossRef
Long‐term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine
Shintaro Akiyama, Katsuyoshi Matsuoka, Kyoko Fukuda, Shunsuke Hamada, Mikiko Shimizu, Kosaku Nanki, Shinta Mizuno, Hiroki Kiyohara, Mari Arai, Shinya Sugimoto, Yasushi Iwao, Haruhiko Ogata, Tadakazu Hisamatsu, Makoto Naganuma, Maiko Motobayashi, Kohei Suz
Journal of Gastroenterology and Hepatology.2019; 34(10): 1751. CrossRef
Systematic review with meta‐analysis: risk factors for thiopurine‐induced leukopenia in IBD
Sara van Gennep, Kadère Konté, Berrie Meijer, Martijn W. Heymans, Geert R. D’Haens, Mark Löwenberg, Nanne K. H. de Boer
Alimentary Pharmacology & Therapeutics.2019; 50(5): 484. CrossRef
Mycophenolate mofetil and prednisolone for cerebral sinus venous thrombosis with Behcet's disease
Shintaro Terashita, Tomomi Tanaka, Hiromichi Taneichi, Yuichi Adachi, Masaaki Mori
Pediatrics International.2019; 61(9): 920. CrossRef
Behcet's Disease With Cerebral Artery Infarction Caused by Cerebral Arteritis as an Early Symptom Only With Elevated Interleukin-8
Hao Yin, Yun Song, Meimei Zheng, Ju Han, Jiyou Tang
Frontiers in Neurology.2019;[Epub] CrossRef
Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping
Yoichi Kakuta, Yoshitaka Kinouchi, Tooru Shimosegawa
Journal of Gastroenterology.2018; 53(2): 172. CrossRef
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study
Yoichi Kakuta, Yosuke Kawai, Daisuke Okamoto, Tetsuya Takagawa, Kentaro Ikeya, Hirotake Sakuraba, Atsushi Nishida, Shoko Nakagawa, Miki Miura, Takahiko Toyonaga, Kei Onodera, Masaru Shinozaki, Yoh Ishiguro, Shinta Mizuno, Masahiro Takahara, Shunichi Yanai
Journal of Gastroenterology.2018; 53(9): 1065. CrossRef
Severe thiopurine‐induced leukocytopenia and hair loss in Japanese patients with defective NUDT15 variant: Retrospective case–control study
Mari Kishibe, Hiroyoshi Nozaki, Mizue Fujii, Shin Iinuma, Sawa Ohtsubo, Satomi Igawa, Kyoko Kanno, Masaru Honma, Kan Kishibe, Kensaku Okamoto, Akemi Ishida‐Yamamoto
The Journal of Dermatology.2018; 45(10): 1160. CrossRef
Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis
Sarah Cargnin, Armando A. Genazzani, Pier Luigi Canonico, Salvatore Terrazzino
Pharmacological Research.2018; 135: 102. CrossRef
A single‐center experience with methotrexate in the treatment of Chinese Crohn’s disease patients
Tian Rong Wang, Yu Qi Qiao, Duo Wu Zou, Zhi Hua Ran
Journal of Digestive Diseases.2018; 19(12): 753. CrossRef

7,776 View
101 Download
36 Web of Science
34 Crossref

Colonic dysmotility and morphological abnormality frequently detected in Japanese patients with irritable bowel syndrome: Takeshi Mizukami, Shinya Sugimoto, Tatsuhiro Masaoka, Hidekazu Suzuki, Takanori Kanai; Intest Res 2017;15(2):236-243. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.236

Abstract PDF PubReader ePub

Background/Aims

Colonoscopy and computed tomography (CT) are used primarily to exclude organic diseases in patients with irritable bowel syndrome (IBS), rather than to assess the pathophysiology of IBS. We aimed to evaluate colonic dysmotility and morphology in Japanese patients with IBS.

Methods

One hundred eighty-four patients with IBS and 49 asymptomatic controls who underwent colonoscopy in combination with CT colonography or barium enema were retrospectively reviewed between 2008 and 2012. Water-aided colonoscopy was performed without sedation by a single endoscopist. The duration and pattern of colonic movement and cecal intubation time were recorded. To assess colonic morphology, barium enema or CT colonography were performed immediately after colonoscopy.

Results

Colonic dysmotility was more frequent in the IBS group (28.8% vs. 2.0% in controls, P<0.001), especially in cases of IBS with diarrhea (IBS-D) (IBS with constipation [IBS-C] 28.8% vs. IBS-D 60.0% vs. mixed IBS [IBS-M] 5.1%, P<0.001). Colonic morphological abnormality was more frequent in the IBS group than in the control group (77.7% vs. 24.5%, P<0.001), especially in IBS-M and IBS-C groups (IBS-C 77.5% vs. IBS-D 48.9% vs. IBS-M 100%, P<0.001). Most patients with IBS with colonic dysmotility had experienced stress related to their symptoms. Cecal intubation time was significantly longer in the IBS group than in the control group (12.1±6.9 minutes vs. 4.6±1.9 minutes, P<0.001).

Conclusions

Unsedated colonoscopy, combined with radiographic findings, can detect colonic dysmotility and morphological abnormality. Technical difficulties observed during cecal intubation may partially explain the pathophysiology of IBS.

Citations

Citations to this article as recorded by

Ultrasound Imaging Equipment for Evaluating Chronic Constipation in Home Healthcare: A Review Article
Yohei Okawa
Gastrointestinal Disorders.2025; 7(1): 12. CrossRef
Efficacy of Glycicumarin and Isoliquiritigenin in Suppressing Colonic Peristalsis in Both an Animal Model and a Clinical Trial
Reo Kobayashi, Ken Inoue, Satoshi Sugino, Ryohei Hirose, Toshifumi Doi, Akihito Harusato, Osamu Dohi, Naohisa Yoshida, Kazuhiko Uchiyama, Takeshi Ishikawa, Tomohisa Takagi, Hideyuki Konishi, Yasuko Hirai, Katsura Mizushima, Yuji Naito, Yoshito Itoh
Biological and Pharmaceutical Bulletin.2024; 47(2): 373. CrossRef
Diagnostic Ability of Ultrasonography Compared with Computed Tomography for Assessing Rectal Feces
Noboru Misawa, Masaru Matsumoto, Momoko Tsuda, Shigeki Tamura, Tsutomu Yoshihara, Keiichi Ashikari, Takaomi Kessoku, Hidenori Ohkubo, Takuma Higurashi, Hiromi Sanada, Mototsugu Kato, Atsushi Nakajima
Journal of the Anus, Rectum and Colon.2024; 8(2): 126. CrossRef
Evidence-Based Clinical Guidelines for Chronic Constipation 2023
Eikichi Ihara, Noriaki Manabe, Hidenori Ohkubo, Naotaka Ogasawara, Haruei Ogino, Kazuki Kakimoto, Motoyori Kanazawa, Hidejiro Kawahara, Chika Kusano, Shiko Kuribayashi, Akinari Sawada, Tomohisa Takagi, Shota Takano, Toshihiko Tomita, Toshihiro Noake, Mari
Digestion.2024; : 1. CrossRef
The effect of alverine citrate plus simethicone (Meteospazmyl ) on effectiveness and tolerability of bowel preparation for colonoscopy
S.V. Kashin, D.V. Zavyalov, A.V. Sidneva
Dokazatel'naya gastroenterologiya.2023; 12(2): 34. CrossRef
Current Management of Chronic Constipation in Japan
Tatsuhiro Masaoka
The Keio Journal of Medicine.2023; 72(4): 95. CrossRef
Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
Shin Fukudo, Toshikatsu Okumura, Masahiko Inamori, Yusuke Okuyama, Motoyori Kanazawa, Takeshi Kamiya, Ken Sato, Akiko Shiotani, Yuji Naito, Yoshiko Fujikawa, Ryota Hokari, Tastuhiro Masaoka, Kazuma Fujimoto, Hiroshi Kaneko, Akira Torii, Kei Matsueda, Hiro
Journal of Gastroenterology.2021; 56(3): 193. CrossRef
NUTRITIONAL STATUS, QUALITY OF LIFE AND LIFE HABITS OF WOMEN WITH IRRITABLE BOWEL SYNDROME: A CASE-CONTROL STUDY
Ana Paula Monteiro de MENDONÇA, Luciana Miyuki YAMASHITA, Esther Dantas SILVA, Isabela SOLAR, Larissa Ariel Oliveira SANTOS, Ana Carolina Junqueira VASQUES
Arquivos de Gastroenterologia.2020; 57(2): 114. CrossRef

34,646 View
91 Download
5 Web of Science
8 Crossref

Current practices in endoscopic submucosal dissection for colorectal neoplasms: a survey of indications among Korean endoscopists: Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Young-Ho Kim, Dong Kyung Chang; Intest Res 2017;15(2):228-235. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.228

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

The indications for colorectal endoscopic submucosal dissection (ESD) vary in clinical practice. To establish colorectal ESD as a standard treatment, standard indications are essential. For establishing standard indications for colorectal ESD, we surveyed the preferences and criteria of endoscopists for colorectal ESD in their practices.

Methods

A multiple-choice questionnaire was sent to 27 members of the Korean Society of Gastrointestinal Endoscopy/ESD group. The indications of endoscopists for selecting ESD as a treatment for colorectal tumors ≥2 cm in diameter were surveyed.

Results

On the basis of the preprocedural assessment of histology, adenoma with high-grade dysplasia, mucosal cancer, and shallow submucosa invasive cancer were included in the indication for ESD. Based on gross morphology, laterally spreading tumor (LST) granular nodular mixed type, LST-nongranular (LST-NG) flat elevated type, and LST-NG pseudodepressed type were included. On the basis of the pit pattern by Kudo classification, types III, IV, and V-I were included. Based on the narrow band imaging pattern by Sano classification, types II and III-a were included. Other lesions, such as sporadic localized tumors in chronic inflammation and local residual early carcinoma after endoscopic resection, were also included in the indication for ESD.

Conclusions

The indications of Korean endoscopists for colorectal ESD are broader than those in recent guidelines, and tend to include more benign-looking tumors. To find the appropriate indications for colorectal ESD, systematic data collection and analysis are required to reach a consensus in a timely manner.

Citations

Citations to this article as recorded by

Traction methods for endoscopic submucosal dissection
Ji Hyun Kim, Sung Chul Park
Journal of Innovative Medical Technology.2024; 2(2): 47. CrossRef
Long-term prognosis of curative endoscopic submucosal dissection for early colorectal cancer according to submucosal invasion: a multicenter cohort study
Jongbeom Shin, Eun Ran Kim, Hyun Joo Jang, Dong Hoon Baek, Dong-Hoon Yang, Bo-In Lee, Kwang Bum Cho, Jin Woong Cho, Sung-Ae Jung, Su Jin Hong, Bong Min Ko, Jung-Won Jeon, Weon Jin Ko, Sun Moon Kim, Young Dae Kim, Kim Chan Gyoo, Gwang Ho Baik, In Kyung Yoo
BMC Gastroenterology.2022;[Epub] CrossRef
Risk of Covert Submucosal Cancer in Patients With Granular Mixed Laterally Spreading Tumors
Ferdinando D’Amico, Arnaldo Amato, Andrea Iannone, Cristina Trovato, Chiara Romana, Stefano Angeletti, Roberta Maselli, Franco Radaelli, Giancarla Fiori, Edi Viale, Emilio Di Giulio, Paola Soriani, Mauro Manno, Emanuele Rondonotti, Piera Alessia Galtieri,
Clinical Gastroenterology and Hepatology.2021; 19(7): 1395. CrossRef
Clinical practice guideline for endoscopic resection of early gastrointestinal cancer
Chan Hyuk Park, Dong-Hoon Yang, Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, Si Hyung Lee, Jung Ho Bae, Hyunsoo Chung, Kee Don Choi, Jun Chul Park, Hyuk Lee, Min-Seob Kwak, Bun Kim, Hyun Jung Lee, Hye Seung Lee, Miyoung Choi, Dong-Ah Park, Jong
Intestinal Research.2021; 19(2): 127. CrossRef
Colonoscopic Polypectomy Preferences of Asian Endoscopists: Results of a Survey-Based Study
Dong-Hoon Yang, Bayasgalan Luvsandagva, Quang Trung Tran, Achmad Fauzi, Panida Piyachaturawat, Thida Soe, Zhiqin Wong, Jeong-Sik Byeon
Gut and Liver.2021; 15(3): 391. CrossRef
Clinical outcomes of submucosal colorectal cancer diagnosed after endoscopic resection: a focus on the need for surgery
Yun Sik Choi, Wan Soo Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
Intestinal Research.2020; 18(1): 96. CrossRef
Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk Park, Dong-Hoon Yang, Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, Si Hyung Lee, Jung Ho Bae, Hyunsoo Chung, Kee Don Choi, Jun Chul Park, Hyuk Lee, Min-Seob Kwak, Bun Kim, Hyun Jung Lee, Hye Seung Lee, Miyoung Choi, Dong-Ah Park, Jong
Clinical Endoscopy.2020; 53(2): 142. CrossRef
Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk Park, Dong-Hoon Yang, Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, Si Hyung Lee, Jung Ho Bae, Hyunsoo Chung, Kee Don Choi, Jun Chul Park, Hyuk Lee, Min-Seob Kwak, Bun Kim, Hyun Jung Lee, Hye Seung Lee, Miyoung Choi, Dong-Ah Park, Jong
The Korean Journal of Gastroenterology.2020; 75(5): 264. CrossRef
Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk Park, Dong-Hoon Yang, Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, Si Hyung Lee, Jung Ho Bae, Hyunsoo Chung, Kee Don Choi, Jun Chul Park, Hyuk Lee, Min-Seob Kwak, Bun Kim, Hyun Jung Lee, Hye Seung Lee, Miyoung Choi, Dong-Ah Park, Jong
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2020; 20(2): 117. CrossRef
The risk factors for delayed bleeding after endoscopic resection of colorectal tumors: a meta-analysis
Yanqin Xu, Shishun Zhong, Wei Liang, Xiao Lu Lin
Expert Review of Gastroenterology & Hepatology.2020; 14(11): 1083. CrossRef
Clinical outcomes of endoscopic resection for colorectal laterally spreading tumors with advanced histology
Jin-Sung Jung, Ji-Yun Hong, Hyung-Hoon Oh, Sun-Seog Kweon, Jun Lee, Sang-Wook Kim, Geom-Seog Seo, Hyun-Soo Kim, Young-Eun Joo
Surgical Endoscopy.2019; 33(8): 2562. CrossRef
Clinicopathological feature and treatment outcome of patients with colorectal laterally spreading tumors treated by endoscopic submucosal dissection
Young-Hoon Jeong, Jun Lee, Sang-Wook Kim, Geom-Seog Seo, Hyun-Soo Kim, Young-Eun Joo
Intestinal Research.2019; 17(1): 127. CrossRef
Outcomes of ulcerative colitis‐associated dysplasia patients referred for potential endoscopic submucosal dissection
Dong‐Hoon Yang, Jihun Kim, Eun Mi Song, Kiju Chang, Sun‐Ho Lee, Sung Wook Hwang, Sang Hyoung Park, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang
Journal of Gastroenterology and Hepatology.2019; 34(9): 1581. CrossRef
Recurrence rate of lateral margin-positive cases after en bloc endoscopic submucosal dissection of colorectal neoplasia
Seohyun Lee, Jihun Kim, Jae Seung Soh, Jungho Bae, Sung Wook Hwang, Sang Hyoung Park, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Dong-Hoon Yang
International Journal of Colorectal Disease.2018; 33(6): 735. CrossRef
Risk factors for procedure-related complications after endoscopic resection of colorectal laterally spreading tumors
Ji-Yun Hong, Sun-Seog Kweon, Jun Lee, Sang-Wook Kim, Geom-Seog Seo, Hyun-Soo Kim, Young-Eun Joo
Medicine.2018; 97(41): e12589. CrossRef

5,620 View
65 Download
15 Web of Science
15 Crossref

Clinical outcome of endoscopic management in delayed postpolypectomy bleeding: Jeong-Mi Lee, Wan Soo Kim, Min Seob Kwak, Sung-Wook Hwang, Dong-Hoon Yang, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon; Intest Res 2017;15(2):221-227. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.221

Abstract PDF PubReader ePub

Background/Aims

The clinical course after endoscopic management of delayed postpolypectomy bleeding (DPPB) has not been clearly determined. This study aimed to assess clinical outcomes after endoscopic hemostasis of DPPB and evaluate risk factors for rebleeding after initial hemostasis.

Methods

We reviewed medical records of 198 patients who developed DPPB and underwent endoscopic hemostasis between January 2010 and February 2015. The performance of endoscopic hemostasis was assessed. Rebleeding negative and positive patients were compared.

Results

DPPB developed 1.4±1.6 days after colonoscopic polypectomy. All patients achieved initial hemostasis. Clipping was the most commonly used technique. Of 198 DPPB patients, 15 (7.6%) had rebleeding 3.3±2.5 days after initial hemostasis. The number of clips required for hemostasis was higher in the rebleeding positive group (3.2±1.6 vs. 4.2±1.9, P=0.047). Combinations of clipping with other modalities such as injection methods were more common in the rebleeding positive group (67/291, 23.0% vs. 12/17, 70.6%; P<0.001). Multivariate analysis showed a large number of clips and combination therapy were independent risk factors for rebleeding. All the rebleeding cases were successfully managed by repeat endoscopic hemostasis.

Conclusions

Endoscopic hemostasis is effective for the management of DPPB because of its high initial hemostasis rate and low rebleeding rate. Endoscopists should carefully observe patients in whom a large number of clips and/or combination therapy have been used to manage DPPB because these may be related to the severity of DPPB and a higher risk of rebleeding.

Citations

Citations to this article as recorded by

Updates on the Prevention and Management of Post-Polypectomy Bleeding in the Colon
Hisham Wehbe, Aditya Gutta, Mark A. Gromski
Gastrointestinal Endoscopy Clinics of North America.2024; 34(2): 363. CrossRef
The Use of Clips to Prevent Post-Polypectomy Bleeding: A Clinical Review
Matthew A. O’Mara, Peter G. Emanuel, Aaron Tabibzadeh, Robert J. Duve, Jonathan S. Galati, Gregory Laynor, Samantha Gross, Seth A. Gross
Journal of Clinical Gastroenterology.2024; 58(8): 739. CrossRef
Is endoscopic hemostasis safe and effective for delayed post-polypectomy bleeding?
Jae-Yong Cho, Yunho Jung, Han Hee Lee, Jung-Wook Kim, Kee Myung Lee, Hyun Lim, Geun-Hyuk Choi, Seong Woo Choi, Bo-In Lee
International Journal of Gastrointestinal Intervention.2024; 13(4): 122. CrossRef
Endoscopic management of delayed bleeding after polypectomy of small colorectal polyps: two or more clips may be safe
Xue-Feng Guo, Xiang-An Yu, Jian-Cong Hu, De-Zheng Lin, Jia-Xin Deng, Ming-Li Su, Juan Li, Wei Liu, Jia-Wei Zhang, Qing-Hua Zhong
Gastroenterology Report.2022;[Epub] CrossRef
Management and Outcomes of Bleeding Within 30 Days of Colonic Polypectomy in a Large, Real-Life, Multicenter Cohort Study
Enrique Rodríguez de Santiago, Maria Hernández-Tejero, Liseth Rivero-Sánchez, Oswaldo Ortiz, Irene García de la Filia-Molina, Jose Ramon Foruny-Olcina, Hector Miguel Marcos Prieto, Maria García-Prada, Almudena González-Cotorruelo, Miguel Angel De Jorge Tu
Clinical Gastroenterology and Hepatology.2021; 19(4): 732. CrossRef
Clinical Features of Re-Colonoscopy after Bleeding after Intestinal Polypectomy
慧敏翟
Advances in Clinical Medicine.2021; 11(11): 5151. CrossRef
Systematic literature review of learning curves for colorectal polyp resection techniques in lower gastrointestinal endoscopy
A. Rajendran, S. Pannick, S. Thomas‐Gibson, S. Oke, C. Anele, N. Sevdalis, A. Haycock
Colorectal Disease.2020; 22(9): 1085. CrossRef
Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy
Hosim Soh, Jaeyoung Chun, Seung Wook Hong, Seona Park, Yun Bin Lee, Hyun Jung Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jong Pil Im, Yoon Jun Kim, Joo Sung Kim, Jung-Hwan Yoon
Gut and Liver.2020; 14(6): 755. CrossRef
Post-polypectomy Visible Vessel
Matthew Woo, Robert Bechara
Journal of the Canadian Association of Gastroenterology.2018; 1(2): 51. CrossRef
Comprehensive review of outcomes of endoscopic treatment of gastrointestinal bleeding
Tae-Geun Gweon, Jinsu Kim
International Journal of Gastrointestinal Intervention.2018; 7(3): 123. CrossRef

5,657 View
73 Download
8 Web of Science
10 Crossref

Clinical outcomes of sigmoid colon volvulus: identification of the factors associated with successful endoscopic detorsion: Tomoya Iida, Suguru Nakagaki, Shuji Satoh, Haruo Shimizu, Hiroyuki Kaneto, Hiroshi Nakase; Intest Res 2017;15(2):215-220. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.215

Abstract PDF PubReader ePub

Background/Aims

Although multiple treatment options exist for the management of sigmoid colon volvulus, no study has examined the factors associated with successful endoscopic detorsion. This study aimed to examine the clinical course of patients with sigmoid colon volvulus and to identify factors related to successful endoscopic detorsion.

Methods

This study included 30 cases (21 patients) of sigmoid volvulus from among 545 cases of intestinal obstruction at a single center. We retrospectively examined the clinical course and the factors associated with the possibility of endoscopic detorsion of sigmoid colon volvulus.

Results

The rate of laxative use among the study participants was 76.2%; the rate of comorbid neuropsychiatric disorders was 61.9%; and 57.1% of patients had a history of open abdominal surgery. All patients were initially treated with endoscopic detorsion, and this procedure had a 61.9% success rate. The recurrence rate after detorsion was as high as 46.2%, but detorsion during revision endoscopy was possible in all cases. Statistical analysis revealed that the absence of abdominal tenderness (P=0.027), the use of laxatives (P=0.027), and a history of open abdominal surgery (P=0.032) were factors predictive of successful endoscopic detorsion.

Conclusions

The results of our study are consistent with previous reports with respect to the success rate of endoscopic detorsion, the subsequent recurrence rate, and the proportion of patients requiring surgical treatment. In addition, we identified the absence of abdominal tenderness, the use of laxatives, and history of open abdominal surgery as factors predicting successful endoscopic detorsion of sigmoid colon volvulus.

Citations

Citations to this article as recorded by

Evaluating Racial Disparities in 30-day Outcomes for African Americans Following Colectomy for Volvulus
Renxi Li, Susan Kartiko
The American Surgeon™.2025; 91(2): 266. CrossRef
Clinical outcome of patients treated with endoscopic decompression after failure of detorsion for uncomplicated sigmoid volvulus
Dai Nakamatsu, Tsutomu Nishida, Aya Sugimoto, Kengo Matsumoto, Masashi Yamamoto
DEN Open.2024;[Epub] CrossRef
Comments on “Percutaneous Endoscopic Sigmoidopexy: Still a Way to Go”
Sabri Selcuk Atamanalp
GE - Portuguese Journal of Gastroenterology.2024; 31(3): 151. CrossRef
Dependent functional status is an independent risk factor for 30-day mortality and morbidities following colectomy for volvulus: An ACS-NSQIP study from the United States
Renxi Li
Clinics and Research in Hepatology and Gastroenterology.2024; 48(7): 102391. CrossRef
Sigmoid volvulus as a rare cause of intestinal obstruction in the pediatric population: case series and literature review
Isabel C. Brito Rojas, Mayra A. Hernández Peñuela, Vanessa Medina Gaviria, Martin La Rotta, John M. Escobar Echeverri
International Journal of Surgery Open.2024; 62(2): 149. CrossRef
Transanal Decompression Tube Placement for Treatment of Sigmoid Volvulus
Sakurako Hattori, Osamu Aramaki, Yoshihiro Watanabe, Tomohisa Kamo, Tadashi Furihata, Takafumi Ushiku, Ryuugaku Kaneshiro, Yuichi Kasakura, Isao Murayama, Hiroharu Yamashita, Yukiyasu Okamura
Journal of the Anus, Rectum and Colon.2024; 8(4): 305. CrossRef
Endoscopic Decompression of Sigmoid Volvulus: Review of 748 Patients
Sabri Selcuk Atamanalp
Journal of Laparoendoscopic & Advanced Surgical Techniques.2022; 32(7): 763. CrossRef
Initial Computed Tomography Findings of Long and Distended Colon Are Risk Factors for the Recurrence of Sigmoid Volvulus
Ryusaku Kusunoki, Hirofumi Fujishiro, Tatsuya Miyake, Shinsuke Suemitsu, Masatoshi Kataoka, Aya Fujiwara, Kosuke Tsukano, Satoshi Kotani, Satoshi Yamanouchi, Masahito Aimi, Masaki Tanaka, Youichi Miyaoka, Naruaki Kohge, Tomonori Imaoka, Kouji Yuasa, Kouji
Digestive Diseases and Sciences.2021; 66(4): 1162. CrossRef
Risk factors affecting failure of colonoscopic detorsion for sigmoid colon volvulus: a single center experience
Ahmet Surek, Cevher Akarsu, Eyup Gemici, Sina Ferahman, Ahmet Cem Dural, Mehmet Abdussamet Bozkurt, Turgut Donmez, Mehmet Karabulut, Halil Alis
International Journal of Colorectal Disease.2021; 36(6): 1221. CrossRef
The Association of Coloproctology of Great Britain and Ireland consensus guidelines in emergency colorectal surgery
Andrew S. Miller, Kathryn Boyce, Benjamin Box, Matthew D. Clarke, Sarah E. Duff, Niamh M. Foley, Richard J. Guy, Lisa H. Massey, George Ramsay, Dominic A. J. Slade, James A. Stephenson, Phil J. Tozer, Danette Wright
Colorectal Disease.2021; 23(2): 476. CrossRef
Endoscopic Detorsion for Early Postoperative Roux Limb Torsion after Laparoscopic Gastrectomy: A Case Report and Literature Review
Nobuyuki Sakurazawa, Hiroki Arai, Tomohiko Yasuda, Komei Kuge, Shou Kuriyama, Hideyuki Suzuki, Hiroshi Yoshida
Journal of Nippon Medical School.2021; 88(6): 544. CrossRef
Perioperative Outcomes and Predictors of Mortality After Surgery for Sigmoid Volvulus
Anthony Easterday, Sarah Aurit, Rebecca Driessen, Austin Person, Devi Mukkai Krishnamurty
Journal of Surgical Research.2020; 245: 119. CrossRef
American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the management of acute colonic pseudo-obstruction and colonic volvulus
Mariam Naveed, Laith H. Jamil, Larissa L. Fujii-Lau, Mohammad Al-Haddad, James L. Buxbaum, Douglas S. Fishman, Terry L. Jue, Joanna K. Law, Jeffrey K. Lee, Bashar J. Qumseya, Mandeep S. Sawhney, Nirav Thosani, Andrew C. Storm, Audrey H. Calderwood, Mouen
Gastrointestinal Endoscopy.2020; 91(2): 228. CrossRef
Endoscopic Decompression of Recurrent Sigmoid Volvulus in Pregnancy
Nathaly Cortez, Manuel Berzosa, Kiranmayi Muddasani, Kfir Ben-David
Journal of Investigative Medicine High Impact Case Reports.2020;[Epub] CrossRef
Endoscopic Management of Sigmoid Volvulus in a Debilitated Population: What Relevance?
Manuel Coelho da Rocha, Tiago Capela, Mário Jorge Silva, Gonçalo Ramos, João Coimbra
GE - Portuguese Journal of Gastroenterology.2020; 27(3): 160. CrossRef
Author's Reply
Tomoya Iida, Hiroyuki Kaneto, Hiroshi Nakase
Intestinal Research.2017; 15(4): 554. CrossRef
Comments on clinical outcomes of sigmoid colon volvulus: identification of the factors associated with successful endoscopic detorsion
Sabri Selcuk Atamanalp
Intestinal Research.2017; 15(4): 552. CrossRef

7,480 View
97 Download
24 Web of Science
17 Crossref

Diagnostic and prognostic value of preoperative ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography for colorectal cancer: comparison with conventional computed tomography: Joo Young Lee, Soon Man Yoon, Jeong Tae Kim, Ki Bae Kim, Mi Jin Kim, Jae Geun Park, Taek-Gu Lee, Sang-Jeon Lee, Sung Soo Koong, Joung-Ho Han, Hee Bok Chae, Seon Mee Park, Sei Jin Youn; Intest Res 2017;15(2):208-214. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.208

Abstract PDF PubReader ePub

Background/Aims

¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) has been used for preoperative staging of colorectal cancer (CRC). However, the diagnostic accuracy of FDG-PET/CT for detection of lymph node or distant metastasis and its prognostic role have not been well established. We therefore evaluated the diagnostic and prognostic value of FDG-PET/CT in comparison with conventional CT for CRC.

Methods

We investigated 220 patients who underwent preoperative FDG-PET/CT and CT, followed by curative surgery for CRC. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of FDG-PET/CT and CT for detection of lymph node metastasis and distant metastasis were evaluated. In addition, we assessed the findings of FDG-PET/CT and CT according to outcomes, including cancer recurrence and cancer-related death, for evaluation of prognostic value.

Results

For detection of lymph node metastasis, FDG-PET/CT had a sensitivity of 44%, a specificity of 84%, and an accuracy of 67%, compared with 59%, 65%, and 62%, respectively, for CT (P=0.029, P=0.000, and P=0.022). For distant metastasis, FDG-PET/CT had a sensitivity of 79%, a specificity of 94%, and an accuracy of 93%, compared with 79%, 87%, and 86%, respectively, for CT (P=1.000, P=0.004, and P=0.037). In addition, positive findings of lymph node metastasis and distant metastasis on FDG-PET/CT were associated significantly with cancer recurrence or cancer-related death (P=0.009, P=0.001, respectively).

Conclusions

Preoperative FDG-PET/CT had a higher specificity and accuracy compared to CT for detection of lymph node metastasis and distant metastasis of CRC. In addition, FDG-PET/CT could be a valuable prognostic tool for CRC.

Citations

Citations to this article as recorded by

Nuclear medicine based multimodal molecular imaging facilitates precision medicine for gastrointestinal tumors
Jing Zhao, Fei Wang, Rong-Fu Wang
World Chinese Journal of Digestology.2024; 32(10): 727. CrossRef
Tomographie par émission de positons en cancérologie digestive
C. Aveline, F. Montravers
EMC - Radiologie et imagerie médicale - Abdominale - Digestive.2024; 42(1): 1. CrossRef
Retrospective audit: Utility of PET scan in routine preoperative rectal cancer staging
Michelle Zhiyun Chen, Xinyi Zhang, Milton Mui, Joseph C. H. Kong, Alexander G. Heriot, Jodie Ellis‐Clark
ANZ Journal of Surgery.2023; 93(3): 617. CrossRef
Impact of routine preoperative 18FDG PET/CT on the surgical management of primary colorectal cancer
Mónica Mogollón‐González, Raquel Conde‐Muiño, Antonio Rodríguez‐Fernández, Mar Navarro‐Pelayo, Mireia Domínguez‐Bastante, Pablo Palma
Journal of Surgical Oncology.2023; 128(2): 295. CrossRef
Investigating ultra-low-dose total-body [18F]-FDG PET/CT in colorectal cancer: initial experience
Hui Tan, Danjie Cai, Xiuli Sui, Chi Qi, Wujian Mao, Yiqiu Zhang, Guobing Liu, Haojun Yu, Shuguang Chen, Pengcheng Hu, Jianying Gu, Hongcheng Shi
European Journal of Nuclear Medicine and Molecular Imaging.2022; 49(3): 1002. CrossRef
Tailoring the clinical management of colorectal cancer by 18F-FDG PET/CT
Yang Shi, Meiqi Wang, Jiyu Zhang, Zheng Xiang, Can Li, Jingjing Zhang, Xing Ma
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical TNM staging for esophageal, gastric, and colorectal cancers in the era of neoadjuvant therapy: A systematic review of the literature
Hideaki Shimada, Takeo Fukagawa, Yoshio Haga, Shin‐ichi Okazumi, Koji Oba
Annals of Gastroenterological Surgery.2021; 5(4): 404. CrossRef
The significant value of predicting prognosis in patients with colorectal cancer using 18F-FDG PET metabolic parameters of primary tumors and hematological parameters
Junyan Xu, Yi Li, Silong Hu, Linjun Lu, Zhiqi Gao, Huiyu Yuan
Annals of Nuclear Medicine.2019; 33(1): 32. CrossRef
Optimal Interval for 18F-FDG-PET After Chemoradiotherapy for Rectal Cancer
Kazushige Kawai, Hiroaki Nozawa, Keisuke Hata, Toshiaki Tanaka, Takeshi Nishikawa, Koji Oba, Toshiaki Watanabe
Clinical Colorectal Cancer.2018; 17(2): e163. CrossRef
Preoperative PET/CT 18F-FDG Standardized Uptake by Lymph Nodes as a Significant Prognostic Factor in Patients with Colorectal Cancer
Ruohua Chen, Yining Wang, Xiang Zhou, Gang Huang, Jianjun Liu
Contrast Media & Molecular Imaging.2018; 2018: 1. CrossRef

6,450 View
63 Download
10 Web of Science
10 Crossref

Red flag symptoms: detailed account of clinicopathological features in young-onset colorectal cancer: Ramish Riaz, Nosheen Masood, Arfa Benish; Intest Res 2017;15(2):203-207. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.203

Abstract PDF PubReader ePub

Background/Aims

Colorectal cancer has long been considered disease of the West, typically occurring in old age; however, the incidence is rising in Asia. The pattern of disease is quite different in Asia, occurring at a younger age and at an advanced stage. Recognition of disease at an early stage is still a challenge for physicians. Few data are available regarding young-onset colorectal cancer in Pakistan. We conducted this study to fill this gap and provide deeper insight into clinical symptoms and histopathological features of young-onset colorectal cancer.

Methods

We collected data regarding clinical features by directly interviewing patients and obtaining histopathological data from hospital records. Patients aged less than 50 years were included in the study. Statistical analysis was performed using IBM SPSS version 20.0.

Results

Results in 105 patients showed mean age at diagnosis was 35.90±9.39, with male predominance; the majority of patients had no family history of colorectal cancer. Most patients had left-sided tumors with advance stage and intermediate grade (grade 2). Mucinous histology was common. Rectal bleeding was the first symptom for left-sided tumors, whereas most of the right-sided lesions presented with sudden obstruction.

Conclusions

Painless rectal bleeding in the early thirties should alert physicians to advise appropriate investigation, as the majority of young-onset colorectal cancer patients develop painless bleeding 2 to 3 years before appearance of other symptoms.

Citations

Citations to this article as recorded by

Genetic and transcriptomic analyses of early-onset colon cancer (EOCC): a post hoc analysis of 2973 patients from two adjuvant randomized trials
A. Gandini, C. Gallois, H. Blons, C. Mulot, N. Agueeff, C. Lepage, R. Guimbaud, L. Mineur, J. Desramé, B. Chibaudel, A. de Reyniès, T. André, P. Laurent-Puig, J. Taieb
ESMO Gastrointestinal Oncology.2025; 7: 100106. CrossRef
Trends and Symptoms Among Increasing Proportion of African Americans with Early-Onset Colorectal Cancer over a 60-Year Period
Hassan Brim, Challa Suryanarayana Reddy, Lakshmi Chirumamilla, Gholamreza Oskrochi, Mrinalini Deverapalli, Rumaisa Rashid, Mudasir Rashid, Vaisakh Nair, Nicole Morrison, Danae Byer, Trae Thompson, Belal Yasin, David Johnson, Alicia Snowden, Priscilla Mamm
Digestive Diseases and Sciences.2025; 70(1): 168. CrossRef
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Jennifer Haynes, Prasath Manogaran
International Journal of Molecular Sciences.2025; 26(5): 1988. CrossRef
Comparison of clinical features and prognosis of early- and late-onset colorectal cancer
Xian Long, Yue Wang, Zi-Qing Jian, Qiong He
World Chinese Journal of Digestology.2024; 32(2): 116. CrossRef
Symptom Burden and Time from Symptom Onset to Cancer Diagnosis in Patients with Early-Onset Colorectal Cancer: A Multicenter Retrospective Analysis
Victoria A. Baronas, Arif A. Arif, Eric Bhang, Gale K. Ladua, Carl J. Brown, Fergal Donnellan, Sharlene Gill, Heather C. Stuart, Jonathan M. Loree
Current Oncology.2024; 31(4): 2133. CrossRef
Multimodal Treatment of Metastatic Rectal Cancer in a Young Patient: Case Report and Literature Review
Ionuț Popescu, Ana-Maria Dudău, Simona Dima, Vlad Herlea, Vlad M. Croitoru, Ioana Mihaela Dinu, Monica Miron, Ioana Lupescu, Irina M. Croitoru-Cazacu, Radu Dumitru, Adina Emilia Croitoru
Medicina.2024; 60(5): 696. CrossRef
Red Flag Signs and Symptoms for Patients With Early-Onset Colorectal Cancer
Joshua Demb, Jennifer M. Kolb, Jonathan Dounel, Cassandra D. L. Fritz, Shailesh M. Advani, Yin Cao, Penny Coppernoll-Blach, Andrea J. Dwyer, Jose Perea, Karen M. Heskett, Andreana N. Holowatyj, Christopher H. Lieu, Siddharth Singh, Manon C. W. Spaander, F
JAMA Network Open.2024; 7(5): e2413157. CrossRef
Clinicopathological features and short-term surgical outcomes of early-onset versus late-onset colorectal cancer at a tertiary hospital in Tanzania: A retrospective-cohort study
George Kanani, Samwel Byabato, Jasmine Mrisho, Vihar Kotecha, Yasin Munis, Felician Kachinde, Ahmed Binde
Surgical Oncology Insight.2024; 1(3): 100061. CrossRef
Early-Onset colorectal Cancer: From the laboratory to the clinic
Annalice Gandini, Julien Taieb, Hélène Blons, Jeanne Netter, Pierre Laurent-Puig, Claire Gallois
Cancer Treatment Reviews.2024; 130: 102821. CrossRef
Differences in characteristics and outcomes between early-onset colorectal cancer and late-onset colorectal cancers
Chun-Kai Liao, Yu-Jen Hsu, Yih-Jong Chern, Yen-Lin Yu, Yueh-Chen Lin, Pao-Shiu Hsieh, Jy-Ming Chiang, Jeng-Fu You
European Journal of Surgical Oncology.2024; 50(12): 108687. CrossRef
Clinicopathologic Characteristics Influencing Overall Survival of Patients With Early- Versus Average-Onset Colorectal Cancer at a Tertiary Care Center in Indonesia
Susanna Hilda Hutajulu, Daniel Howdon, Yasjudan Rastrama Putra, Susanti Susanti, Didik Setyo Heriyanto, Naomi Yoshuantari, Adeodatus Yuda Handaya, Bambang Purwanto Utomo, Sri Retna Dwidanarti, Johan Kurnianda, Aru Wisaksono Sudoyo, Mohammad Ilyas, Matthew
JCO Global Oncology.2024;[Epub] CrossRef
Is early-onset colorectal cancer an evolving pandemic? Real-world data from a tertiary cancer center
Angelos Angelakas, Thekla Christodoulou, Konstantinos Kamposioras, Jorge Barriuso, Michael Braun, Jurjees Hasan, Kalena Marti, Vivek Misra, Saifee Mullamitha, Mark Saunders, Natalie Cook
The Oncologist.2024; 29(12): e1680. CrossRef
A 21-Year-Old Male With Metastatic Colorectal Cancer: A Case Report and Literature Overview of Early-Onset Colorectal Cancer
Daniel Aintabi, Stephanie Mackenzie, Wael Al-Yaman, Kevin Wenzke, Jeffrey Berinstein
Cureus.2024;[Epub] CrossRef
Oncotherapeutic Strategies in Early Onset Colorectal Cancer
Mary O’Reilly, Anna Linehan, Aleksandar Krstic, Walter Kolch, Kieran Sheahan, Des C. Winter, Ray Mc Dermott
Cancers.2023; 15(2): 552. CrossRef
Characteristics and symptomatology of colorectal cancer in the young
Mary Kate Skalitzky, Peige P. Zhou, Paolo Goffredo, Kristina Guyton, Scott K. Sherman, Irena Gribovskaja-Rupp, Imran Hassan, Muneera R. Kapadia, Jennifer E. Hrabe
Surgery.2023; 173(5): 1137. CrossRef
Early-onset colorectal cancer: A review of current knowledge
Margarida R Saraiva, Isadora Rosa, Isabel Claro
World Journal of Gastroenterology.2023; 29(8): 1289. CrossRef
Sulfur Metabolism of the Gut Microbiome and Colorectal Cancer: The Threat to the Younger Generation
Ji-Yeon Moon, Bong-Hyeon Kye, Seung-Hyun Ko, Ri Na Yoo
Nutrients.2023; 15(8): 1966. CrossRef
Early-Onset Colorectal Cancer: Current Insights
Fauzia Ullah, Ashwathy Balachandran Pillai, Najiullah Omar, Danai Dima, Seema Harichand
Cancers.2023; 15(12): 3202. CrossRef
Early Onset Metastatic Colorectal Cancer: Current Insights and Clinical Management of a Rising Condition
Bianca Medici, Beatrice Riccò, Eugenia Caffari, Silvia Zaniboni, Massimiliano Salati, Andrea Spallanzani, Ingrid Garajovà, Stefania Benatti, Chiara Chiavelli, Massimo Dominici, Fabio Gelsomino
Cancers.2023; 15(13): 3509. CrossRef
The analysis between clinicopathological aspect of early-onset vs. late-onset colorectal cancer and mortality rate: a cross-sectional study
Kiki Lukman, Andi Mulyawan, Annisa Dewi Nugrahani, Reno Rudiman, Etis Primastari
Annals of Medicine & Surgery.2023; 85(6): 2496. CrossRef
The role of colonoscopy in young patients with rectal bleeding: a systematic review and meta-analysis
Tuane Colles, Patrícia K. Ziegelmann, Daniel C. Damin
International Journal of Colorectal Disease.2023;[Epub] CrossRef
A comprehensive framework for early-onset colorectal cancer research
Cathy Eng, Alexandre A Jácome, Rajiv Agarwal, Muhammad Hashim Hayat, Mariana X Byndloss, Andreana N Holowatyj, Christina Bailey, Christopher H Lieu
The Lancet Oncology.2022; 23(3): e116. CrossRef
Strengthening Breast Cancer Screening Mammography Services in Pakistan Using Islamabad Capital Territory as a Pilot Public Health Intervention
Ayesha Isani Majeed, Assad Hafeez, Shahzad Ali Khan
Healthcare.2022; 10(6): 1106. CrossRef
Young-onset colorectal cancer risk among individuals with iron-deficiency anaemia and haematochezia
Joshua Demb, Lin Liu, Caitlin C. Murphy, Chyke A. Doubeni, María Elena Martínez, Samir Gupta
Gut.2021; 70(8): 1529. CrossRef
Is colorectal cancer associated with altered bowel habits in young patients?
Ashray Rajagopalan, Ellathios Antoniou, Marina Morkos, Ellen Rajagopalan, Asiri Arachchi, Hanumant Chouhan, Thang Chien Nguyen, William Teoh
ANZ Journal of Surgery.2021; 91(5): 943. CrossRef
Why is colorectal cancer increasing in younger age groups in the United States?
Obaida Dairi, Joseph C. Anderson, Lynn F. Butterly
Expert Review of Gastroenterology & Hepatology.2021; 15(6): 623. CrossRef
The Time to Act Is Now: The Rationale to Start Colorectal Cancer Screening at Age 45
Peter M. Fields, Joseph C. Anderson, Stacey A. Fedewa
Current Treatment Options in Gastroenterology.2021; 19(3): 421. CrossRef
Assessing Presenting Symptoms, Co-Morbidities, and Risk Factors for Mortality in Underserved Patients With Non-Hereditary Early-Onset Colorectal Cancer
Shravani Reddy, Awf Mouchli, Lindsey Bierle, Miranda Gerrard, Chirstopher Walsh, Adil Mir, David P Lebel, Christopher Mason, Douglas Grider, Marrieth Rubio
Cureus.2021;[Epub] CrossRef
Colorectal cancer patients in a tertiary hospital in Indonesia: Prevalence of the younger population and associated factors
Dadang Makmun, Marcellus Simadibrata, Murdani Abdullah, Ari F Syam, Hamzah Shatri, Achmad Fauzi, Kaka Renaldi, Hasan Maulahela, Amanda P Utari, Rabbinu R Pribadi, Virly N Muzellina, Saskia A Nursyirwan
World Journal of Clinical Cases.2021; 9(32): 9804. CrossRef
Obscure Gastrointestinal Bleeding Due to Colonic Source
Robert W. Klapheke, Ethan Bortniker
Current Treatment Options in Gastroenterology.2020; 18(3): 394. CrossRef
AGA Clinical Practice Update on Young Adult–Onset Colorectal Cancer Diagnosis and Management: Expert Review
Lisa A. Boardman, Eduardo Vilar, Y. Nancy You, Jewel Samadder
Clinical Gastroenterology and Hepatology.2020; 18(11): 2415. CrossRef
Age at menarche and risk of colorectal adenoma
Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn, Kyuyong Choi, Yoon Suk Jung
The Korean Journal of Internal Medicine.2019; 34(5): 998. CrossRef
Early‐onset colorectal cancer in young individuals
Gianluca Mauri, Andrea Sartore‐Bianchi, Antonio‐Giampiero Russo, Silvia Marsoni, Alberto Bardelli, Salvatore Siena
Molecular Oncology.2019; 13(2): 109. CrossRef
Colorectal Cancer in Young Adults
Anand Venugopal, Elena M. Stoffel
Current Treatment Options in Gastroenterology.2019; 17(1): 89. CrossRef
Analysis of population‐based colorectal cancer screening in Guangzhou, 2011‐2015
Feng Zhiqiang, Cao Jie, Nie Yuqiang, Gong Chenghua, Wang Hong, Sun Zheng, Li Wanglin, Zhou Yongjian, Dai Liping, Zeng Lizhong, Zhao DeJian
Cancer Medicine.2019; 8(5): 2496. CrossRef
Optimal Starting Age for Colorectal Cancer Screening in an Era of Increased Metabolic Unhealthiness: A Nationwide Korean Cross-Sectional Study
Yoon Jin Choi, Dong Ho Lee, Kyung-Do Han, Hyun Soo Kim, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim
Gut and Liver.2018; 12(6): 655. CrossRef
Is colorectal cancer screening necessary before 50 years of age?
Yoon Suk Jung
Intestinal Research.2017; 15(4): 550. CrossRef

7,544 View
92 Download
33 Web of Science
37 Crossref

Patients with computed tomography-proven acute diverticulitis require follow-up to exclude colorectal cancer: Shafquat Zaman, Warren Chapman, Imtiyaz Mohammed, Kathryn Gill, Stephen Thomas Ward; Intest Res 2017;15(2):195-202. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.195

Abstract PDF PubReader ePub

Background/Aims

Traditionally, patients with acute diverticulitis undergo follow-up endoscopy to exclude colorectal cancer (CRC). However, its usefulness has been debated in this era of high-resolution computed tomography (CT) diagnosis. We assessed the frequency and outcome of endoscopic follow-up for patients with CT-proven acute diverticulitis, according to the confidence in the CT diagnosis.

Methods

Records of patients with CT-proven acute diverticulitis between October 2007 and March 2014 at Sandwell & West Birmingham Hospitals NHS Trust were retrieved. The National Cancer Registry confirmed the cases of CRC. Endoscopy quality indicators were compared between these patients and other patients undergoing the same endoscopic examination over the same period.

Results

We identified 235 patients with CT-proven acute diverticulitis, of which, 187 were managed conservatively. The CT report was confident of the diagnosis of acute diverticulitis in 75% cases. Five of the 235 patients were subsequently diagnosed with CRC (2.1%). Three cases of CRC were detected in the 187 patients managed conservatively (1.6%). Forty-eight percent of the conservatively managed patients underwent follow-up endoscopy; one case of CRC was identified. Endoscopies were often incomplete and caused more discomfort for patients with diverticulitis compared with controls.

Conclusions

CRC was diagnosed in patients with CT-proven diverticulitis at a higher rate than in screened asymptomatic populations, necessitating follow-up. CT reports contained statements regarding diagnostic uncertainty in 25% cases, associated with an increased risk of CRC. Follow-up endoscopy in patients with CT-proven diverticulitis is associated with increased discomfort and high rates of incompletion. The use of other follow-up modalities should be considered.

Citations

Citations to this article as recorded by

Ambulatory management of acute uncomplicated diverticulitis (AmbUDiv study): a multicentre, propensity score matching study
Ali Yasen Mohamedahmed, Mohammed Hamid, Mohamed Issa, Mohamed Albendary, Emiko Sultana, Shafquat Zaman, Santosh Bhandari, Diwakar Sarma, William Ball, Pradeep Thomas, Najam Husain
International Journal of Colorectal Disease.2024;[Epub] CrossRef
Endoscopic findings after CT proven acute diverticulitis: a systematic review and meta‐analysis
Amy Millicent Yesheng Cao, Vincent Wai Lam, Matthew John Francis Xavier Rickard
ANZ Journal of Surgery.2023; 93(5): 1150. CrossRef
Comparison of colonoscopy after colonic diverticulitis and positive fecal immunochemical tests for the detection of colorectal neoplasia
Dai Nakamatsu, Tsutomu Nishida, Shinji Kuriki, Li-sa Chang, Kazuki Aochi, Emi Meren, Tatsuya Sakamoto, Ryo Tomita, Yu Higaki, Naoto Osugi, Aya Sugimoto, Kei Takahashi, Kaori Mukai, Kengo Matsumoto, Shiro Hayashi, Sachiko Nakajima, Masashi Yamamoto, Koji F
Endoscopy International Open.2021; 09(03): E331. CrossRef
Imaging Modalities for Evaluation of Intestinal Obstruction
David W. Nelms, Brian R. Kann
Clinics in Colon and Rectal Surgery.2021; 34(04): 205. CrossRef
Computed Tomography of Common Bowel Emergencies
Kishan Patel, Nanxi Zha, Shana Neumann, Mitiadis Nicholas Tembelis, Mario Juliano, Naziya Samreen, Jawad Hussain, Mariam Moshiri, Michael N. Patlas, Douglas S. Katz
Seminars in Roentgenology.2020; 55(2): 150. CrossRef
Short‐ and Long‐Term Outcomes of Right‐Sided Diverticulitis: Over 15 Years of North American Experience
Jesse Zuckerman, Richard Garfinkle, Carol‐Ann Vasilevksy, Gabriela Ghitulescu, Julio Faria, Nancy Morin, Marylise Boutros
World Journal of Surgery.2020; 44(6): 1994. CrossRef
Diverticulitis: An Update From the Age Old Paradigm
Alexander T. Hawkins, Paul E. Wise, Tiffany Chan, Janet T. Lee, Tamara Glyn, Verity Wood, Timothy Eglinton, Frank Frizelle, Adil Khan, Jason Hall, M.I. Mohammed Ilyas, Maria Michailidou, Valentine N. Nfonsam, Michelle L. Cowan, Jennifer Williams, Scott R.
Current Problems in Surgery.2020; 57(10): 100862. CrossRef
Duodenal Diverticulosis as an Unusual Cause of Severe Abdominal Pain
Wajd A Aljabri, Mohammed Hasosah, Abeer AlMehdar, Dohaa Bakhsh, Faris O Alturkistany
Cureus.2020;[Epub] CrossRef
CT colonography: implementation, indications, and technical performance – a follow-up national survey
Fredrik Thorén, Åse A Johnsson, John Brandberg, Mikael Hellström
Acta Radiologica.2019; 60(3): 271. CrossRef
Risk of Colorectal Cancer in Patients With Acute Diverticulitis: A Systematic Review and Meta-analysis of Observational Studies
Jeremy Meyer, Lorenzo A. Orci, Christophe Combescure, Alexandre Balaphas, Philippe Morel, Nicolas C. Buchs, Frédéric Ris
Clinical Gastroenterology and Hepatology.2019; 17(8): 1448. CrossRef
Meta-analysis of the role of colonoscopy after an episode of left-sided acute diverticulitis
S J Rottier, S T Dijk, A A W Geloven, W H Schreurs, W A Draaisma, W A Enst, J B C M Puylaert, M G J Boer, B R Klarenbeek, J A Otte, R J F Felt, M A Boermeester
British Journal of Surgery.2019; 106(8): 988. CrossRef

5,900 View
50 Download
11 Web of Science
11 Crossref

Evaluation of Xpert MTB/RIF assay performance in the diagnosis of abdominal tuberculosis: Suraj Kumar, Sawan Bopanna, Saurabh Kedia, Pratap Mouli, Rajan Dhingra, Rajesh Padhan, Mikashmi Kohli, Jigyasa Chaubey, Rohini Sharma, Prasenjit Das, S Dattagupta, Govind Makharia, SK Sharma, Vineet Ahuja; Intest Res 2017;15(2):187-194. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.187

Abstract PDF PubReader ePub

Background/Aims

The use of genetic probes for the diagnosis of pulmonary tuberculosis (TB) has been well described. However, the role of these assays in the diagnosis of intestinal tuberculosis is unclear. We therefore assessed the diagnostic utility of the Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF) assay, and estimated the prevalence of multidrug-resistant (MDR) TB in the Indian population.

Methods

Of 99 patients recruited, 37 had intestinal TB; two control groups comprised 43 with Crohn's disease (CD) and 19 with irritable bowel syndrome. Colonoscopy was performed before starting any therapy; mucosal biopsies were subjected to histopathology, acid-fast bacilli staining, Lowenstein-Jensen culture, and nucleic acid amplification testing using the Xpert MTB/RIF assay. Patients were followed up for 6 months to confirm the diagnosis and response to therapy. A composite reference standard was used for diagnosis of TB and assessment of the diagnostic utility of the Xpert MTB/RIF assay.

Results

Of 37 intestinal TB patients, the Xpert MTB/RIF assay was positive in three of 37 (8.1%), but none had MDR-TB. The sensitivity, specificity, positive predictive value, and negative predictive value of the Xpert MTB/RIF assay was 8.1%, 100%, 100%, and, 64.2%, respectively.

Conclusions

The Xpert MTB/RIF assay has low sensitivity but high specificity for intestinal TB, and may be helpful in endemic tuberculosis areas, when clinicians are faced with difficulty differentiating TB and CD. Based on the Xpert MTB/RIF assay, the prevalence of intestinal MDR-TB is low in the Indian population.

Citations

Citations to this article as recorded by

Mistakes to avoid in the management of abdominal tuberculosis
Abhirup Chatterjee, Daya Krishna Jha, Aravind Sekar, Vishal Sharma
Expert Review of Anti-infective Therapy.2025; : 1. CrossRef
Perfusion Computed Tomography May Help in Discriminating Gastrointestinal Tuberculosis and Crohn’s Disease
Raghav Seth, Pankaj Gupta, Uma Debi, Kaushal Kishore Prasad, Harjeet Singh, Vishal Sharma
Diagnostics.2023; 13(7): 1255. CrossRef
Clinical characteristics and diagnosis of intestinal tuberculosis in clinical practice at Thailand’s largest national tertiary referral center: An 11-year retrospective review
Asawin Sudcharoen, Gahwin Ruchikajorndech, Sitthipong Srisajjakul, Ananya Pongpaibul, Popchai Ngamskulrungroj, Orawan Tulyaprawat, Julajak Limsrivilai, Mao-Shui Wang
PLOS ONE.2023; 18(4): e0282392. CrossRef
Analytical performances of the Xpert MTB/RIF assay using stool specimens to improve the diagnosis of pulmonary tuberculosis in Burkina Faso, a tuberculosis endemic country
Odilon D. Kaboré, Anselme Millogo, Bintou Sanogo, Emile Birba, Armel Poda, Boubacar Nacro, Olivier Marcy, Sylvain Godreuil, Abdoul-Salam Ouédraogo, Mao-Shui Wang
PLOS ONE.2023; 18(7): e0288671. CrossRef
Meta-analysis of diagnostic accuracy of nucleic acid amplification tests for abdominal tuberculosis
Yanqin Shen, Likui Fang, Bo Ye, Guocan Yu, Kamal Kishore Chopra
PLOS ONE.2023; 18(11): e0289336. CrossRef
Chapitre 7: La tuberculose extrapulmonaire
Leila Barss, William J. A. Connors, Dina Fisher
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.2023; 7(6): 365. CrossRef
Recent updates in diagnosis of abdominal tuberculosis with emphasis on nucleic acid amplification tests
Preeti Mor, Bhawna Dahiya, Sanjeev Parshad, Pooja Gulati, Promod K. Mehta
Expert Review of Gastroenterology & Hepatology.2022; 16(1): 33. CrossRef
Chapter 7: Extra-pulmonary tuberculosis
Leila Barss, William J. A. Connors, Dina Fisher
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.2022; 6(sup1): 87. CrossRef
Abdominal Tuberculosis Mimicking Ovarian Cancer: A Case Report and Review of the Literature
Ikhwan Rinaldi, Abdul Muthalib, Djaja Gosal, Teguh Wijayadi, Barlian Sutedja, Tjondro Setiawan, Andika Gunawan, Nelly Susanto, Lingga Magdalena, Diah Rini Handjari, Fetisari Kurniawan, Aisyah Rifani, Kevin Winston
International Medical Case Reports Journal.2022; Volume 15: 169. CrossRef
Intestinal Tuberculosis Presenting with Gastrointestinal Bleeding in Patient on Warfarin Therapy
Werimo Pascal Kuka, Joe Rakiro, Joseph Gatheru, Felix Riunga, Allan Rajula, Daniel C. Damin
Case Reports in Gastrointestinal Medicine.2022; 2022: 1. CrossRef
Evaluating diagnostic performance of Truenat MTB Plus for gastrointestinal tuberculosis
Kusum Sharma, Megha Sharma, Vishal Sharma, Megha Sharma, Jayanta Samanta, Aman Sharma, Rakesh Kochhar, Saroj Kant Sinha
Journal of Gastroenterology and Hepatology.2022; 37(8): 1571. CrossRef
Totally laparoscopic treatment of intestinal tuberculosis complicated with bowel perforation: The first case report in worldwide literature with a brief review
Giuseppe Di Buono, Roberta Vella, Giuseppe Amato, Giorgio Romano, Vito Rodolico, Marta Saverino, Giovanni De Lisi, Giorgio Romano, Salvatore Buscemi, Antonino Agrusa
Frontiers in Surgery.2022;[Epub] CrossRef
Acid fast bacillus smear, mycobacterial culture and Xpert MTB/RIF assay for the diagnosis of tuberculous peritonitis in patients with and without end stage renal failure
Richa Misra, Mitra Kar, Samir Mohindra, Amit Gupta
Access Microbiology .2022;[Epub] CrossRef
Diagnostic accuracy of the Xpert MTB/RIF assay for abdominal tuberculosis: a systematic review and meta-analysis
Vishal Sharma, Hariom Soni, Praveen Kumar-M, Saurabh Dawra, Shubhra Mishra, Harshal S Mandavdhare, Harjeet Singh, Usha Dutta
Expert Review of Anti-infective Therapy.2021; 19(2): 253. CrossRef
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults
Mikashmi Kohli, Ian Schiller, Nandini Dendukuri, Mandy Yao, Keertan Dheda, Claudia M Denkinger, Samuel G Schumacher, Karen R Steingart
Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
Intestinal tuberculosis or Crohn's disease: Illusion or delusion or allusion
Saurabh Kedia, Vineet Ahuja
JGH Open.2021; 5(2): 177. CrossRef
Application value of tissue tuberculosis antigen combined with Xpert MTB/RIF detection in differential diagnoses of intestinal tuberculosis and Crohn’s disease
Baoying Fei, Lin Zhou, Yu Zhang, Linhe Luo, Yuanyuan Chen
BMC Infectious Diseases.2021;[Epub] CrossRef
Gastrointestinal tuberculosis
Adnan B. Al-Zanbagi, M. K. Shariff
Saudi Journal of Gastroenterology.2021; 27(5): 261. CrossRef
A combination of circulating microRNA-375-3p and chemokines CCL11, CXCL12, and G-CSF differentiate Crohn’s disease and intestinal tuberculosis
Susree Roy, Suchandrima Ghosh, Mallica Banerjee, Sayantan Laha, Dipanjan Bhattacharjee, Rajib Sarkar, Sujay Ray, Arko Banerjee, Ranajoy Ghosh, Aniket Halder, Alakendu Ghosh, Raghunath Chatterjee, Simanti Datta, Gopal Krishna Dhali, Soma Banerjee
Scientific Reports.2021;[Epub] CrossRef
An Outcome-Based Composite Approach for the Diagnosis of Intestinal Tuberculosis: A Pilot Study from a Tertiary Care Centre in South India
Roopa Rachel Paulose, V Anil Kumar, Aparna Sharma, Aditi Damle, Divya Saikumar, Abish Sudhakar, Anoop K Koshy, Rama P Venu
Journal of the Royal College of Physicians of Edinburgh.2021; 51(4): 344. CrossRef
Abdominal Tuberculosis in Children: Challenges, Uncertainty, and Confusion
Giulia Sartoris, James A Seddon, Helena Rabie, Etienne D Nel, H Simon Schaaf
Journal of the Pediatric Infectious Diseases Society.2020; 9(2): 218. CrossRef
How can gastro-intestinal tuberculosis diagnosis be improved? A prospective cohort study
Christopher Lowbridge, Soraya A. M. Fadhil, Gayathri D. Krishnan, Emma Schimann, Raman Muthu Karuppan, Nagaraj Sriram, Giri Shan Rajahram, Jayaram Menon, Aatish Patel, Timothy William, Dawn Carmel Paul, Anna P. Ralph
BMC Infectious Diseases.2020;[Epub] CrossRef
Abdominal Tuberculosis Mimicking Ovarian Cancer: A Diagnostic Dilemma
Anitha Thomas, Ajit Sebastian, Rachel George, Dhanya Susan Thomas, Grace Rebekah, Priscila Rupali, Joy Sarojini Michael, Abraham Peedicayil
The Journal of Obstetrics and Gynecology of India.2020; 70(4): 304. CrossRef
Apoptosis in peripheral blood lymphocytes in intestinal tuberculosis and Crohn’s disease: Implications to diagnostic differentiation
Suprabha Suresh Nayak, Mamatha Vishwanatha Shetty, Cannanore Ganesh Pai, Kanive Parashiva Guruprasad, Kapaettu Satyamoorthy
Indian Journal of Gastroenterology.2020; 39(4): 338. CrossRef
Tuberculose abdominale
I. Diallo, T. Omar Soko, A. Rajack Ndiaye, F. Klotz
EMC - Radiologie et imagerie médicale - Abdominale - Digestive.2020; 38(1): 1. CrossRef
Tuberculose abdominale
I. Diallo, T. Omar Soko, A. Rajack Ndiaye, F. Klotz
EMC - Gastro-entérologie.2020; 37(1): 1. CrossRef
Multiplex Polymerase Chain Reaction for diagnosis of gastrointestinal tuberculosis
Sarthak Malik, Kusum Sharma, Kim Vaiphei, Narendra Dhaka, Neha Berry, Pankaj Gupta, Megha Sharma, Bipadabhanjan Mallick, Rakesh Kochhar, Saroj K Sinha
JGH Open.2019; 3(1): 32. CrossRef
Differentiating Crohn’s disease from intestinal tuberculosis
Saurabh Kedia, Prasenjit Das, Kumble Seetharama Madhusudhan, Siddhartha Dattagupta, Raju Sharma, Peush Sahni, Govind Makharia, Vineet Ahuja
World Journal of Gastroenterology.2019; 25(4): 418. CrossRef
Utility of tissue Xpert-Mtb/Rif for the diagnosis of intestinal tuberculosis in patients with ileocolonic ulcers
Balaji L Bellam, Harshal S Mandavdhare, Kusum Sharma, Siddharth Shukla, Hariom Soni, Praveen Kumar-M, Harjeet Singh, Kaushal K Prasad, Usha Dutta, Vishal Sharma
Therapeutic Advances in Infectious Disease.2019;[Epub] CrossRef
GeneXpert in stool: Diagnostic yield in Intestinal Tuberculosis
Abu Talib, Shaheen Bhatty, Khalid Mehmood, Huda Naim, Iftikhar Haider, Hari Lal, Gohar Ali, Muhammad Nashit
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.2019; 17: 100131. CrossRef
GENEXPERT FOR ABDOMINAL TUBERCULOSIS
Alka SHARMA
Arquivos de Gastroenterologia.2019; 56(4): 454. CrossRef
A diagnostic approach for differentiating abdominal tuberculosis from ovarian malignancy: a case series and literature review
Moh Nailul Fahmi, Annisaa Pelita Harti
BMC Proceedings.2019;[Epub] CrossRef
Xpert®MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance
Mikashmi Kohli, Ian Schiller, Nandini Dendukuri, Keertan Dheda, Claudia M Denkinger, Samuel G Schumacher, Karen R Steingart
Cochrane Database of Systematic Reviews.2018;[Epub] CrossRef
Surgery for Abdominal Tuberculosis in the Present Era: Experience from a Tertiary-Care Center
Harjeet Singh, Gautham Krishnamurthy, Jayapal Rajendran, Vishal Sharma, Harshal Mandavdhare, Hemanth Kumar, Thakur Deen Yadav, Rakesh Kumar Vasishta, Rajinder Singh
Surgical Infections.2018; 19(6): 640. CrossRef
Making a Positive Diagnosis of Intestinal Tuberculosis with the Aid of New Biologic and Histologic Features: How Far Have We Reached?
Vatsal Mehta, Devendra Desai, Philip Abraham, Camilla Rodrigues
Inflammatory Intestinal Diseases.2018; 3(4): 155. CrossRef
Editor’s Pick: Recent Advances in the Diagnosis and Management of Abdominal Tuberculosis
Harshal S. Mandavdhare, Harjeet Singh, Vishal Sharma
EMJ Gastroenterology.2017; : 52. CrossRef

7,296 View
100 Download
31 Web of Science
36 Crossref

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease: Cheng-Chun Ji, Shota Takano; Intest Res 2017;15(2):182-186. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.182

Abstract PDF PubReader ePub

Background/Aims

Infliximab has proven to be effective in the treatment of perianal fistulas in Crohn's disease (CD) but the efficacy of adalimumab is still unclear. The aim of this study is to assess the clinical efficacy of adalimumab and compare the results with those for infliximab.

Methods

Forty-seven CD patients treated for perianal fistulas with infliximab from September 2005 to December 2010 (n=31), or with adalimumab from November 2010 to May 2012 (n=16), were enrolled in this retrospective study. The following patient characteristics were analyzed; intestinal lesion site, fistula classification, seton placement, index of inflammatory bowel disease, C-reactive protein level, follow-up period, and the cumulative rate of nonrecurrence or aggravation of fistula.

Results

There were no significant differences in the intestinal lesion site, fistula classification, inflammatory bowel disease index, C-reactive protein level, and the frequency of injection between the infliximab group and the adalimumab group. The cumulative rate of nonrecurrence or aggravation of fistula was 62.5% in the adalimumab group and 83.9% in the infliximab group at 24 months after treatment (P=0.09). The risk factors for recurrence or aggravation may be related to seton placement (P=0.02), gender (P=0.06), and fistula classification (P=0.07).

Conclusions

There was no significant difference in the clinical efficacy of adalimumab and infliximab in the treatment of perianal fistulas in CD. However, fistula classification may be an important risk factor for recurrence or aggravation. The preliminary findings in this study show that further research is warranted.

Citations

Citations to this article as recorded by

Epidemiology and Treatment Patterns of Fistulizing Crohn’s Disease in a Large, Real-World Australasian Cohort
Jack McNamara, William Wilson, Joseph L. Pipicella, Simon Ghaly, Jakob Begun, Ian C. Lawrance, Richard Gearry, Jane M. Andrews, Susan J. Connor
Gastro Hep Advances.2025; 4(4): 100594. CrossRef
Management of Perianal Fistulizing Crohn’s Disease
Arshdeep Singh, Vandana Midha, Gursimran Singh Kochhar, Bo Shen, Ajit Sood
Inflammatory Bowel Diseases.2024; 30(9): 1579. CrossRef
Choosing Therapy for Moderate to Severe Crohn’s Disease
Malcolm Irani, Bincy Abraham
Journal of the Canadian Association of Gastroenterology.2024; 7(1): 1. CrossRef
The use of core descriptors from the ENiGMA code study in recent literature: a systematic review
Saher‐Zahra Khan, Andrea Arline, Kate M. Williams, Matthew J. Lee, Emily Steinhagen, Sharon L. Stein
Colorectal Disease.2024; 26(3): 428. CrossRef
The potential for medical therapies to address fistulizing Crohn’s disease: a state-of-the-art review
Mohammad Shehab, Davide De Marco, Peter L. Lakatos, Talat Bessissow
Expert Opinion on Biological Therapy.2024; 24(8): 733. CrossRef
Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021
Hiroshi Nakase, Motohiro Esaki, Fumihito Hirai, Taku Kobayashi, Katsuyoshi Matsuoka, Minoru Matsuura, Makoto Naganuma, Masayuki Saruta, Kiichiro Tsuchiya, Motoi Uchino, Kenji Watanabe, Tadakazu Hisamatsu, Akira Andoh, Shigeki Bamba, Motohiro Esaki, Mikihi
Journal of Gastroenterology.2023; 58(4): 313. CrossRef
Perianal fistulas in Crohn's disease (review)
I. S. Anosov, B. A. Nanaeva, A. V. Vardanyan, M. A. Zakharov
Koloproktologia.2023; 22(1): 128. CrossRef
Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae
Laura Maas, Ruiyi Gao, Vivy Cusumano, Ellen Spartz, Reezwana Chowdhury, Mahesh Krishna, Mark Lazarev, Joanna Melia, Florin Selaru, Sowmya Sharma, Berkeley Limketkai, Alyssa Parian
Digestive Diseases and Sciences.2023; 68(10): 3994. CrossRef
Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
Gustavo Drügg Hahn, Petra Anna Golovics, Panu Wetwittayakhlang, Alex Al Khoury, Talat Bessissow, Peter Laszlo Lakatos
Biomedicines.2022; 10(4): 749. CrossRef
The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials
Panu Wetwittayakhlang, Alex Al Khoury, Gustavo Drügg Hahn, Peter Laszlo Lakatos
Journal of Clinical Medicine.2022; 11(11): 3045. CrossRef
Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
Hua-Hua Yang, Yi Huang, Xu-Chun Zhou, Ruo-Nan Wang
World Journal of Clinical Cases.2022; 10(18): 6091. CrossRef
An AAV-Based NF-κB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases
Tao Luo, Yile Wang, Hailin Tang, Fei Zhou, Ying Chen, Bing Pei, Jinke Wang
Journal of Inflammation Research.2022; Volume 15: 3447. CrossRef
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
Gut and Liver.2021; 15(1): 92. CrossRef
Predictors of reoperation for perianal fistula in Crohn's disease
Kwangwoo Nam, Won Beom Jung, Seung Bum Lee, Jae Seung Soh, Song Soo Yang, Seok Won Jung
Journal of Digestive Diseases.2021; 22(6): 334. CrossRef
Managing Complex Perianal Fistulizing Disease
Karina E. Pedersen, Amy L. Lightner
Journal of Laparoendoscopic & Advanced Surgical Techniques.2021; 31(8): 890. CrossRef
Predictors of long-term outcomes of radiologically defined perianal fistulizing Crohn’s disease treated with antitumor necrosis factor-alpha agents based on Parks’ classification
Nahla Azzam, Othman Alharbi, Majid Almadi, Abdulrahman Aljebreen, Turki AlAmeel, Mohammed Alabbas, Salman Bahammam, Ahmed Bashmail, Yasser Alomar, Mahmoud Mosli
European Journal of Gastroenterology & Hepatology.2020; 32(2): 187. CrossRef
Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
The Korean Journal of Gastroenterology.2020; 75(1): 29. CrossRef
Characteristics of biological therapy in pediatric patients with Crohn’s disease
Andras Tarnok, Zoltan Kiss, Orsolya Kadenczki, Gabor Veres
Expert Opinion on Biological Therapy.2019; 19(3): 181. CrossRef
Endorectal Advancement Flaps for Perianal Fistulae in Crohn’s Disease: Careful Patient Selection Leads to Optimal Outcomes
Michelle T. Roper, Stephen M. Trinidad, Sonia L. Ramamoorthy, Lisa A. Parry, Nicole E. Lopez, Sergey Khaitov, Randolph Steinhagen, Samuel G. Eisenstein
Journal of Gastrointestinal Surgery.2019; 23(11): 2277. CrossRef
Maneuvering Clinical Pathways for Crohn’s Disease
Thomas X. Lu, Russell D. Cohen
Current Gastroenterology Reports.2019;[Epub] CrossRef
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chia
Journal of Gastroenterology and Hepatology.2019; 34(8): 1296. CrossRef
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chia
Intestinal Research.2019; 17(3): 285. CrossRef
Long‐term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first‐line biologics
Toshihiro Inokuchi, Sakuma Takahashi, Sakiko Hiraoka, Tatsuya Toyokawa, Shinjiro Takagi, Koji Takemoto, Jiro Miyaike, Tsuyoshi Fujimoto, Reiji Higashi, Yuki Morito, Toru Nawa, Seiyuu Suzuki, Mamoru Nishimura, Masafumi Inoue, Jun Kato, Hiroyuki Okada
Journal of Gastroenterology and Hepatology.2019; 34(8): 1329. CrossRef
Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
Jong Pil Im
Intestinal Research.2017; 15(2): 147. CrossRef

5,896 View
75 Download
22 Web of Science
24 Crossref

Parthenolide promotes apoptotic cell death and inhibits the migration and invasion of SW620 cells: Yu Chuan Liu, Se Lim Kim, Young Ran Park, Soo-Teik Lee, Sang Wook Kim; Intest Res 2017;15(2):174-181. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.174

Abstract PDF PubReader ePub

Background/Aims

Parthenolide (PT), a principle component derived from feverfew (Tanacetum parthenium), is a promising anticancer agent and has been shown to promote apoptotic cell death in various cancer cells. In this study, we focused on its functional role in apoptosis, migration, and invasion of human colorectal cancer (CRC) cells.

Methods

SW620 cells were employed as representative human CRC cells. We performed the MTT assay and cell cycle analysis to measure apoptotic cell death. The wound healing, Transwell migration, and Matrigel invasion assays were performed to investigate the effect of PT on cell migration/invasion. Western blotting was used to establish the signaling pathway of apoptosis and cell migration/invasion.

Results

PT exerts antiproliferative effect and induces apoptotic cell death of SW620 cells. In addition, PT prevents cell migration and invasion in a dose-dependent manner. Moreover, PT markedly suppressed migration/invasion-related protein expression, including E-cadherin, β-catenin, vimentin, Snail, cyclooxygenase-2, matrix metalloproteinase-2 (MMP-2), and MMP-9 in SW620 cells. PT also inhibited the expression of antiapoptotic proteins (Bcl-2 and Bcl-xL) and activated apoptosis terminal factor (caspase-3) in a dose-dependent manner.

Conclusions

Our results suggest that PT is a potential novel therapeutic agent for aggressive CRC treatment.

Citations

Citations to this article as recorded by

Sesquiterpene Lactones as Promising Phytochemicals to Cease Metastatic Propagation of Cancer
Fatemeh Mehdikhani, Homa Hajimehdipoor, Mojgan Tansaz, Marc Maresca, Sadegh Rajabi
Biomolecules.2025; 15(2): 268. CrossRef
Sesquiterpene lactones and cancer: new insight into antitumor and anti-inflammatory effects of parthenolide-derived Dimethylaminomicheliolide and Micheliolide
Jian Li, Xin Li, Hongwei Liu
Frontiers in Pharmacology.2025;[Epub] CrossRef
Cyanidin-3-O-glucoside inhibits the malignant progression of colorectal cancer by regulating Kruppel-like factor 4-mediated ERK/p38 signaling pathway
Jian Chang, Geqiong Xiao
Toxicology and Applied Pharmacology.2025; 497: 117268. CrossRef
Novel formulation of parthenolide-loaded liposome coated with chitosan and evaluation of its potential anticancer effects in vitro
Parisa Karimian Ensaf, Mohammad Taghi Goodarzi, Masoud Homayouni Tabrizi, Ali Neamati, Samira Sadat Hosseinyzadeh
Molecular Biology Reports.2024;[Epub] CrossRef
Sesquiterpene lactones as emerging biomolecules to cease cancer by targeting apoptosis
Chou-Yi Hsu, Sadegh Rajabi, Maryam Hamzeloo-Moghadam, Abhinav Kumar, Marc Maresca, Pallavi Ghildiyal
Frontiers in Pharmacology.2024;[Epub] CrossRef
Exploring the Phytochemistry, Signaling Pathways, and Mechanisms of Action of Tanacetum parthenium (L.) Sch.Bip.: A Comprehensive Literature Review
Ali Kashkooe, Atefeh Jalali, Mohammad M. Zarshenas, Azadeh Hamedi
Biomedicines.2024; 12(10): 2297. CrossRef
Bitter taste signaling in cancer
Ana R. Costa, Ana C. Duarte, Ana R. Costa-Brito, Isabel Gonçalves, Cecília R.A. Santos
Life Sciences.2023; 315: 121363. CrossRef
Parthenolide inhibits proliferation and invasion, promotes apoptosis, and reverts the cell–cell adhesion loss through downregulation of NF‐κB pathway TNF‐α‐activated in colorectal cancer cells
Adriana S. Gehren, Waldemir F. de Souza, Annie C. M. Sousa‐Squiavinato, Diego A. A. Ramos, Bruno R. B. Pires, Eliana S. F. W. Abdelhay, Jose A. Morgado‐Diaz
Cell Biology International.2023; 47(9): 1638. CrossRef
Novel shikonin derivative suppresses tumor growth and metastasis intervention of Wnt/β-catenin pathway
Hongwei Han, Zhongling Wen, Xiaohui Lai, Minkai Yang, Jiangyan Fu, Liangjie Yang, Qingqing Chen, Yudi Ma, Wencai Jie, Changyi Wang, Tongming Yin, Guihua Lu, Xiaoming Wang, Shucun Sun, Quan Zhao, Jinliang Qi, Hongyan Lin, Yonghua Yang
Process Biochemistry.2023; 132: 297. CrossRef
Parthenolide repressed endometriosis induced surgically in rats: Role of PTEN/PI3Kinase/AKT/GSK-3β/β-catenin signaling in inhibition of epithelial mesenchymal transition
Soad L. Kabil, Hayam E. Rashed, Noura Mostafa Mohamed, Nisreen E. Elwany
Life Sciences.2023; 331: 122037. CrossRef
TGF-β in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer
Sumeet Singh, Vinita Gouri, Mukesh Samant
Medical Oncology.2023;[Epub] CrossRef
Decoding Systems Biology of Inflammation Signatures in Cancer Pathogenesis: Pan-Cancer Insights from 12 Common Cancers
Beste Turanli
OMICS: A Journal of Integrative Biology.2023; 27(10): 483. CrossRef
Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties
Daniela Carlisi, Marianna Lauricella, Antonella D’Anneo, Anna De Blasio, Adriana Celesia, Giovanni Pratelli, Antonietta Notaro, Giuseppe Calvaruso, Michela Giuliano, Sonia Emanuele
Biomedicines.2022; 10(2): 514. CrossRef
Parthenolide reverses the epithelial to mesenchymal transition process in breast cancer by targeting TGFbeta1: In vitro and in silico studies
Hazera Binte Sufian, Julianna Maria Santos, Zeina S. Khan, Sobia Ahsan Halim, Ajmal Khan, Maliha Tabassum Munir, MD Khurshidul Zahid, Ahmed Al-Harrasi, Lauren S. Gollahon, Fazle Hussain, Shaikh Mizanoor Rahman
Life Sciences.2022; 301: 120610. CrossRef
Sesquiterpene Lactones and Cancer: New Insight into Antitumor and Anti-inflammatory Effects of Parthenolide-Derived Dimethylaminomicheliolide and Micheliolide
Yubo Dong, Xuanjin Qian, Jian Li, Ahmed Faeq Hussein
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Recent advances on the structural modification of parthenolide and its derivatives as anticancer agents
Xingchen LIU, Xiaobing WANG
Chinese Journal of Natural Medicines.2022; 20(11): 814. CrossRef
Roles of Inflammasomes in Epstein–Barr Virus-Associated Nasopharyngeal Cancer
Chin King Looi, Ling-Wei Hii, Felicia Fei-Lei Chung, Chun-Wai Mai, Wei-Meng Lim, Chee-Onn Leong
Cancers.2021; 13(8): 1786. CrossRef
Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma
Magdalena Rausch, Adriano Rutz, Pierre-Marie Allard, Céline Delucinge-Vivier, Mylène Docquier, Olivier Dormond, Paul J. Dyson, Jean-Luc Wolfender, Patrycja Nowak-Sliwinska
Cancers.2021; 13(16): 3978. CrossRef
6 α-Hydroxy-4[14], 10[15]-guainadien-8β, 12-olide induced cell cycle arrest via modulation of EMT and Wnt/β-catenin pathway in HER-2 positive breast cancer cells
Gitanjali Javir, Kalpana Joshi, Vijay Khedkar, Supada Rojatkar
The Journal of Steroid Biochemistry and Molecular Biology.2020; 197: 105514. CrossRef
Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth
Xue Li, Lingmei Kong, Qihong Yang, Aizhu Duan, Xiaoman Ju, Bicheng Cai, Lin Chen, Tao An, Yan Li
Journal of Biological Chemistry.2020; 295(11): 3576. CrossRef
Metabonomic study of the intervention effects of Parthenolide on anti-thyroid cancer activity
Lili Yuan, Zhe Wang, Dongyang Zhang, Jiahe Wang
Journal of Chromatography B.2020; 1150: 122179. CrossRef
ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF‐κB activation
Xiao‐Han Jin, Yong‐Sheng Jia, Ye‐Hui Shi, Qiu‐Ying Li, Shi‐Qi Bao, Wen‐Ping Lu, Zhong‐Sheng Tong
Journal of Cellular Biochemistry.2019; 120(2): 1386. CrossRef
Collateral Sensitivity of Parthenolide via NF-κB and HIF-α Inhibition and Epigenetic Changes in Drug-Resistant Cancer Cell Lines
Mona Dawood, Edna Ooko, Thomas Efferth
Frontiers in Pharmacology.2019;[Epub] CrossRef
Parthenolide inhibits transforming growth factor β1-induced epithelial-mesenchymal transition in colorectal cancer cells
Shi Mao Zhu, Yong Ran Park, Seung Yong Seo, In Hee Kim, Soo Teik Lee, Sang Wook Kim
Intestinal Research.2019; 17(4): 527. CrossRef
Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer
Luksana Chaiswing, William H. St. Clair, Daret K. St. Clair
Antioxidants & Redox Signaling.2018; 29(13): 1237. CrossRef
Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 - dependent apoptosis and inhibiting VEGF expression
Wamidh H. Talib, Lina T. Al Kury
Biomedicine & Pharmacotherapy.2018; 107: 1488. CrossRef
Synergistic effects and mechanisms of impressic acid or acankoreanogein in combination with docetaxel on prostate cancer
Sen Jiang, Kun Zhang, Yan He, Xuetao Xu, Dongli Li, Shupeng Cheng, Xi Zheng
RSC Advances.2018; 8(5): 2768. CrossRef
The combined administration of parthenolide and ginsenoside CK in long circulation liposomes with targeted tLyp-1 ligand induce mitochondria-mediated lung cancer apoptosis
Xin Jin, Jianping Zhou, Zhenhai Zhang, Huixia Lv
Artificial Cells, Nanomedicine, and Biotechnology.2018; 46(sup3): 931. CrossRef

7,385 View
96 Download
32 Web of Science
28 Crossref

Intestinal barrier integrity and function in infants with cholestasis: Nagla H. Abu Faddan, Tahra M. K. Sherif, Omnia A. Mohammed, Khalid A. Nasif, Ebtesam M. El Gezawy; Intest Res 2017;15(1):118-123. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.118

Abstract PDF PubReader ePub

Background/Aims

The safety of the human body is maintained by effective monitoring of the mucosal surface integrity and protection against potentially harmful compounds. This function of the gut called intestinal barrier function can be affected by cholestasis and the absence of bile in the intestinal lumen. We aimed to determine whether the gut barrier integrity is impaired in infants with cholestasis by evaluation of the intestinal fatty acid binding proteins (I-FABP) and ileal bile acid binding protein (I-BABP) as markers of intestinal epithelial cell damage and plasma D-lactate level as a marker of gut wall permeability.

Methods

This case-control study included 53 infants with cholestasis and 29 controls. Serum levels of I-FABP, I-BABP, and D-lactate were measured in all subjects.

Results

Both groups of patients with neonatal hepatitis and biliary atresia showed significantly higher levels of I-FABP and I-BABP than the controls. There were no differences in the serum D-lactate level between the cases and controls. There was no difference between the two groups of patients (I and II) regarding any of the parameters studied. No significant correlations between serum levels of I-FABP, I-BABP, or D-lactate and total or direct bilirubin levels were found in the cholestatic infants.

Conclusions

The intestinal epithelial barrier integrity is breached nearly in all parts of the intestine in infants with cholestasis. Further research is recommended to determine the impact of this finding on the management of these infants. The relationship between physical intestinal barrier damage and its functional failure remains subject for further research.

Citations

Citations to this article as recorded by

The association of human milk intake and outcomes in biliary atresia
Mary Elizabeth M. Tessier, Jeremy M. Schraw, Stacey Beer, Sanjiv Harpavat, M. Kyle Jensen, John C. Magee, Vicky Ng, Michael E. Scheurer, Sarah A. Taylor, Benjamin L. Shneider
Journal of Pediatric Gastroenterology and Nutrition.2025; 80(1): 163. CrossRef
Data-independent acquisition-based blood proteomics unveils predictive biomarkers for neonatal necrotizing enterocolitis
Feng Chen, Kezhe Tan, Zhibao Lv, Faling Chen, Weijue Xu, Xiaohui Gong, Li Lu, Hailiang Sun, Qinqin Fu, Wenjun Zhuang
Analytical and Bioanalytical Chemistry.2025; 417(1): 199. CrossRef
Biliary atresia: the role of gut microbiome, and microbial metabolites
Sansan Feng, Yongkang Cheng, Chuqiao Sheng, Chunfeng Yang, Yumei Li
Frontiers in Cellular and Infection Microbiology.2024;[Epub] CrossRef
Modulating intestinal barrier function by sphingosine-1-phosphate receptor 1 specific agonist SEW2871 attenuated ANIT-induced cholestatic hepatitis via the gut-liver axis
Tingting Yang, Lin Li, Jiale Pang, Cai Heng, Chujing Wei, Xue Wang, Ziyin Xia, Xin Huang, Luyong Zhang, Zhenzhou Jiang
International Immunopharmacology.2023; 125: 111150. CrossRef
Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer
Chenchen Bi, Geqiong Xiao, Chunyan Liu, Junwei Yan, Jiaqi Chen, Wenzhang Si, Jian Zhang, Zheng Liu
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Noninvasive Biomarkers of Gut Barrier Function in Patients Suffering from Diarrhea Predominant-IBS: An Update
Michele Linsalata, Giuseppe Riezzo, Caterina Clemente, Benedetta D’Attoma, Francesco Russo, Roberta Rizzo
Disease Markers.2020; 2020: 1. CrossRef
A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis
Eleanor A Fallon, Bethany M Biron-Girard, Chun-Shiang Chung, Joanne Lomas-Neira, Daithi S Heffernan, Sean F Monaghan, Alfred Ayala
Journal of Leukocyte Biology.2018; 103(6): 1151. CrossRef

5,886 View
60 Download
11 Web of Science
7 Crossref

Determining the optimal surveillance interval after a colonoscopic polypectomy for the Korean population?: Jung Lok Lee, Jae Myung Cha, Hye Min Lee, Jung Won Jeon, Min Seob Kwak, Jin Young Yoon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee, Dong Il Park; Intest Res 2017;15(1):109-117. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.109

Abstract PDF PubReader ePub

Background/Aims

Western surveillance strategies cannot be directly adapted to the Korean population. The aim of this study was to estimate the risk of metachronous neoplasia and the optimal surveillance interval in the Korean population.

Methods

Clinical and pathological data from index colonoscopy performed between June 2006 and July 2008 and who had surveillance colonoscopies up to May 2015 were compared between low- and high-risk adenoma (LRA and HRA) groups. The 3- and 5-year cumulative risk of metachronous colorectal neoplasia in both groups were compared.

Results

Among 895 eligible patients, surveillance colonoscopy was performed in 399 (44.6%). Most (83.3%) patients with LRA had a surveillance colonoscopy within 5 years and 70.2% of patients with HRA had a surveillance colonoscopy within 3 years. The cumulative risk of metachronous advanced adenoma was 3.2% within 5 years in the LRA group and only 1.7% within 3 years in the HRA group. The risk of metachronous neoplasia was similar between the surveillance interval of <5 and ≥5 years in the LRA group; however, it was slightly higher at surveillance interval of ≥3 than <3 years in the HRA group (9.4% vs. 2.4%). In multivariate analysis, age and the ≥3-year surveillance interval were significant independent risk factors for metachronous advanced adenoma (P=0.024 and P=0.030, respectively).

Conclusions

Patients had a surveillance colonoscopy before the recommended guidelines despite a low risk of metachronous neoplasia. However, the risk of metachronous advanced adenoma was increased in elderly patients and those with a ≥3-year surveillance interval.

Citations

Citations to this article as recorded by

Risk of developing metachronous colorectal neoplasia after the resection of proximal versus distal adenomas
Yoon Suk Jung, Nam Hee Kim, Youngwoo Kim, Dong Il Park
Digestive and Liver Disease.2022; 54(4): 537. CrossRef
Post-polypectomy surveillance interval and advanced neoplasia detection rates: a multicenter, retrospective cohort study
Amanda J. Cross, Emma C. Robbins, Kevin Pack, Iain Stenson, Matthew D. Rutter, Andrew M. Veitch, Brian P. Saunders, Stephen W. Duffy, Kate Wooldrage
Endoscopy.2022; 54(10): 948. CrossRef
Comparison of Risk of Metachronous Advanced Colorectal Neoplasia in Patients with Sporadic Adenomas Aged < 50 Versus ≥ 50 years: A Systematic Review and Meta-Analysis
Yoon Suk Jung, Jung Ho Park, Chan Hyuk Park
Journal of Personalized Medicine.2021; 11(2): 120. CrossRef
British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines
Matthew D Rutter, James East, Colin J Rees, Neil Cripps, James Docherty, Sunil Dolwani, Philip V Kaye, Kevin J Monahan, Marco R Novelli, Andrew Plumb, Brian P Saunders, Siwan Thomas-Gibson, Damian J M Tolan, Sophie Whyte, Stewart Bonnington, Alison Scope,
Gut.2020; 69(2): 201. CrossRef
Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer
Eun Ran Kim, Hyuk Nam Kwon, Hoonsik Nam, Jae J. Kim, Sunghyouk Park, Young-Ho Kim
Scientific Reports.2019;[Epub] CrossRef
A Comparison of the Cumulative Incidences of Metachronous Colorectal Adenoma and Cancer According to the Initial FindingsAmong Colonoscopically Followed-up Patients
Seiji Kimura, Masanori Tanaka, Shinsaku Fukuda
Nippon Daicho Komonbyo Gakkai Zasshi.2019; 72(6): 395. CrossRef
Impact of obesity and metabolic abnormalities on the risk of metachronous colorectal neoplasia after polypectomy in men
Nam Hee Kim, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
Journal of Gastroenterology and Hepatology.2019; 34(9): 1504. CrossRef
Risk of developing metachronous advanced colorectal neoplasia after colonoscopic polypectomy in patients aged 30 to 39 and 40 to 49 years
Nam Hee Kim, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
Gastrointestinal Endoscopy.2018; 88(4): 715. CrossRef
Quality is the Key for Emerging Issues of Population-Based Colonoscopy Screening
Jin Young Yoon, Jae Myung Cha, Yoon Tae Jeen
Clinical Endoscopy.2018; 51(1): 50. CrossRef
Histologic discrepancy between endoscopic forceps biopsy and endoscopic mucosal resection specimens of colorectal polyp in actual clinical practice
Moon Joo Hwang, Kyeong Ok Kim, A Lim Kim, Si Hyung Lee, Byung Ik Jang, Tae Nyeun Kim
Intestinal Research.2018; 16(3): 475. CrossRef
Quality is the key for emerging issues of population-based colonoscopy screening
Jin Young Yoon, Jae Myung Cha, Yoon Tae Jeen
Intestinal Research.2018; 16(1): 48. CrossRef

6,439 View
60 Download
11 Web of Science
11 Crossref

Status of serum vitamin B₁₂ and folate in patients with inflammatory bowel disease in China: Shaozhong Huang, Jiayi Ma, Mingming Zhu, Zhihua Ran; Intest Res 2017;15(1):103-108. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.103

Abstract PDF PubReader ePub

Background/Aims

Inflammatory bowel disease (IBD) primarily involves the intestinal tract and can affect vitamin absorption. This study was designed to assess the prevalence of vitamin B₁₂ and folate deficiencies in patients with IBD, and to identify the risk factors associated with abnormal serum vitamin B₁₂ and folate levels.

Methods

We evaluated the medical records of 195 patients with Crohn's disease (CD) and 62 patients with ulcerative colitis (UC), and selected 118 healthy subjects for the control group.

Results

There were more CD patients with vitamin B₁₂ deficiency than UC patients (14.9% vs. 3.2%, P=0.014) and controls (14.9% vs. 4.2%, P=0.003). The prevalence of folate deficiency was higher in CD patients than in controls (13.3% vs. 3.4%, P=0.004). There were no significant differences in the serum vitamin B₁₂ and folate statuses of the UC and control groups. Patients with prior ileal or ileocolic resection showed a higher prevalence of abnormal vitamin B₁₂ levels than those without prior resection (n=6/16, n=23/179; P=0.018). A disease duration within 5 years was a risk factor of abnormal folate levels in CD patients.

Conclusions

This study showed that vitamin B₁₂ and folate deficiencies were more common in patients with CD than in UC patients and controls. Prior ileal or ileocolonic resection was a risk factor of serum vitamin B₁₂ abnormalities, and a disease duration within 5 years was a risk factor of low serum folate levels in CD patients.

Citations

Citations to this article as recorded by

Anemia in inflammatory bowel disease—A comprehensive review
Amit Kumar Dutta, Hemanth Chinthala, John Titus George, David Mathew Thomas, Anjilivelil Joseph Joseph
Indian Journal of Gastroenterology.2025;[Epub] CrossRef
Integrated Macrogenomics and Metabolomics Analysis of the Effect of Sea Cucumber Ovum Hydrolysates on Dextran Sodium Sulfate-Induced Colitis
Shunmin Gong, Liqin Sun, Yongjun Sun, Wenming Ju, Gongming Wang, Jian Zhang, Xuejun Fu, Chang Lu, Yu Zhang, Wenkui Song, Mingbo Li, Leilei Sun
Marine Drugs.2025; 23(2): 73. CrossRef
Fatigue in children and adolescents with inflammatory bowel disease: a cross-sectional study
Yahui Zuo, Jinjin Cao, Yuanyuan Wang, Wenqian Cai, Mei Li
Frontiers in Pediatrics.2024;[Epub] CrossRef
Role of micronutrients in inflammatory bowel disease
Wen-Xuan Song, Zi-Han Yu, Xiang-Feng Ren, Ji-Hua Chen, Xin Chen
World Chinese Journal of Digestology.2023; 31(17): 711. CrossRef
Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel disease
Nojoud Faqerah, Daniel Walker, Konstantinos Gerasimidis
Alimentary Pharmacology & Therapeutics.2023; 58(10): 984. CrossRef
Group B Vitamins: From Homeostasis to Pathogenesis and Treatment of Multiple Sclerosis
I. N. Abdurasulova, A. V. Dmitriev
Успехи физиологических наук.2023; 54(1): 26. CrossRef
An assessment of serum vitamin B12 and folate in patients with Crohn’s disease
Sabiye Akbulut
Medicine.2022; 101(50): e31892. CrossRef
A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease
Mariangela Rondanelli, Silvia Lamburghini, Milena A. Faliva, Gabriella Peroni, Antonella Riva, Pietro Allegrini, Daniele Spadaccini, Clara Gasparri, Giancarlo Iannello, Vittoria Infantino, Tariq A. Alalwan, Simone Perna, Alessandra Miccono
Endocrinología, Diabetes y Nutrición.2021; 68(1): 17. CrossRef
A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease
Mariangela Rondanelli, Silvia Lamburghini, Milena A. Faliva, Gabriella Peroni, Antonella Riva, Pietro Allegrini, Daniele Spadaccini, Clara Gasparri, Giancarlo Iannello, Vittoria Infantino, Tariq A. Alalwan, Simone Perna, Alessandra Miccono
Endocrinología, Diabetes y Nutrición (English ed.).2021; 68(1): 17. CrossRef
Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies
Jordan J. McGing, Shellie Jean Radford, Susan T. Francis, Sébastien Serres, Paul L. Greenhaff, Gordon W. Moran
Alimentary Pharmacology & Therapeutics.2021; 54(4): 368. CrossRef
Nutritional supplementation for vitamin B12 and vitamin K2 deficiency following ileostomy or colostomy formation
David Mantle
Gastrointestinal Nursing.2020; 18(Sup4): S12. CrossRef
Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases
Alicja Ewa Ratajczak, Anna Maria Rychter, Agnieszka Zawada, Agnieszka Dobrowolska, Iwona Krela-Kaźmierczak
Nutrients.2020; 12(6): 1702. CrossRef
Methyl-donor supplementation prevents intestinal colonization by Adherent-Invasive E. coli in a mouse model of Crohn’s disease
Elodie Gimier, Mélissa Chervy, Allison Agus, Adeline Sivignon, Elisabeth Billard, Maud Privat, Sandrine Viala, Régine Minet-Quinard, Anthony Buisson, Emilie Vazeille, Nicolas Barnich, Jérémy Denizot
Scientific Reports.2020;[Epub] CrossRef
Parkinson’s disease: Are gut microbes involved?
Yogesh Bhattarai, Purna C. Kashyap
American Journal of Physiology-Gastrointestinal and Liver Physiology.2020; 319(5): G529. CrossRef
Vitamin D deficiency is associated with disease activity in patients with Crohn’s disease
Kyoung Ho Ko, You Sun Kim, Bo Kyung Lee, Jong Hyun Choi, Yong Moon Woo, Jin Young Kim, Jeong Seop Moon
Intestinal Research.2019; 17(1): 70. CrossRef
Metagenomic analysis of microbe-mediated vitamin metabolism in the human gut microbiome
Promi Das, Parizad Babaei, Jens Nielsen
BMC Genomics.2019;[Epub] CrossRef
Effective Use of the Laboratory in the Management of Patients with Inflammatory Bowel Diseases
M. Nedim Ince, David E. Elliott
Gastroenterology Clinics of North America.2019; 48(2): 237. CrossRef

8,170 View
60 Download
15 Web of Science
17 Crossref

Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India: Parnita Harsh, Vipin Gupta, Saurabh Kedia, Sawan Bopanna, Sucharita Pilli, Surendernath, Govind Kumar Makharia, Vineet Ahuja; Intest Res 2017;15(1):97-102. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.97

Abstract PDF PubReader ePub

Background/Aims

Patients with inflammatory bowel disease (IBD) often require immunosuppressive therapy and blood transfusions and therefore are at a high risk of contracting infections due to hepatitis B (HBV) and hepatitis C (HCV) and human immunodeficiency virus (HIV). In the present study, we assessed the prevalence of these infections in patients with IBD.

Methods

This retrospective study included 908 consecutive patients with IBD (ulcerative colitis [UC], n=581; Crohn's disease [CD], n=327) who were receiving care at a tertiary care center. Ninety-five patients with intestinal tuberculosis (ITB) were recruited as disease controls. Prospectively maintained patient databases were reviewed for the prevalence of HBV surface antigen, anti-HCV antibodies, and HIV (enzyme-linked immunosorbent assay method). HCV RNA was examined in patients who tested positive for anti-HCV antibodies. Prevalence data of the study were compared with that of the general Indian population (HBV, 3.7%; HCV, 1%; HIV, 0.3%).

Results

The prevalence of HBV, HCV, and HIV was 2.4%, 1.4%, and 0.1%, respectively, in the 908 patients with IBD. Among the 581 patients with UC, 2.2% (12/541) had HBV, 1.7% (9/517) had HCV, and 0.2% (1/499) had HIV. Among the 327 patients with CD, 2.8% (8/288) had HBV, 0.7% (2/273) had HCV, and 0% (0/277) had HIV. One patient with CD had HBV and HCV coinfection. The prevalence of HBV, HCV, and HIV in patients with ITB was 5.9% (4/67), 1.8% (1/57), and 1.2% (1/84), respectively.

Conclusions

The prevalence of HBV, HCV, and HIV in north Indian patients with IBD is similar to the prevalence of these viruses in the general community. Nonetheless, the high risk of flare after immunosuppressive therapy mandates routine screening of patients with IBD for viral markers.

Citations

Citations to this article as recorded by

Managing IBD Patients with Concomitant HIV Infection - a Systematic Review
Hugo Sousa, Joana Barroso, Raquel Tavares, Joana Torres
Current Gastroenterology Reports.2024; 26(1): 1. CrossRef
Brucellosis in a patient with Crohn's disease treated with infliximab: A case report
Mansour Altuwaijri, Nasser Alkhraiji, Mosaab Almasry, Saad Alkhowaiter, Nuha Al Amaar, Ammar Alotaibi
Arab Journal of Gastroenterology.2024;[Epub] CrossRef
Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis
Suprabhat Giri, Dhiraj Agrawal, Shivaraj Afzalpurkar, Sunil Kasturi, Amrit Gopan, Sridhar Sundaram, Aditya Kale
Intestinal Research.2023; 21(3): 392. CrossRef
Expert consensus on vaccination in patients with inflammatory bowel disease in Japan
Takashi Ishige, Toshiaki Shimizu, Kenji Watanabe, Katsuhiro Arai, Koichi Kamei, Takahiro Kudo, Reiko Kunisaki, Daisuke Tokuhara, Makoto Naganuma, Tatsuki Mizuochi, Atsuko Murashima, Yuta Inoki, Naomi Iwata, Itaru Iwama, Sachi Koinuma, Hirotaka Shimizu, Ke
Journal of Gastroenterology.2023; 58(2): 135. CrossRef
Prevalence of viral hepatitis infection in India: A systematic review and meta-analysis
Dhasarathi Kumar, Roshni M. Peter, Alex Joseph, Kalpana Kosalram, Harpreet Kaur
Journal of Education and Health Promotion.2023;[Epub] CrossRef
Frequency of hepatitis C virus infection in patients with pediatric inflammatory bowel disease: a cross-sectional study
Sara Tarek, Ayman E. Eskander, Safa Meshaal, Eman Badr, Asmaa Abd El-Hakeem
Egyptian Pediatric Association Gazette.2023;[Epub] CrossRef
Pancreatic Disorders in Patients with Inflammatory Bowel Disease
Marilia L. Montenegro, Juan E. Corral, Frank J. Lukens, Baoan Ji, Paul T. Kröner, Francis A. Farraye, Yan Bi
Digestive Diseases and Sciences.2022; 67(2): 423. CrossRef
Vaccination strategies for Korean patients with inflammatory bowel disease
Yoo Jin Lee, Eun Soo Kim
The Korean Journal of Internal Medicine.2022; 37(5): 920. CrossRef
Viral Hepatitis in Patients with Inflammatory Bowel Disease
Seung Hwan Shin, Sang Hyoung Park
The Korean Journal of Gastroenterology.2022; 80(2): 51. CrossRef
Involvement of HHV-4 (Epstein–Barr Virus) and HHV-5 (Cytomegalovirus) in Inflammatory Bowel Disease and Colorectal Cancer: A Meta-Analysis
Luigi Marongiu, Sascha Venturelli, Heike Allgayer
Cancers.2022; 14(20): 5085. CrossRef
Prevalence of serological markers of hepatitis B in inflammatory bowel disease – Experience from a tertiary care centre in South India
Amol Prabhakar Patil, Ebby George Simon, Amit Kumar Dutta, Anjilivelil Joseph Joseph, Reuben Thomas Kurien, Sudipta Dhar Chowdhury
Tropical Doctor.2021; 51(3): 326. CrossRef
Comorbidity before and after a diagnosis of inflammatory bowel disease
Charles N. Bernstein, Zoann Nugent, Seth Shaffer, Harminder Singh, Ruth Ann Marrie
Alimentary Pharmacology & Therapeutics.2021; 54(5): 637. CrossRef
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye, H Gordon, K Karmiris, U Kopylov, J Kirchgesner, E MacMahon, F Magro, C Maaser, L de Ridder, C Taxonera, M Toruner, L Tremblay, M Scharl, N
Journal of Crohn's and Colitis.2021; 15(6): 879. CrossRef
Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment
Georgios Axiaris, Evanthia Zampeli, Spyridon Michopoulos, Giorgos Bamias
World Journal of Gastroenterology.2021; 27(25): 3762. CrossRef
Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia
Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng
The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076. CrossRef
Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
Intestinal Research.2018; 16(3): 400. CrossRef
Inflammatory bowel disease is no longer a risk factor of viral hepatitis infection in Asia
Eun Soo Kim
Intestinal Research.2017; 15(1): 5. CrossRef

6,148 View
53 Download
15 Web of Science
17 Crossref

Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases: Naoki Minami, Minoru Matsuura, Yorimitsu Koshikawa, Satoshi Yamada, Yusuke Honzawa, Shuji Yamamoto, Hiroshi Nakase; Intest Res 2017;15(1):90-96. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.90

Abstract PDF PubReader ePub

Background/Aims

Our physicians work to expand the possibilities to treat female patients with inflammatory bowel disease (IBD) who wish to become pregnant. Although many drugs, including 5-aminosalicylate (5-ASA), corticosteroids, immunomodulators, and biologics, are used safely during pregnancy, few reports have described the therapeutic regimen throughout pregnancy and the management of patients who relapse during pregnancy precisely. The aim of this study was to assess the management of patients with IBD during pregnancy.

Methods

We identified 19 patients (five with Crohn's disease and 14 with ulcerative colitis [UC]) who became pregnant with a total of 23 pregnancies between May 2005 and May 2015 by reviewing the medical records of Kyoto University Hospital. The following data were collected: the maternal variables, the IBD treatment type, the disease activity, the pregnancy outcome, and the mode of delivery.

Results

Among the 19 patients, 18 had become pregnant after being diagnosed with IBD, while one had developed UC newly after pregnancy. Throughout the gestation, all patients were treated with probiotics, 5-ASA, prednisolone, cytapheresis, or infliximab. The relapse rate during pregnancy was 21.7% (5/23 cases). The five patients who experienced a relapse were able to pursue their pregnancy after intensification of their treatments. There were no adverse fetal or neonatal problems, except in one case that required an emergency Caesarean section because of placental dysfunction and in which a very low-birth-weight infant was born preterm.

Conclusions

Our present data confirmed that even if the disease flares up during pregnancy, good pregnancy outcomes can be achieved with an optimal intensification of the patient's treatment.

Citations

Citations to this article as recorded by

The pregnancy outcome and drug usage during pregnancy among Taiwanese inflammatory bowel disease patients
Chen‐Wang Chang, Shu‐Chen Wei, Jen‐Wei Chou, Tien‐Yu Huang, Chia‐Jung Kuo, Wen‐Hung Hsu, Chen‐Shuan Chung, Tzu‐Chi Hsu, Wei‐Chen Lin, Ming‐Jen Chen, Horng‐Yuan Wang
Advances in Digestive Medicine.2023; 10(4): 226. CrossRef
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
Drugs.2020; 80(16): 1699. CrossRef

5,443 View
78 Download
2 Web of Science
2 Crossref

Analysis of the clinical indications for opiate use in inflammatory bowel disease: Youran Gao, Sundas Khan, Meredith Akerman, Keith Sultan; Intest Res 2017;15(1):83-89. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.83

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Opiate use for inflammatory bowel disease (IBD), particularly high-dose (HD) use, is associated with increased mortality. It's assumed that opiate use is directly related to IBD-related complaints, although this hasn't been well defined. Our goal was to determine the indications for opiate use as a first step in developing strategies to prevent or decrease opiate use.

Methods

A retrospective cohort was formed of adults who were diagnosed with IBD and for whom outpatient evaluations from 2009 to 2014 were documented. Opiate use was defined if opiates were prescribed for a minimum of 30 days over a 365-day period. Individual chart notes were then reviewed to determine the clinical indication(s) for low-dose (LD) and HD opiate use.

Results

After a search of the electronic records of 1,109,277 patients, 3,226 patients with IBD were found. One hundred four patients were identified as opiate users, including 65 patients with Crohn's and 39 with ulcerative colitis; a total of 134 indications were available for these patients. IBD-related complaints accounted for 49.25% of the opiate indications, with abdominal pain (23.13%) being the most common. Overall, opiate use for IBD-related complaints (81.40% vs. 50.82%; P=0.0014) and abdominal pain (44.19% vs. 19.67%; P=0.0071) was more common among HD than among LD.

Conclusions

Our findings show that most IBD patients using opiates, particularly HD users, used opiates for IBD-related complaints. Future research will need to determine the degree to which these complaints are related to disease activity and to formulate non-opiate pain management strategies for patients with both active and inactive IBD.

Citations

Citations to this article as recorded by

Opioid Legislation in Patients With Inflammatory Bowel Disease: A State-wide Retrospective Cohort Study
Waseem Ahmed, Wade Billing, Timothy E Stump, Thomas Strobel, Sashidhar Sagi, Monika Fischer, Mathew Bohm
Inflammatory Bowel Diseases.2023; 29(9): 1355. CrossRef
Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project
Samantha Baillie, Jimmy K Limdi, Ash Bassi, Aileen Fraser, Gareth Parkes, Glyn Scott, Tim Raine, Christopher A Lamb, Nicholas A Kennedy, Natalia Fumis, Melissa A Smith, Andrew Nicolaou, Holly Emms, John Wye, Anouk Lehmann, Isabel Carbery, James Goodhand,
Frontline Gastroenterology.2023; 14(6): 497. CrossRef
Abdominal pain in quiescent inflammatory bowel disease
Matthew D. Coates, Ansh Johri, Venkata Subhash Gorrepati, Parth Maheshwari, Shannon Dalessio, Vonn Walter, August Stuart, Walter Koltun, Nana Bernasko, Andrew Tinsley, Emmanuelle D. Williams, Kofi Clarke
International Journal of Colorectal Disease.2021; 36(1): 93. CrossRef
High-Dose Opioid Use Among Veterans with Unexplained Gastrointestinal Symptoms Versus Structural Gastrointestinal Diagnoses
Salva N. Balbale, Lishan Cao, Itishree Trivedi, Jonah J. Stulberg, Katie J. Suda, Walid F. Gellad, Charlesnika T. Evans, Bruce L. Lambert, Neil Jordan, Laurie A. Keefer
Digestive Diseases and Sciences.2021; 66(11): 3938. CrossRef
Opioid Use Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Blake Niccum, Oluwatoba Moninuola, Kaia Miller, Hamed Khalili
Clinical Gastroenterology and Hepatology.2021; 19(5): 895. CrossRef
Pain in Inflammatory Bowel Disease Is Not Improved During Hospitalization: The Impact of Opioids on Pain and Healthcare Utilization
Sameer K. Berry, Will Takakura, Catherine Bresee, Gil Y. Melmed
Digestive Diseases and Sciences.2020; 65(6): 1777. CrossRef
Predictors of mortality in inflammatory bowel disease patients treated for pneumonia
Offir Ukashi, Yifatch Barash, Michael J. Segel, Bella Ungar, Shelly Soffer, Shomron Ben-Horin, Eyal Klang, Uri Kopylov
Therapeutic Advances in Gastroenterology.2020;[Epub] CrossRef
Integrated Psychological Care is Needed, Welcomed and Effective in Ambulatory Inflammatory Bowel Disease Management: Evaluation of a New Initiative
Taryn Lores, Charlotte Goess, Antonina Mikocka-Walus, Kathryn L Collins, Anne L J Burke, Anna Chur-Hansen, Paul Delfabbro, Jane M Andrews
Journal of Crohn's and Colitis.2019; 13(7): 819. CrossRef

6,054 View
48 Download
8 Web of Science
8 Crossref

15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue: Dong-Hoon Yang, Yeon-Mi Ryu, Sun-Mi Lee, Jin-Yong Jeong, Soon Man Yoon, Byong Duk Ye, Jeong-Sik Byeon, Suk-Kyun Yang, Seung-Jae Myung; Intest Res 2017;15(1):75-82. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.75

Abstract PDF PubReader ePub

Background/Aims

Cyclooxygenase-2 (COX-2), 15-hydroxyprostaglandin dehydrogenase (15-PGDH), and microsomal prostaglandin E synthase-1 (mPGEs-1) regulate prostaglandin E₂ (PGE₂) expression and are involved in colon carcinogenesis. We investigated the expression of PGE₂ and its regulating genes in sporadic human colon tumors and matched normal tissues.

Methods

Twenty colonic adenomas and 27 colonic adenocarcinomas were evaluated. COX-2 and 15-PGDH expression was quantified by real-time polymerase chain reaction. The expression of PGE₂ and mPGEs-1 was measured using enzyme-linked immunosorbent assay and Western blotting, respectively.

Results

The expression of COX-2, mPGEs-1, and PGE₂ did not differ between the adenomas and matched distant normal tissues. 15-PGDH expression was lower in adenomas than in the matched normal colonic tissues (P<0.001). In adenocarcinomas, mPGEs-1 and PGE₂ expression was significantly higher (P<0.001 and P=0.020, respectively), and COX-2 expression did not differ from that in normal tissues (P=0.207). 15-PGDH expression was significantly lower in the normal colonic mucosa from adenocarcinoma patients than in the normal mucosa from adenoma patients (P=0.018).

Conclusions

Early inactivation of 15-PGDH, followed by activation of COX-2 and mPGEs-1, contributes to PGE₂ production, leading to colon carcinogenesis. 15-PGDH might be a novel candidate marker for early detection of field defects in colon carcinogenesis.

Citations

Citations to this article as recorded by

Targeting cyclooxygenase-2 for chemoprevention of inflammation-associated intestinal carcinogenesis: An update
Kyung-Soo Chun, Eun-Hee Kim, Do-Hee Kim, Na-Young Song, Wonki Kim, Hye-Kyung Na, Young-Joon Surh
Biochemical Pharmacology.2024; 228: 116259. CrossRef
Dietary intake of walnut prevented Helicobacter pylori-associated gastric cancer through rejuvenation of chronic atrophic gastritis
Jong Min Park, Young Min Han, Yong Jin Park, Ki Baik Hahm
Journal of Clinical Biochemistry and Nutrition.2021; 68(1): 37. CrossRef
Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials
Nagendra S. Yarla, Venkateshwar Madka, Gopal Pathuri, Chinthalapally V. Rao
International Journal of Molecular Sciences.2020; 21(24): 9609. CrossRef
A glance at…antioxidant and antiinflammatory properties of dietary cobalt
Michael J. Glade, Michael M. Meguid
Nutrition.2018; 46: 62. CrossRef
The prostanoid pathway contains potential prognostic markers for glioblastoma
Alexandros Theodoros Panagopoulos, Renata Nascimento Gomes, Fernando Gonçalves Almeida, Felipe da Costa Souza, José Carlos Esteves Veiga, Anna Nicolaou, Alison Colquhoun
Prostaglandins & Other Lipid Mediators.2018; 137: 52. CrossRef

5,649 View
54 Download
6 Web of Science
5 Crossref

Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients: Shinta Mizuno, Kosaku Nanki, Katsuyoshi Matsuoka, Keiichiro Saigusa, Keiko Ono, Mari Arai, Shinya Sugimoto, Hiroki Kiyohara, Moeko Nakashima, Kozue Takeshita, Makoto Naganuma, Wataru Suda, Masahira Hattori, Takanori Kanai; Intest Res 2017;15(1):68-74. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.68

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Recent developments in analytical techniques including next-generation sequencing have clarified the correlation between intestinal microbiota and inflammatory bowel disease. Fecal microbiota transplantation (FMT) for patients with ulcerative colitis (UC) is proposed as a potential approach to resolving their dysbiosis; however, its safety and efficacy have not been confirmed. This single-arm, open-label, non-randomized study aimed to evaluate the safety and efficacy of FMT for Japanese patients with UC as the first registered clinical trial in Japan.

Methods

We enrolled 10 patients with active UC despite medical therapy. The donors were the patients' relatives and were carefully screened for infectious diseases. Fecal material was administered via colonoscopy, and the primary endpoint was the presence or absence of serious adverse events related to FMT. The secondary endpoint was a change in partial Mayo score at 12 weeks post-FMT. Scores ≤2 were considered a clinical response. Fecal samples were collected to follow changes in gut microbiota, while extracted complementary DNA were analyzed by a next-generation sequencer. We obtained written informed consent from all patients and donors. This study was approved by our Institutional Review Board and is registered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN 000012814).

Results

Five patients with moderate disease and five with severe disease were enrolled. No severe adverse effects were observed. One patient achieved clinical response; however, none of the patients' microbiota diversity recovered to the donor levels.

Conclusions

The use of single FMT for UC was safe; however, we failed to show its clinical efficacy and potential to change the intestinal microbiota.

Citations

Citations to this article as recorded by

Single-Donor and Pooling Strategies for Fecal Microbiota Transfer Product Preparation in Ulcerative Colitis: A Systematic Review and Meta-analysis
Benoît Levast, Mathieu Fontaine, Stéphane Nancey, Pierre Dechelotte, Joël Doré, Philippe Lehert
Clinical and Translational Gastroenterology.2023; 14(5): e00568. CrossRef
Recipient-independent, high-accuracy FMT-response prediction and optimization in mice and humans
Oshrit Shtossel, Sondra Turjeman, Alona Riumin, Michael R. Goldberg, Arnon Elizur, Yarin Bekor, Hadar Mor, Omry Koren, Yoram Louzoun
Microbiome.2023;[Epub] CrossRef
Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial
Andreas Stallmach, Philip Grunert, Johannes Stallhofer, Bettina Löffler, Michael Baier, Jürgen Rödel, Michael Kiehntopf, Sophie Neugebauer, Dietmar H. Pieper, Howard Junca, Andrea Tannapfel, Ute Merkel, Ulrike Schumacher, Maria Breternitz-Gruhne, Tabitha
Trials.2022;[Epub] CrossRef
An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis
Taobi Huang, Jinlan Xu, Maoying Wang, Ke Pu, Longquan Li, Huiyun Zhang, Yuan Liang, Weiming Sun, Yuping Wang
Medicine.2022; 101(30): e29790. CrossRef
Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease
Xiaochen Zhang, Dai Ishikawa, Toshifumi Ohkusa, Shinji Fukuda, Akihito Nagahara
Frontiers in Medicine.2022;[Epub] CrossRef
The Effects of Multi-Donor Fecal Microbiota Transplantation Capsules Combined with Thalidomide on Hormone-Dependent Ulcerative Colitis
Xiao-He Guo, Yan-Li Zhu, Lu Yang, Wen-Jing Li, Xue-Fang Du
Infection and Drug Resistance.2022; Volume 15: 7495. CrossRef
Fecal microbiota transplantation for ulcerative colitis
Katsuyoshi Matsuoka
Immunological Medicine.2021; 44(1): 30. CrossRef
Bacteriotherapy for inflammatory bowel disease
Yusuke Yoshimatsu, Yohei Mikami, Takanori Kanai
Inflammation and Regeneration.2021;[Epub] CrossRef
Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis
Valentin Mocanu, Sabitha Rajaruban, Jerry Dang, Janice Y. Kung, Edward C. Deehan, Karen L. Madsen
Journal of Clinical Medicine.2021; 10(5): 959. CrossRef
Current status, complications and prospects of fecal microbiota transplantation therapy
Ohara Tadashi
Archives of Pathology and Clinical Research.2021; 5(1): 004. CrossRef
Fecal Microbial Transplantation in Critically Ill Patients—Structured Review and Perspectives
Ivana Cibulková, Veronika Řehořová, Jan Hajer, František Duška
Biomolecules.2021; 11(10): 1459. CrossRef
Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation
Herbert L. DuPont, Zhi-Dong Jiang, Andrew W. DuPont, Netanya S. Utay
Digestive Diseases and Sciences.2020; 65(3): 741. CrossRef
Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao
Journal of Digestive Diseases.2020; 21(3): 147. CrossRef
Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis
Luciane de Fátima Caldeira, Helena H. Borba, Fernanda S. Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo, Udai P. Singh
PLOS ONE.2020; 15(9): e0238910. CrossRef
Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy
Ajit Sood, Arshdeep Singh, Vandana Midha, Ramit Mahajan, Dina Kao, David T Rubin, Charles N Bernstein
Crohn's & Colitis 360.2020;[Epub] CrossRef
Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta‐analysis
Hai Lan Zhao, Shu Zhen Chen, Hao Ming Xu, You Lian Zhou, Jie He, Hong Li Huang, Jing Xu, Yu Qiang Nie
Journal of Digestive Diseases.2020; 21(10): 534. CrossRef
Fecal Microbiota Transplantation in Intestinal Disorders: A Primer for Physicians
Ajit Sood, Vandana Midha, Harmeet Kaur, Arshdeep Singh
Journal of Gastrointestinal Infections.2020; 10(1): 16. CrossRef
Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of steroid-dependent ulcerative colitis
Young-Seok Cho
Intestinal Research.2019; 17(1): 6. CrossRef
RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
Jung Hoon Song, You Sun Kim
Gut and Liver.2019; 13(1): 16. CrossRef
1) Microbiota and Gastrointestinal Diseases
Takanori Kanai
Nihon Naika Gakkai Zasshi.2019; 108(3): 401. CrossRef
Fecal microbial transplantation
Sonia Bouri, Ailsa Hart
Current Opinion in Clinical Nutrition & Metabolic Care.2018; 21(5): 405. CrossRef
The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis
Yantian Cao, Bangjie Zhang, Yuanyuan Wu, Qingzhi Wang, Jie Wang, Fangfang Shen
Gastroenterology Research and Practice.2018; 2018: 1. CrossRef
Gut microbiota‐immune‐brain interactions in chemotherapy‐associated behavioral comorbidities
Kelley R. Jordan, Brett R. Loman, Michael T. Bailey, Leah M. Pyter
Cancer.2018; 124(20): 3990. CrossRef
Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
Current Infectious Disease Reports.2018;[Epub] CrossRef
Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?
Chang Soo Eun
Intestinal Research.2017; 15(2): 145. CrossRef
Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome
Shinta Mizuno, Tatsuhiro Masaoka, Makoto Naganuma, Taishiro Kishimoto, Momoko Kitazawa, Shunya Kurokawa, Moeko Nakashima, Kozue Takeshita, Wataru Suda, Masaru Mimura, Masahira Hattori, Takanori Kanai
Digestion.2017; 96(1): 29. CrossRef
Intestinal immune response is regulated by gut microbe
Shun TANEMOTO, Tomohisa SUJINO, Takanori KANAI
Japanese Journal of Clinical Immunology.2017; 40(6): 408. CrossRef

8,020 View
97 Download
26 Web of Science
27 Crossref

The submucosal fibrosis: what does it mean for colorectal endoscopic submucosal dissection?: Eun Kyoung Kim, Dong Soo Han, Youngouk Ro, Chang Soo Eun, Kyo-Sang Yoo, Young-Ha Oh; Intest Res 2016;14(4):358-364. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.358

Abstract PDF PubReader

Background/Aims

Endoscopic submucosal dissection (ESD) allows removal of colorectal epithelial neoplasms en bloc regardless of size. Colorectal ESD is a difficult procedure because of technical difficulties and risks of complications. This study aimed to assess the relationship between ESD outcome and degree of submucosal fibrosis.

Methods

Patients with colorectal tumors undergoing ESD and their medical records were reviewed retrospectively. The degree of submucosal fibrosis was classified into three types. The relationship between ESD outcome and degree of submucosal fibrosis was analyzed.

Results

ESD was performed in 158 patients. Thirty-eight cases of F0 (no) fibrosis (24.1%) and 46 cases of F2 (severe) fibrosis (29.1%) were observed. Complete resection was achieved for 138 lesions (87.3%). Multivariate analysis demonstrated that submucosal invasion of tumor and histology of carcinoma were independent risk factors for F2 fibrosis. Severe fibrosis was an independent risk factor for incomplete resection.

Conclusions

Severe fibrosis is an important factor related to incomplete resection during colorectal ESD. In cases of severe fibrosis, the rate of complete resection was low even when ESD was performed by an experienced operator. Evaluation of submucosal fibrosis may be helpful to predict the submucosal invasion of tumors and technical difficulties in ESD.

Citations

Citations to this article as recorded by

Learning curve of colorectal endoscopic submucosal dissection of an endoscopist experienced hands‐on training in Japan
Sukit Pattarajierapan, Yutaka Saito, Hiroyuki Takamaru, Naoya Toyoshima, Naruemon Wisedopas, Natcha Wanpiyarat, Nathawadee Lerttanatum, Supakij Khomvilai
Journal of Gastroenterology and Hepatology.2025; 40(1): 226. CrossRef
Feasibility, safety and efficacy of endoscopic submucosal dissection for recurrent superficial rectal neoplastic lesions after transanal microsurgery
Ali Jaafar, Jeremie Jacques, Sarah Leblanc, Romain Legros, Vincent Lepilliez, Arthur Berger, Edouard Chabrun, Yann Le Baleur, Mathieu Pioche, Maximilien Barret, Timothee Wallenhorst, Thibault Degand, Felix Corre, Marion Schaefer, Xavier Dray
Digestive and Liver Disease.2025; 57(1): 68. CrossRef
Risk Factors for Perforation in Endoscopic Treatment for Early Colorectal Cancer: A Nationwide ENTER-K Study
Ik Hyun Jo, Hyun Gun Kim, Young-Seok Cho, Hyun Jung Lee, Eun Ran Kim, Yoo Jin Lee, Sung Wook Hwang, Kyeong-Ok Kim, Jun Lee, Hyuk Soon Choi, Yunho Jung, Chang Mo Moon
Gut and Liver.2025; 19(1): 95. CrossRef
Delays in definitive endoscopic resection of previously manipulated colorectal polyps as a risk factor for inferior resection outcomes
Fares Ayoub, Grace E. Kim, Wenfei Wang, Dennis Chen, Uzma D. Siddiqui
Gastrointestinal Endoscopy.2024; 100(1): 109. CrossRef
Is there a best choice of equipment for colorectal endoscopic submucosal dissection?
Francesco Cocomazzi, Sonia Carparelli, Nunzia Labarile, Antonio Capogreco, Marco Gentile, Roberta Maselli, Jahnvi Dhar, Jayanta Samanta, Alessandro Repici, Cesare Hassan, Francesco Perri, Antonio Facciorusso
Expert Review of Medical Devices.2024; 21(7): 561. CrossRef
Risk Factors for Post-Endoscopic Submucosal Dissection Electrocoagulation Syndrome in Patients with Colorectal Neoplasms: A Multicenter, Large-Scale, Retrospective Cohort Study by the Honam Association for the Study of Intestinal Disease (HASID)
Hyo-Yeop Song, Seong-Jung Kim, Jun Lee, Byung Chul Jin, Dong Hyun Kim, Hyun-Soo Kim, Hyung-Hoon Oh, Young-Eun Joo, Dae-Seong Myung, Sang-Wook Kim, Geom-Seog Seo
Journal of Clinical Medicine.2024; 13(13): 3932. CrossRef
Hybrid Versus Conventional Colorectal Endoscopic Submucosal Dissection: A Multicenter Randomized Controlled Trial (Short-Endoscopic Submucosal Dissection)
Dennis Yang, Muhammad K. Hasan, Salmaan Jawaid, Gurdeep Singh, Yasi Xiao, Mai Khalaf, Yutaka Tomizawa, Neil S. Sharma, Peter V. Draganov, Mohamed O. Othman
American Journal of Gastroenterology.2024; 119(12): 2436. CrossRef
The Derivation and External Validation of a Fibrosis Risk Model for Colorectal Tumours Undergoing Endoscopic Submucosal Dissection
Sandro Sferrazza, Marcello Maida, Giulio Calabrese, Antonio Facciorusso, Lorenzo Fuccio, Leonardo Frazzoni, Roberta Maselli, Alessandro Repici, Roberto Di Mitri, João Santos-Antunes
Journal of Clinical Medicine.2024; 13(15): 4517. CrossRef
Development and validation of a predictive model for submucosal fibrosis in patients with early gastric cancer undergoing endoscopic submucosal dissection: experience from a large tertiary center
Yunqing Zeng, Jinhou Li, Yuan Zheng, Di Zhang, Ning Zhong, Xiuli Zuo, Yanqing Li, Wenbin Yu, Jiaoyang Lu
Annals of Medicine.2024;[Epub] CrossRef
Comparing underwater endoscopic submucosal dissection and conventional endoscopic submucosal dissection for large laterally spreading tumor: a randomized controlled trial (with video)
Chang Kyo Oh, Hwe Hoon Chung, Jae Keun Park, Jiyoon Jung, Hee Yeon Lee, Yu Jin Kim, Jin Bae Kim
Gastrointestinal Endoscopy.2024; 100(6): 1079. CrossRef
Outcomes and Learning Curve in Endoscopic Submucosal Dissection of Rectal Neoplasms with Severe Fibrosis: Experience of a Western Center
Catarina Félix, Pedro Barreiro, Rui Mendo, André Mascarenhas, Cristina Chagas
GE - Portuguese Journal of Gastroenterology.2023; 30(3): 221. CrossRef
Endoscopic submucosal dissection for colorectal polyps: outcome determining factors
Chi Woo Samuel Chow, Tak Lit Derek Fung, Pak Tat Chan, Kam Hung Kwok
Surgical Endoscopy.2023; 37(2): 1293. CrossRef
Safety and feasibility of same-day discharge after endoscopic submucosal dissection: a Western multicenter prospective cohort study
William King, Peter Draganov, V.Subhash Gorrepati, Maham Hayat, Hiroyuki Aihara, Michael Karasik, Saowanee Ngamruengphong, Abdul Aziz Aadam, Mohamed O. Othman, Neil Sharma, Ian S. Grimm, Alaa Rostom, B. Joseph Elmunzer, Dennis Yang
Gastrointestinal Endoscopy.2023; 97(6): 1045. CrossRef
Is colorectal endoscopic submucosal dissection safe and effective for 15–19-mm tumors?
Yunho Jung, Young Hwangbo, Young Sin Cho, Seong Woo Choi, Seong Ran Jeon, Hyun Gun Kim, Bong Min Ko, Jin-O Kim
International Journal of Colorectal Disease.2023;[Epub] CrossRef
Initial multicenter experience using a novel articulating through-the-scope traction device for endoscopic submucosal dissection
Maham Hayat, Alexander Schlachterman, Grace Schiavone, Meir Mizrahi, Jong Kyu Park, Vivek Kumbhari, Antonio Cheesman, Peter V Draganov, Muhammad Khalid Hasan, Dennis Yang
Endoscopy International Open.2023; 11(08): E778. CrossRef
Novel beagle model of gastric local fibrotic target lesions for the evaluation and training of endoscopic techniques
Xiao-Jian He, Xiao-Ling Wang, Chuan-Shen Jiang, Dong-Gui Hong, Hai-Lan Lin, Yun-Ping Zheng, Han Li, Xin-Jiang Chen, Jian-Xiao Huang, Ling-Shuang Dai, Mei-Yan Liu, Bao-Xiang Luo, Dong-Liang Li, Da-Zhou Li, Wen Wang
BMC Gastroenterology.2023;[Epub] CrossRef
Comparison of precutting endoscopic mucosal resection and endoscopic submucosal dissection for large (20–30 mm) flat colorectal lesions
Chang Kyo Oh, Young Wook Cho, In Hyoung Choi, Han Hee Lee, Chul‐Hyun Lim, Jin Su Kim, Bo‐In Lee, Young‐Seok Cho
Journal of Gastroenterology and Hepatology.2022; 37(3): 568. CrossRef
Endoscopic Submucosal Dissection in North America: A Large Prospective Multicenter Study
Peter V. Draganov, Hiroyuki Aihara, Michael S. Karasik, Saowanee Ngamruengphong, Abdul Aziz Aadam, Mohamed O. Othman, Neil Sharma, Ian S. Grimm, Alaa Rostom, B. Joseph Elmunzer, Salmaan A. Jawaid, Donevan Westerveld, Yaseen B. Perbtani, Brenda J. Hoffman,
Gastroenterology.2021; 160(7): 2317. CrossRef
Pocket-creation method improves efficacy of colorectal endoscopic submucosal dissection: a system review and meta-analysis
Jian Gong, Tong Chen, Yuyong Tan, Deliang Liu
European Journal of Gastroenterology & Hepatology.2021; 33(10): 1241. CrossRef
Impact of Procedure Time of Preceding Endoscopic Submucosal Dissection on the Difficulty of Laparoscopic Rectal Surgery
Hiroaki Nozawa, Kazushige Kawai, Kazuhito Sasaki, Shigenobu Emoto, Koji Murono, Hirofumi Sonoda, Hiroaki Ishii, Soichiro Ishihara
International Surgery.2021; 105(1-3): 528. CrossRef
Factors Associated with Fibrosis during Colorectal Endoscopic Submucosal Dissection: Does Pretreatment Biopsy Potentially Elicit Submucosal Fibrosis and Affect Endoscopic Submucosal Dissection Outcomes?
Masatake Kuroha, Hisashi Shiga, Yoshitake Kanazawa, Hiroshi Nagai, Tomoyuki Handa, Ryo Ichikawa, Motoyuki Onodera, Takeo Naito, Rintaro Moroi, Tomoya Kimura, Katsuya Endo, Yoichi Kakuta, Yoshitaka Kinouchi, Tooru Shimosegawa, Atsushi Masamune
Digestion.2021; 102(4): 590. CrossRef
Endoscopic submucosal dissection in rectal tumors extending or not to the dentate line: A comparative analysis
Déborah Roland, Gabriel Rahmi, Enrique Pérez-Cuadrado-Robles, Guillaume Perrod, Jérémie Jacques, Maximilien Barret, Sarah Leblanc, Arthur Berger, Jérémie Albouys, Stanislas Chaussade, Christophe Cellier
Digestive and Liver Disease.2020; 52(3): 296. CrossRef
Novel approach to endoscopic submucosal dissection of a cecal lesion with nonlifting sign by submucosal fatty tissue with use of selective-regulation high-pressure water-jet method and immersion in saline solution
Felipe Ramos-Zabala, Sabina Beg, Marian García-Mayor, Adolfo Parra-Blanco, Luis Moreno-Almazán
VideoGIE.2020; 5(3): 116. CrossRef
Review on colorectal endoscopic submucosal dissection focusing on the technical aspect
Tak Lit Derek Fung, Chi Woo Samuel Chow, Pak Tat Chan, Kam Hung Kwok
Surgical Endoscopy.2020; 34(9): 3766. CrossRef
Endoscopic Biopsy in Differential Diagnosis of Colorectal Serrated Lesions
K. D. Khalin, M. Yu. Agapov, L. V. Zvereva, K. V. Stegniy
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2020; 30(3): 42. CrossRef
Predictors for Submucosal Fibrosis in Patients With Superficial Squamous Esophageal Neoplasia Undergoing Endoscopic Submucosal Dissection
Xiaoduan Zhuang, Ming Xu, Zhenyu Chen, Jianqi Wang, Kai Qian, Shihao Wang, Guoming Deng, Yang Bai
Clinical and Translational Gastroenterology.2020; 11(8): e00188. CrossRef
Hybrid resection with ESD and FTRD: Could this be a rescue treatment in the presence of severe submucosal fibrosis?
Gianluca Andrisani, Francesco Maria Di Matteo
Digestive and Liver Disease.2019; 51(4): 607. CrossRef
Factors Predictive of Complete Excision of Large Colorectal Neoplasia Using Hybrid Endoscopic Submucosal Dissection: A KASID Multicenter Study
Yunho Jung, Jong Wook Kim, Jeong-Sik Byeon, Hoon Sup Koo, Sun-Jin Boo, Jun Lee, Young Hwangbo, Yoon Mi Jeen, Hyun Gun Kim
Digestive Diseases and Sciences.2018; 63(10): 2773. CrossRef
Perforation and Postoperative Bleeding Associated with Endoscopic Submucosal Dissection in Colorectal Tumors: An Analysis of 398 Lesions Treated in Saga, Japan
Koji Yamamoto, Ryo Shimoda, Shinichi Ogata, Megumi Hara, Yoichiro Ito, Naoyuki Tominaga, Atsushi Nakayama, Yasuhisa Sakata, Nanae Tsuruoka, Ryuichi Iwakiri, Kazuma Fujimoto
Internal Medicine.2018; 57(15): 2115. CrossRef
The efficacy of the pocket-creation method for cases with severe fibrosis in colorectal endoscopic submucosal dissection
Naohisa Yoshida, Yuji Naito, Ritsu Yasuda, Takaaki Murakami, Ryohei Hirose, Kiyoshi Ogiso, Yutaka Inada, Hideyuki Konishi, Rafiz Abdul Rani, Mitsuo Kishimoto, Eiichi Konishi, Masayoshi Nakanishi, Yoshito Itoh
Endoscopy International Open.2018; 06(08): E975. CrossRef
Local recurrence and subsequent endoscopic treatment after endoscopic piecemeal mucosal resection with or without precutting in the colorectum
Myeongsook Seo, Eun Mi Song, Gwang Un Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
Intestinal Research.2017; 15(4): 502. CrossRef

5,911 View
60 Download
34 Web of Science
31 Crossref

A wide variation of the quality of colonoscopy reporting system in the real clinical practice in southeastern area of Korea: Jung Min Lee, Yu Jin Kang, Eun Soo Kim, Yoo Jin Lee, Kyung Sik Park, Kwang Bum Cho, Seong Woo Jeon, Min Kyu Jung, Hyun Seok Lee, Eun Young Kim, Jin Tae Jung, Byung Ik Jang, Kyeong Ok Kim, Yun Jin Chung, Chang Hun Yang; Intest Res 2016;14(4):351-357. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.351

Abstract PDF PubReader

Background/Aims

Establishment of a colonoscopy reporting system is a prerequisite to determining and improving quality. This study aimed to investigate colonoscopists' opinions and the actual situation of a colonoscopy reporting system in a clinical practice in southeastern area of Korea and to assess the factors predictive of an inadequate reporting system.

Methods

Physicians who performed colonoscopies in the Daegu-Gyeongbuk province of Korea and were registered with the Korean Society of Gastrointestinal Endoscopy (KSGE) were interviewed via mail about colonoscopy reporting systems using a standardized questionnaire.

Results

Of 181 endoscopists invited to participate, 125 responded to the questionnaires (response rate, 69%). Most responders were internists (105/125, 84%) and worked in primary clinics (88/125, 70.4%). Seventy-one specialists (56.8%) held board certifications for endoscopy from the KSGE. A median of 20 colonoscopies (interquartile range, 10–47) was performed per month. Although 88.8% of responders agreed that a colonoscopy reporting system is necessary, only 18.4% (23/125) had achieved the optimal reporting system level recommended by the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. One-third of endoscopists replied that they did not use a reporting document for the main reasons of "too busy" and "inconvenience." Non-endoscopy specialists and primary care centers were independent predictive factors for failure to use a colonoscopy reporting system.

Conclusions

The quality of colonoscopy reporting systems varies widely and is considerably suboptimal in actual clinical practice settings in southeastern Korea, indicating considerable room for quality improvements in this field.

Citations

Citations to this article as recorded by

Association of Poor Differentiation or Positive Vertical Margin with Residual Disease in Patients with Subsequent Colectomy after Complete Macroscopic Endoscopic Resection of Early Colorectal Cancer
Ki Ju Kim, Hyun Seok Lee, Seong Woo Jeon, Sun Jin, Sang Won Lee
Gastroenterology Research and Practice.2017; 2017: 1. CrossRef
Derivation and validation of a risk scoring model to predict advanced colorectal neoplasm in adults of all ages
Hyo‐Joon Yang, Sungkyoung Choi, Soo‐Kyung Park, Yoon Suk Jung, Kyu Yong Choi, Taesung Park, Ji Yeon Kim, Dong Il Park
Journal of Gastroenterology and Hepatology.2017; 32(7): 1328. CrossRef
Screening strategy for colorectal cancer according to risk
Dong Soo Han
Journal of the Korean Medical Association.2017; 60(11): 893. CrossRef

7,090 View
36 Download
3 Web of Science
3 Crossref

Symptomatic improvement with gluten restriction in irritable bowel syndrome: a prospective, randomized, double blinded placebo controlled trial: Vinay G Zanwar, Sunil V Pawar, Pravir A Gambhire, Samit S Jain, Ravindra G Surude, Vinaya B Shah, Qais Q Contractor, Pravin M Rathi; Intest Res 2016;14(4):343-350. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.343

Abstract PDF PubReader

Background/Aims

The existence of non-celiac gluten sensitivity has been debated. Indeed, the intestinal and extra-intestinal symptoms of many patients with irritable bowel syndrome (IBS) but without celiac disease or wheat allergy have been shown to improve on a gluten-free diet. Therefore, this study set out to evaluate the effects of gluten on IBS symptoms.

Methods

We performed a double-blind randomized placebo-controlled rechallenge trial in a tertiary care hospital with IBS patients who fulfilled the Rome III criteria. Patients with celiac disease and wheat allergy were appropriately excluded. The participants were administered a gluten-free diet for 4 weeks and were asked to complete a symptom-based questionnaire to assess their overall symptoms, abdominal pain, bloating, wind, and tiredness on the visual analog scale (0-100) at the baseline and every week thereafter. The participants who showed improvement were randomly assigned to one of two groups to receive either a placebo (gluten-free breads) or gluten (whole cereal breads) as a rechallenge for the next 4 weeks.

Results

In line with the protocol analysis, 60 patients completed the study. The overall symptom score on the visual analog scale was significantly different between the two groups (P<0.05). Moreover, the patients in the gluten intervention group scored significantly higher in terms of abdominal pain, bloating, and tiredness (P<0.05), and their symptoms worsened within 1 week of the rechallenge.

Conclusions

A gluten diet may worsen the symptoms of IBS patients. Therefore, some form of gluten sensitivity other than celiac disease exists in some of them, and patients with IBS may benefit from gluten restrictions.

Citations

Citations to this article as recorded by

The role of gluten and wheat in irritable bowel syndrome and noncoeliac gluten or wheat sensitivity
Tom van Gils, Magnus Simrén
Current Opinion in Gastroenterology.2025;[Epub] CrossRef
Gluten-free grains: Importance, processing and its effect on quality of gluten-free products
Samandeep Kaur, Kshitiz Kumar, Lochan Singh, Vijay Singh Sharanagat, Prabhat K. Nema, Vijendra Mishra, Bharat Bhushan
Critical Reviews in Food Science and Nutrition.2024; 64(7): 1988. CrossRef
Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology
Uday C. Ghoshal, Sanjeev Sachdeva, Nitesh Pratap, Arun Karyampudi, Uzma Mustafa, Philip Abraham, Chetan B. Bhatt, Karmabir Chakravartty, Sujit Chaudhuri, Omesh Goyal, Govind K. Makharia, Manas Kumar Panigrahi, Prasanta Kumar Parida, Sudhanshu Patwari, Raj
Indian Journal of Gastroenterology.2023; 42(2): 249. CrossRef
Current evidence for dietary therapies in irritable bowel syndrome
Anupam Rej, Hugo A. Penny
Current Opinion in Gastroenterology.2023; 39(3): 219. CrossRef
The Role of Gluten in Gastrointestinal Disorders: A Review
Sabrina Cenni, Veronica Sesenna, Giulia Boiardi, Marianna Casertano, Giuseppina Russo, Alfonso Reginelli, Susanna Esposito, Caterina Strisciuglio
Nutrients.2023; 15(7): 1615. CrossRef
Gluten restriction in irritable bowel syndrome, yes or no?: a GRADE-assessed systematic review and meta-analysis
Erfan Arabpour, Dorsa Alijanzadeh, Amir Sadeghi, Sina Khoshdel, Azita Hekmatdoost, Hamed Kord-Varkaneh, Mohammad Abdehagh
Frontiers in Nutrition.2023;[Epub] CrossRef
Boosting biomedical document classification through the use of domain entity recognizers and semantic ontologies for document representation: The case of gluten bibliome
Martín Pérez-Pérez, Tânia Ferreira, Anália Lourenço, Gilberto Igrejas, Florentino Fdez-Riverola
Neurocomputing.2022; 484: 223. CrossRef
Management of bloating
Jordi Serra
Neurogastroenterology & Motility.2022;[Epub] CrossRef
Evidence-Based and Emerging Diet Recommendations for Small Bowel Disorders
Anupam Rej, Michael D. E. Potter, Nicholas J. Talley, Ayesha Shah, Gerald Holtmann, David Surendran Sanders
American Journal of Gastroenterology.2022; 117(6): 958. CrossRef
Diet and irritable bowel syndrome: an update from a UK consensus meeting
A. Rej, A. Avery, I. Aziz, C. J. Black, R. K. Bowyer, R. L. Buckle, L. Seamark, C. C. Shaw, J. Thompson, N. Trott, M. Williams, D. S. Sanders
BMC Medicine.2022;[Epub] CrossRef
Belgian consensus on irritable bowel syndrome
S Kindt, H Louis, H De Schepper, J Arts, P Caenepeel, D De Looze, A Gerkens, T Holvoet, P Latour, T Mahler, F Mokaddem, S Nullens, H Piessevaux, P Poortmans, G Rasschaert, M Surmont, H Vafa, K Van Malderen, T Vanuytsel, F Wuestenberghs, J Tack
Acta Gastro Enterologica Belgica.2022; 85(2): 360. CrossRef
A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease
Mariangela Rondanelli, Silvia Lamburghini, Milena A. Faliva, Gabriella Peroni, Antonella Riva, Pietro Allegrini, Daniele Spadaccini, Clara Gasparri, Giancarlo Iannello, Vittoria Infantino, Tariq A. Alalwan, Simone Perna, Alessandra Miccono
Endocrinología, Diabetes y Nutrición.2021; 68(1): 17. CrossRef
Non-responsive celiac disease may coincide with additional food intolerance/malabsorption, including histamine intolerance
Wolfgang J. Schnedl, Harald Mangge, Michael Schenk, Dietmar Enko
Medical Hypotheses.2021; 146: 110404. CrossRef
Non-celiac wheat sensitivity: rationality and irrationality of a gluten-free diet in individuals affected with non-celiac disease: a review
Consolato Sergi, Vincenzo Villanacci, Antonio Carroccio
BMC Gastroenterology.2021;[Epub] CrossRef
Personalizing Dietary Therapies For Irritable Bowel Syndrome: What Is Gluten’s Role?
Anupam Rej, Imran Aziz, David S. Sanders
Clinical Gastroenterology and Hepatology.2021; 19(11): 2270. CrossRef
A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease
Mariangela Rondanelli, Silvia Lamburghini, Milena A. Faliva, Gabriella Peroni, Antonella Riva, Pietro Allegrini, Daniele Spadaccini, Clara Gasparri, Giancarlo Iannello, Vittoria Infantino, Tariq A. Alalwan, Simone Perna, Alessandra Miccono
Endocrinología, Diabetes y Nutrición (English ed.).2021; 68(1): 17. CrossRef
Histamine Intolerance Originates in the Gut
Wolfgang J. Schnedl, Dietmar Enko
Nutrients.2021; 13(4): 1262. CrossRef
Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms
Annamaria Altomare, Claudia Di Rosa, Elena Imperia, Sara Emerenziani, Michele Cicala, Michele Pier Luca Guarino
Nutrients.2021; 13(5): 1506. CrossRef
Adherence to treatment of patients with irritable bowel syndrome: state of the issue
S.A. Sukhanova, A.Yu. Timakova, M.A. Livzan, M.M. Fedorin, Yu.P. Skirdenko, O.V. Gaus, K.A. Andreev, A.V. Gorbenko, M.I. Plinder
Profilakticheskaya meditsina.2021; 24(8): 101. CrossRef
Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastr
P. Layer, V. Andresen, H. Allescher, S. C. Bischoff, M. Claßen, S. Elsenbruch, M. Freitag, T. Frieling, M. Gebhard, M. Goebel-Stengel, W. Häuser, G. Holtmann, J. Keller, M. E. Kreis, W. Kruis, J. Langhorst, P. Lynen Jansen, A. Madisch, H. Mönnikes, S. Mül
Zeitschrift für Gastroenterologie.2021; 59(12): 1323. CrossRef
Nutrition in Patients with Lactose Malabsorption, Celiac Disease, and Related Disorders
Michele J. Alkalay
Nutrients.2021; 14(1): 2. CrossRef
Letter: the gluten‐free diet as a bottom‐up approach for irritable bowel syndrome
Anupam Rej, Rachel Louise Buckle, Christian Charles Shaw, Nick Trott, Imran Aziz, David Surendran Sanders
Alimentary Pharmacology & Therapeutics.2020; 51(1): 184. CrossRef
Irritable Bowel Syndrome and Gluten-Related Disorders
Paolo Usai-Satta, Gabrio Bassotti, Massimo Bellini, Francesco Oppia, Mariantonia Lai, Francesco Cabras
Nutrients.2020; 12(4): 1117. CrossRef
Ernährungsmedizinische Aspekte beim Reizdarmsyndrom – ein Update
Larissa Hetterich, Andreas Stengel
Aktuelle Ernährungsmedizin.2020; 45(04): 276. CrossRef
The Two Faces of Wheat
Herbert Wieser, Peter Koehler, Katharina A. Scherf
Frontiers in Nutrition.2020;[Epub] CrossRef
Low Fermentable Oligo- Di- and Mono-Saccharides and Polyols (FODMAPs) or Gluten Free Diet: What Is Best for Irritable Bowel Syndrome?
Massimo Bellini, Sara Tonarelli, Maria Gloria Mumolo, Francesco Bronzini, Andrea Pancetti, Lorenzo Bertani, Francesco Costa, Angelo Ricchiuti, Nicola de Bortoli, Santino Marchi, Alessandra Rossi
Nutrients.2020; 12(11): 3368. CrossRef
Breaking bread!
Anupam Rej, Imran Aziz, David Surendran Sanders
Proceedings of the Nutrition Society.2019; 78(1): 118. CrossRef
Efficacy of the gluten free diet in the management of functional gastrointestinal disorders: a systematic review on behalf of the Italian Society of Paediatrics
Elena Scarpato, Renata Auricchio, Francesca Penagini, Angelo Campanozzi, Gian Vincenzo Zuccotti, Riccardo Troncone
Italian Journal of Pediatrics.2019;[Epub] CrossRef
The overlap of irritable bowel syndrome and noncoeliac gluten sensitivity
Anupam Rej, David S. Sanders
Current Opinion in Gastroenterology.2019; 35(3): 199. CrossRef
Gluten Vehicle and Placebo for Non-Celiac Gluten Sensitivity Assessment
Oscar Gerardo Figueroa-Salcido, Noé Ontiveros, Francisco Cabrera-Chavez
Medicina.2019; 55(5): 117. CrossRef
The role of diet in irritable bowel syndrome: implications for dietary advice
A. Rej, I. Aziz, H. Tornblom, D. S. Sanders, M. Simrén
Journal of Internal Medicine.2019; 286(5): 490. CrossRef
Does Irritable Bowel Syndrome Exist? Identifiable and Treatable Causes of Associated Symptoms Suggest It May Not
Benjamin I. Brown
Gastrointestinal Disorders.2019; 1(3): 314. CrossRef
Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm
Giuseppe Losurdo, Mariabeatrice Principi, Andrea Iannone, Annacinzia Amoruso, Enzo Ierardi, Alfredo Di Leo, Michele Barone
World Journal of Gastroenterology.2018; 24(14): 1521. CrossRef
Is an enzyme supplement for celiac disease finally on the cards?
Julia König, Robert J. Brummer
Expert Review of Gastroenterology & Hepatology.2018; 12(6): 531. CrossRef
Non-celiac gluten sensitivity: people without celiac disease avoiding gluten—is it due to histamine intolerance?
Wolfgang J. Schnedl, Sonja Lackner, Dietmar Enko, Michael Schenk, Harald Mangge, Sandra J. Holasek
Inflammation Research.2018; 67(4): 279. CrossRef
Gluten sensitivities and the allergist: Threshing the grain from the husks
J. G. Burkhardt, A. Chapa‐Rodriguez, S. L. Bahna
Allergy.2018; 73(7): 1359. CrossRef
Prevalence and factors associated with gluten sensitivity in inflammatory bowel disease
Berkeley N. Limketkai, Rachel Sepulveda, Tressia Hing, Neha D. Shah, Monica Choe, David Limsui, Shamita Shah
Scandinavian Journal of Gastroenterology.2018; 53(2): 147. CrossRef
Non‐celiac gluten or wheat sensitivity: It's complicated!
Maria I. Pinto‐Sanchez, Elena F. Verdu
Neurogastroenterology & Motility.2018;[Epub] CrossRef
Canadian packaged gluten-free foods are less nutritious than their regular gluten-containing counterparts
Jennifer A. Jamieson, Mary Weir, Laura Gougeon
PeerJ.2018; 6: e5875. CrossRef
Consensus document on exclusion diets in irritable bowel syndrome (IBS)
Francesc Casellas, Rosa Burgos, Ascensión Marcos, Javier Santos, Constanza Ciriza de los Ríos, Álvaro García Manzanares, Isabel Polanco, María Puy Portillo, Antonio Villarino, Beatriz Lema Marqués, María del Carmen Vázquez Alférez
Revista Española de Enfermedades Digestivas.2018;[Epub] CrossRef
Gluten-Free Diet and Its ‘Cousins’ in Irritable Bowel Syndrome
Anupam Rej, David Surendran Sanders
Nutrients.2018; 10(11): 1727. CrossRef
IRRITABLE BOWEL SYNDROME, FOOD INTOLERANCE AND NON- CELIAC GLUTEN SENSITIVITY. A NEW CLINICAL CHALLENGE
Rosa Leonôra Salerno SOARES
Arquivos de Gastroenterologia.2018; 55(4): 417. CrossRef
Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting
Julia König, Savanne Holster, Maaike J. Bruins, Robert J. Brummer
Scientific Reports.2017;[Epub] CrossRef
The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update
Carlo Catassi, Armin Alaedini, Christian Bojarski, Bruno Bonaz, Gerd Bouma, Antonio Carroccio, Gemma Castillejo, Laura De Magistris, Walburga Dieterich, Diana Di Liberto, Luca Elli, Alessio Fasano, Marios Hadjivassiliou, Matthew Kurien, Elena Lionetti, Ch
Nutrients.2017; 9(11): 1268. CrossRef
Irritable bowel syndrome and diet
Eirini Dimidi, Megan Rossi, Kevin Whelan
Current Opinion in Clinical Nutrition & Metabolic Care.2017; 20(6): 456. CrossRef
Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!
Anamaria Cozma-Petruţ, Felicia Loghin, Doina Miere, Dan Lucian Dumitraşcu
World Journal of Gastroenterology.2017; 23(21): 3771. CrossRef

8,263 View
107 Download
47 Web of Science
46 Crossref

Thirty-day mortality after percutaneous gastrostomy by endoscopic versus radiologic placement: a systematic review and meta-analysis: Joo Hyun Lim, Seung Ho Choi, Changhyun Lee, Ji Yeon Seo, Hae Yeon Kang, Jong In Yang, Su Jin Chung, Joo Sung Kim; Intest Res 2016;14(4):333-342. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.333

Abstract PDF PubReader

Background/Aims

A percutaneous gastrostomy can be placed either endoscopically (percutaneous endoscopic gastrostomy, PEG) or radiologically (radiologically-inserted gastrostomy, RIG). However, there is no consistent evidence of the safety and efficacy of PEG compared to RIG. Recently, 30-day mortality has become considered as the most important surrogate index for evaluating the safety and efficacy of percutaneous gastrostomy. The aim of this meta-analysis was to compare the 30-day mortality rates between PEG and RIG.

Methods

Major electronic databases (MEDLINE, Embase, Scopus, and Cochrane library) were queried for comparative studies on the two insertion techniques of gastrostomy among adults with swallowing disturbance. The primary outcome was the 30-day mortality rate after gastrostomy insertion. Forest and funnel plots were generated for outcomes using STATA version 14.0.

Results

Fifteen studies (n=2,183) met the inclusion criteria. PEG was associated with a lower risk of 30-day mortality after tube placement compared with RIG (odds ratio, 0.60; 95% confidence interval [CI], 0.38–0.94; P=0.026). The pooled prevalence of 30-day mortality of PEG was 5.5% (95% CI, 4.0%–6.9%) and that of RIG was 10.5% (95% CI, 6.8%–14.3%). No publication bias was noted.

Conclusions

The present meta-analysis demonstrated that PEG is associated with a lower probability of 30-day mortality compared to RIG, suggesting that PEG should be considered as the first choice for long-term enteral tube feeding. Further prospective randomized studies are needed to evaluate and compare the safety of these two different methods of gastrostomy.

Citations

Citations to this article as recorded by

Factors Predicting Major Complications and Mortality in Percutaneous Endoscopic Gastrostomy: 8 Years of Experience of a Tertiary Surgery Center
Murat Yildirim, Asim Kocabay, Bulent Koca, Ali Ihsan Saglam, Namik Ozkan
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2025;[Epub] CrossRef
S3-Leitlinie Heimenterale und heimparenterale Ernährung der Deutschen Gesellschaft für Ernährungsmedizin (DGEM)
Stephan C. Bischoff, Jann Arends, Christiane Decker-Baumann, Elisabeth Hütterer, Sebastian Koch, Stefan Mühlebach, Ingeborg Roetzer, Andrea Schneider, Claudia Seipt, Ralph Simanek, Zeno Stanga
Aktuelle Ernährungsmedizin.2024; 49(02): 73. CrossRef
Percutaneous radiologic gastrostomy versus percutaneous endoscopic gastrostomy for enteral feeding: A systematic review and meta‐analysis
Matheus Coelho Meine, Isabela Ho Tusato, Nathalia Hoffmeister, Gilmara Coelho Meine
Journal of Parenteral and Enteral Nutrition.2024; 48(6): 667. CrossRef
Direct Percutaneous Endoscopic Gastrostomy Versus Radiological Gastrostomy in Patients Unable to Undergo Transoral Endoscopic Pull Gastrostomy
Divyanshoo R. Kohli, Craig Smith, Omer Chaudhry, Madhav Desai, Dion DePaolis, Prateek Sharma
Digestive Diseases and Sciences.2023; 68(3): 852. CrossRef
Complications of Percutaneous Radiologic Gastrostomy Among Patients in a Tertiary Care Hospital in Riyadh, Saudi Arabia
Najla Alrasheed, Haneen S Khair, Renad M Aljohani, Noof M Alharbi, Nahlah N Alotaibi, Shahad F AlEdrees, Aamir Omair
Cureus.2023;[Epub] CrossRef
A retrospective study of outcomes and the validation of the Sheffield Gastrostomy Score in PEGs, RIGs and PIGs
Heather Parr, Lloyd Thomas, Prabhsimran Singh, Salma Mohammed, Khin Nu, John S. Kane, Fred Lee, Thomas Welbank, Andrew D. Hopper, Mark E. McAlindon, Elizabeth A. Williams, David S. Sanders
Scandinavian Journal of Gastroenterology.2023; 58(12): 1542. CrossRef
Endoscopic vs radiologic gastrostomy for enteral feeding: A systematic review and meta-analysis
Evellin Souza Valentim dos Santos, Guilherme Henrique Peixoto de Oliveira, Diogo Turiani Hourneaux de Moura, Bruno Salomão Hirsch, Roberto Paolo Trasolini, Wanderley Marques Bernardo, Eduardo Guimarães Hourneaux de Moura
World Journal of Meta-Analysis.2023; 11(6): 277. CrossRef
Outcomes of push and pull percutaneous endoscopic gastrostomy placements in 854 patients: A single‐center study
Hicham Bouchiba, Maarten A J M Jacobs, Gerd Bouma, Dewkoemar Ramsoekh
JGH Open.2022; 6(1): 57. CrossRef
Factors affecting late complications of percutaneous endoscopic gastrostomy tube replacement
Kasenee Tiankanon, Satimai Aniwan, Julalak Karuehardsuwan, Sumitra Wiangngoen, Rungsun Rerknimitr
Clinical Nutrition ESPEN.2022; 49: 378. CrossRef
The Outcomes of Nutritional Support Techniques in Patients with Gastrointestinal Cancers
Vlad-Alexandru Ionescu, Gina Gheorghe, Ruxandra Oprita, Madalina Stan-Ilie, Raluca-Ioana Dascalu, Ondin Zaharia, Viorel Jinga, Camelia Cristina Diaconu, Gabriel Constantinescu
Gastroenterology Insights.2022; 13(3): 245. CrossRef
Improving 30-day mortality after PEG tube placement in England from 2007 to 2019: a retrospective national cohort analysis of 87,862 patients
Umair Kamran, Pui Chi Lee, Ben Coupland, Abdullah Abbasi, Helen Steed, Sissi Ispoglou, Fumi Varyani, Nigel Trudgill
Gastrointestinal Endoscopy.2022; 96(6): 943. CrossRef
Outcomes following percutaneous endoscopic gastrostomy versus fluoroscopic procedures in the Medicare population
Samantha Maasarani, Syed I. Khalid, Chantal Creighton, Athena J. Manatis-Lornell, Aaron L. Wiegmann, Samantha L. Terranella, Nicholas J. Skertich, Laura DeCesare, Edie Y. Chan
Surgery Open Science.2021; 3: 2. CrossRef
Safety of endoscopic gastrostomy tube placement compared with radiologic or surgical gastrostomy: nationwide inpatient assessment
Divyanshoo R. Kohli, Kevin F. Kennedy, Madhav Desai, Prateek Sharma
Gastrointestinal Endoscopy.2021; 93(5): 1077. CrossRef
Laparoscopic vs open insertion of feeding gastrostomy tube in adults with head and neck cancers: A case‐matched comparative study
Balqees Omari, Huthaifa Asmer, Hani Al‐Najjar, Issa Mohamad, Omar Al‐Saraireh, Basil J. Ammori
International Journal of Clinical Practice.2021;[Epub] CrossRef
Percutaneous endoscopic gastrostomy
Xudong Liu, Zhengqiang Yang, Shun He, Guiqi Wang
International Journal of Gastrointestinal Intervention.2021; 10(2): 42. CrossRef
Scheduled percutaneous endoscopic gastrostomy tube replacement did not reduce PEG-related complications
Wisam Sbeit, Anas Kadah, Amir Shahin, Samer Shbat, Moeen Sbeit, Tawfik Khoury
Scandinavian Journal of Gastroenterology.2021; 56(11): 1386. CrossRef
Comparative Safety of Endoscopic vs Radiological Gastrostomy Tube Placement: Outcomes From a Large, Nationwide Veterans Affairs Database
Divyanshoo R. Kohli, Kevin F. Kennedy, Madhav Desai, Prateek Sharma
American Journal of Gastroenterology.2021; 116(12): 2367. CrossRef
ESPEN guideline on home enteral nutrition
Stephan C. Bischoff, Peter Austin, Kurt Boeykens, Michael Chourdakis, Cristina Cuerda, Cora Jonkers-Schuitema, Marek Lichota, Ibolya Nyulasi, Stéphane M. Schneider, Zeno Stanga, Loris Pironi
Clinical Nutrition.2020; 39(1): 5. CrossRef
Technical success rate and safety of radiologically inserted gastrostomy versus percutaneous endoscopic gastrostomy in motor neuron disease patients undergoing: A systematic review and meta-analysis
Tian-wen Yuan, Yang He, Sai-bo Wang, Peng Kong, Jun Cao
Journal of the Neurological Sciences.2020; 410: 116622. CrossRef
Predictors for 30-day mortality and complications following radiologically inserted gastrostomies: a single centre, large cohort review
J. Delf, S. Jepson, S. Ramachandran, M. Elabassy, B. Morgan, R. Kenningham, J.H. Mullineux, J.A. Stephenson
Clinical Radiology.2020; 75(5): 375. CrossRef
Gastropexy can be as safe as conventional percutaneous endoscopic gastrostomy (PEG), and biomarkers do not predict short-term or long-term outcomes: a 7-year follow-up audit
Ross J Porter, Alastair W McKinlay, Emma L Metcalfe
Frontline Gastroenterology.2020; 11(5): 364. CrossRef
Early versus Delayed Feeding after Percutaneous Endoscopic Gastrostomy Placement in Children: A Meta-Analysis
Jun Watanabe, Kazuhiko Kotani
Children.2020; 7(9): 124. CrossRef
Reducing 30-day post gastrostomy insertion mortality with a feeding issues multidisciplinary team meeting
A. Bond, T. Conley, J. Fiske, V. Raymond, A. Young, P. Collins, M. Dibb, P.J. Smith
Clinical Nutrition ESPEN.2020; 40: 282. CrossRef
Nutritional Support of Cancer Patients without Oral Feeding: How to Select the Most Effective Technique?
Gonçalo Nunes, Jorge Fonseca, Ana Teresa Barata, Mário Dinis-Ribeiro, Pedro Pimentel-Nunes
GE - Portuguese Journal of Gastroenterology.2020; 27(3): 172. CrossRef
Retrospective comparison of outcomes and associated complications between large bore radiologically inserted gastrostomy tube types
David J. Tischfield, Gregory J. Nadolski, Stephen J. Hunt, Maxim Itkin, Richard D. Shlansky-Goldberg, Terence P. Gade
Abdominal Radiology.2019; 44(1): 318. CrossRef
Percutaneous endoscopic gastrostomy for enteral nutrition: a 5-year clinical experience with 324 patients
Ezekiel W. Toh Yoon, Kaori Yoneda, Kazuki Nishihara
Minerva Gastroenterologica e Dietologica.2019;[Epub] CrossRef
Simple Bedside Predictors of Survival after Percutaneous Gastrostomy Tube Insertion
Wisam Sbeit, Anas Kadah, Amir Mari, Mahmud Mahamid, Tawfik Khoury
Canadian Journal of Gastroenterology and Hepatology.2019; 2019: 1. CrossRef
Risk factors for complications and mortality of percutaneous endoscopic gastrostomy insertion
Gyu Young Pih, Hee Kyong Na, Ji Yong Ahn, Kee Wook Jung, Do Hoon Kim, Jeong Hoon Lee, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung
BMC Gastroenterology.2018;[Epub] CrossRef
A Systematic Review and Meta-Analysis on Outcomes and Complications of Percutaneous Endoscopic Versus Radiologic Gastrostomy for Enteral Feeding
Denise Strijbos, Daniel Keszthelyi, Roel M.M. Bogie, Lennard P.L. Gilissen, Martin Lacko, Janneke G.J. Hoeijmakers, Christiaan van der Leij, Rogier de Ridder, Michiel W. de Haan, Ad A.M. Masclee
Journal of Clinical Gastroenterology.2018; 52(9): 753. CrossRef
Percutaneous Endoscopic Transgastric Jejunostomy (PEG‐J) Tube Placement for Levodopa‐Carbidopa Intrajejunal Gel Therapy in the Interventional Radiology Suite: A Long‐term Follow‐up
Maria Valeria Saddi, Marianna Sarchioto, Giulia Serra, Daniela Murgia, Valeria Ricchi, Marta Melis, Roberta Arca, Pierpaolo Carreras, Loredana Sitzia, Sandro Zedda, Giovanni Dui, Rosario Rossi, Anna Ticca, Maurizio Melis, Giovanni Cossu
Movement Disorders Clinical Practice.2018; 5(2): 191. CrossRef
Percutaneous Radiologically-Guided Gastrostomy (PRG): Safety, Efficacy and Trends in a Single Institution
Gerard ZX Low, Chow Wei Too, Yen Yeong Poh, Richard HG Lo, Bien Soo Tan, Apoorva Gogna, Farah Gillan Irani, Kiang Hiong Tay
Annals of the Academy of Medicine, Singapore.2018; 47(11): 494. CrossRef

6,945 View
82 Download
36 Web of Science
31 Crossref

First
Prev
Page of 17
Next
Last

Original article